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Chapter 1 General introduction and outline of the thesis
General introduction
Allogeneic stem cell transplantation (SCT) can be a curative treatment option for patients 
suffering from hematological malignancies due to alloreactive T cell responses recognizing 
minor histocompatibility antigens (MiHAs) expressed on the malignant cells. Despite 
induction of robust MiHA-specific T cell responses and long-term persistence of alloreactive 
memory T cells specific for the tumor, often these T cells fail to respond efficiently to tumor 
recurrence. This lack of responsiveness may result from immunosuppressive mechanisms 
exploited by the tumor cells, including disrupted antigen presentation, secretion of immuno-
suppressive cytokines, recruitment of regulatory T cells and myeloid-derived suppressor 
cells (MDSCs), but also modulation of the expression levels of co-stimulatory and 
co-inhibitory molecules and their subsequent signaling. In this thesis, we investigated the 
involvement of the co-inhibitory molecules PD-1 and BTLA in the functional impairment 
of MiHA-specific T cell responses after allogeneic SCT. As in many patients the induction 
and/or reactivation of MiHA-specific T cell responses is inadequate, potent post-transplant 
immunotherapies are required to boost graft-versus-tumor (GVT) immunity. Dendritic cell 
(DC)-based vaccination boosting MiHA-specific T cell immunity is an appealing strategy 
to prevent or counteract tumor recurrence, but improvement of DC immunogenicity and 
interference with negative co-signaling pathways is essential to reactivate and boost GVT 
immunity, and improve clinical outcome post-transplantation. Therefore, we explored the 
pre-clinical potential of such immunotherapeutic strategies, including treatment with the 
combination of MiHA peptide-loaded DC vaccines and anti-PD-1 or anti-BTLA blocking 
antibodies, and vaccination with PD-1 ligand silenced DCs loaded with MiHA peptide or 
mRNA. 
Hematological malignancies
Hematological malignancies comprise a group of heterogeneous neoplasms that account 
for approximately 7% of all newly diagnosed cancers in Europe1. Based on clinical features 
these are generally categorized in four major groups: acute leukemias, chronic leukemias, 
malignant lymphomas and plasma cell malignancies. Among these groups etiology, 
incidence and prognosis greatly varies. Patient age, health status and genetic abnormalities 
of the tumor are important factors influencing disease prognosis, and consequently 
determine the choice of therapy. Standard treatment for hematological malignancies 
includes chemotherapy and radiotherapy, which reduce tumor burden and can induce 
long-term remission. Moreover, in the past years new therapeutic agents have been 
developed that more specifically target tumor cells. Currently, the first-line drug in chronic 
myeloid leukemia (CML) is imatinib, a tyrosine kinase activity blocker that inhibits the 
BCR-ABL fusion protein2. Also treatment of B-cell lymphomas has greatly improved after 
the introduction of the anti-CD20 monoclonal antibody rituximab3. Other promising 
drugs are bortezomib, a proteasome inhibitor4, and lenalidomide, which is reported to 
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host-disease (GVHD). The last decade, reduced intensity chemotherapy regimens have 
been introduced that have greatly improved treatment related mortality (TRM), and allow 
older patients to benefit from allogeneic SCT as well11-13. Furthermore, to decrease the 
incidence and severity of GVHD complete or partial T cell-depleted SCT can be performed, 
thereby limiting the induction of dangerous alloreactive T cell responses shortly after 
transplant14;15. In addition, immunosuppressive drugs are administered during the first 
period after allogeneic SCT. After 6 months when the conditioning-related inflammation 
has resolved, pre-emptive donor lymphocyte infusions (DLI) can be given to boost or 
induce GVT immunity with limited risk of GVHD16. 
 The immunogenic potential of hematological malignancies has been evidently 
demonstrated by the observation of increased tumor-reactive T cell responses and tumor 
regression following hematopoietic SCT17-19. Especially, the implementation of allogeneic 
SCT has greatly enhanced the curative rate in leukemia and lymphoma14;19;20. Furthermore, 
DLI has been shown to mediate clinical and molecular remissions in case of residual, 
refractory or relapsed disease21;22. Nevertheless, hematological malignancies vary in their 
sensitivity to this treatment. In particular chronic phase CML is highly sensitive to DLI, 
which is likely due to the recipient DCs being part of the malignant clone. In addition, also 
acute myeloid leukemia (AML), MM and lymphoma can respond relatively well to DLI. In 
contrast, acute lymphoblastic leukemia (ALL) hardly responds to DLI, indicating that there 
are intrinsic differences between these cancers22.
Immunobiology of GVT responses
Both in solid organ transplantation, as well as in hematopoietic SCT the human leukocyte 
antigen (HLA) molecules are known to play a critical role in donor graft acceptance, 
rejection and GVHD6;23. There are two types of HLA molecules, class I (HLA-A, -B, -C) that 
are involved in antigen presentation to CD8+ T cells, and class II (HLA-DR, -DQ, -DP) which 
present antigens to CD4+ T cells. Without HLA-matching in allogeneic SCT, severe 
alloreactive T cell responses will be elicited towards normal tissues and cells expressing 
the foreign recipient-specific HLA molecules, causing the detrimental complication GVHD. 
Therefore, it is essential to transplant these patients with a donor stem cell graft that is 
matched for 8-10 out of 10 HLA molecules, not considering HLA-DP. 
 The most important immune effectors involved in GVT immunity are the 
donor-derived T cells and natural killer (NK) cells. NK cells recognize their target cells 
independent of HLA-antigen complexes as their activation is dependent on the balance 
of signals delivered by activating and inhibitory receptors. Normally NK cells receive 
inhibitory signals via HLA class I molecules, however on virus-infected cells and malignant 
cells HLA class I expression can be down-regulated, thereby mediating NK cell activation. 
In contrast, T cells can only recognize specific antigens presented by HLA molecules via 
their T cell receptor (TCR). Due to a wide variability in rearrangements of TCR gene 
segments, the specificity of the naive T cell repertoire is extremely diverse. Upon encounter 
have cytotoxic and immunomodulatory function5, especially for treatment of multiple 
myeloma (MM). Although much progress has been achieved, current treatments still have 
many limitations. Next to the risk on drug resistance, patients may suffer from severe side 
effects. Furthermore, still many patients relapse eventually. Cellular immunotherapy is an 
attractive adjuvant treatment option to cure hematological malignancies. Such cell-based 
immunotherapies include allogeneic SCT, T cell and NK cell adoptive transfer, and vaccina-
tion-based approaches using various antigen formulations or DCs. The power of these 
immunotherapeutic approaches lies in the induction of effective anti-tumor immune 
effector responses and the formation of long-term tumor-specific immune memory, that 
exerts a surveillance function and has the potency to quickly respond upon tumor 
re-encounter.
Hematopoietic stem cell transplantation and donor lymphocyte infusions
Hematopoietic SCT is a well-established treatment modality for patients with a hematological 
malignancy6;7. Patients are pretreated with chemotherapy with/without radiotherapy, 
which interferes with the cell division of fast-proliferating tumor cells. Thereby tumor 
burden is reduced and a situation of minimal residual disease (MRD) can be achieved. 
Unfortunately, also rapidly dividing normal cells in the bone marrow, gastrointestinal tract 
and hair follicles are affected, causing side-effects like pancytopenia, mucositis and hair 
loss. To restore hematopoiesis and provide the patient with a new and healthy immune 
system, hematopoietic SCT is performed. The hematopoietic stem cells can be isolated 
from bone marrow (BM), peripheral blood (PB) following mobilization with granulocyte 
colony-stimulating factor (G-CSF), or umbilical cord blood7;8. Reconstitution of the various 
immune cells starts within 2-3 weeks after successful stem cell engraftment. In various 
randomized trials it has been demonstrated that engraftment and subsequent immune 
recovery is usually faster upon SCT with PB as compared to BM9, which is probably due to 
the higher number of CD34+ hematopoietic stem cells in the mobilized PB stem cell grafts.
 There are two types of hematopoietic SCT, namely autologous SCT that uses the 
patient’s own stem cells obtained prior to conditioning therapy, and allogeneic SCT where 
stem cells from another person (either a sibling or voluntary unrelated donor) are infused 
into the patient7. Depending on the type of hematological malignancy, and certain patient 
and tumor characteristics the patient receives either an autologous or allogeneic stem cell 
graft. Although treatment related toxicity is low with autologous SCT, as compared to 
allogeneic SCT, the disadvantage is that the stem cell graft may contain residual tumor 
cells, contributing to eventual relapse of the disease. Allogeneic SCT on the other hand, 
not only provides the patient with a new healthy immune system, but can also be 
regarded as a highly potent cellular immunotherapy due to donor-derived GVT 
responses8;10. These can competently eliminate residual tumor cells, resulting in long-term 
remission and possibly cure of the disease. Unfortunately, allogeneic SCT also causes high 
morbidity and mortality due to conditioning-related toxicity, infections and graft-versus-
1
12 13
Chapter 1 General introduction and outline of the thesis
indicate the attractiveness of MiHAs as potent target antigens in post-transplantation 
immunotherapy to prevent or treat tumor recurrences. Furthermore, by selection of he-
matopoietic-restricted MiHAs, that are solely expressed by the redundant patient 
hematopoietic system and residual tumor cells, GVT immunity can be selectively 
augmented, without causing GVHD. Interesting therapeutic MiHA-candidates in this 
respect are HA-129, HA-242, LRH-131, ARHGDIB32, BCL2A143 and UTA2-144.
Dynamic of graft-versus-tumor T cell responses
In order to eradicate tumor cells, efficient activation of tumor-reactive T cells by highly 
competent antigen presenting cells (APCs) is crucial. DCs are the most potent professional 
APCs of the immune system that can effectively initiate and reactivate T cell-based immune 
responses45;46. They originate from myeloid bone marrow precursors that differentiate into 
immature DCs, which are highly competent in scanning the environment for antigens, 
engulfment of the antigen and subsequent processing. Upon antigen uptake, maturation of 
the DCs is initiated resulting in increased expression of peptide-HLA complexes and 
acquirement of many accessory molecules involved in cell adhesion, cell migration, and co-
stimulation47. Subsequently, the mature DCs home to the lymph nodes where they present 
the processed antigen to passing T cells (Figure 1). To activate the T cells with the 
corresponding TCR two signals are required48-50. Firstly, the TCR-CD3 complex needs to 
interact with the cognate peptide presented in HLA molecules on the DCs. Secondly, a 
co-stimulatory signal should be delivered, which is generally provided by CD28, expressed 
on the T cell, interacting with its ligands CD80 and CD86 on the DCs. In the absence of 
co-stimulation the T cell will become functionally anergic, and thereby tolerant to the 
antigen, which is one of the physiological mechanisms involved in elimination of self-reactive 
T cells. In addition to these two essential signals, inflammatory cytokines can also contribute 
to T cell activation. Furthermore, cytokines such as interleukin (IL)-2 and IL-15 are important 
for the proliferation and survival of the antigen-activated T cells.
 As the MiHAs are foreign to the donor immune cells, presentation of the cognate 
MiHA peptide by recipient APCs in combination with correct co-stimulation results in 
activation of the MiHA-specific CD8+ T cells. These T cells then clonally expand and 
differentiate into effector cells, that produce inflammatory cytokines like interferon (IFN)-γ 
and tumor necrosis factor (TNF)-α, and have strong cytolytic potential51. Thereby, they can 
competently eliminate MiHA-expressing malignant cells. After the initial immune response, 
most of the MiHA-reactive CD8+ T cells die through apoptosis during the contraction 
phase52. Nevertheless, a small but substantial pool of long-lived memory cells survives, 
that is capable of quickly responding to recurrence of the antigen. These memory T cells 
play an important role in protective immunity in SCT patients. However, even though 
alloreactive CD8+ memory T cells are present for a long time after transplantation, these T 
cells do not always respond efficiently to recurring tumor cells31;53, suggesting that their 
functionality is affected and this failure may contribute to the occurrence of tumor relapses.
with their cognate antigen and appropriate co-stimulation, the naive T cells become 
activated and respond. Important antigens in post-transplant anti-tumor immunity are 
tumor-associated antigens (TAAs) and alloantigens24-27. TAAs are antigens which are highly 
expressed by tumor cells, but generally also at low levels by normal cells. The 
immunogenicity of TAAs varies, and immunotolerance could occur as these antigens are 
derived from self proteins. In contrast, highly potent T cell-based immunity can be elicited 
against recipient-specific alloantigens independent of HLA-matching. These T cell 
responses have been demonstrated to be directed against MiHAs, which are polymorphic 
peptides derived from cellular proteins that are presented in HLA molecules26;28. Due to 
genetic variations amongst individuals, the patient and donor can be disparate for various 
MiHAs. Especially in case of transplantation with a graft from an unrelated donor the 
likelihood of polymorphic differences, and thus numerous MiHA disparities, is high. Often 
single nucleotide polymorphisms (SNPs) lead to an amino acid change, however 
frame-shifts, early stop codons and alternative splicing can also occur, resulting in a new 
immunogenic peptide. As the presentation of a MiHA peptide is restricted to a certain 
HLA molecule, both the MiHA allele frequency rate and HLA allele frequency determine 
the MiHA disparity rate within the SCT population. Upon processing and presentation of 
the MiHA peptide in the HLA molecules, the donor immune system can recognize the 
antigen as foreign and elicit powerful CD8, but also CD4, T cell responses resulting in 
attack of the MiHA-expressing target cells. While several autosomal-encoded MiHAs are 
exclusively expressed by hematopoietic cells and their malignant counterparts, others 
show an ubiquitous expression pattern and can cause GVHD, especially in the skin, liver 
and gastrointestinal tract. 
 Since the discovery of the first MiHAs and the awareness of the importance of these 
polymorphic antigens in GVT immunity, increasing numbers of MiHAs have been 
identified using different approaches like peptide elution29, cDNA expression cloning30 
and genetic linkage analysis31. Although the conventional methods are time-consuming 
and laborious, with the introduction of new and revisited genetic techniques, like whole 
genome association scanning32, this process is accelerated and multiple novel MiHAs can 
be identified simultaneously. In several studies an association between mismatches in 
MiHAs and clinical outcome after HLA-matched allogeneic SCT has been reported. On the 
molecular level, disparities in individual MiHAs, including HA-1, HA-2 and HA-8, were 
associated with an increased occurrence of GVHD and lower relapse rate33-35, although 
other reports could not confirm this36-38. In addition mismatches in the ubiquitously 
expressed HY antigens, which are the result of transplantation of a male recipient with a 
female donor graft, were associated with a higher incidence of severe acute and chronic 
GVHD and a reduced relapse rate39. However, more important are post-transplantation 
MiHA-specific T cell responses and their association with clinical outcome. In various 
malignancies, the emergence of MiHA-specific T cell responses was shown to precede 
clinical remission in patients treated with allogeneic SCT and DLI31;40;41. These observations 
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Secondly, defects in components of the antigen presentation machinery can occur, 
including the transporter associated with antigen processing 1 (TAP-1) and subunits of the 
immunoproteasome (LMP-2, LMP-7), resulting in improper processing and loading of 
tumor antigens in the HLA class I molecules57. In addition, tumor cells can down-regulate 
or even lose the expression of HLA class I proteins. The complete or partial loss of HLA-I 
Immune escape by the tumor cells
Despite the powerful aspects of immune reactions, tumor cells exploit various mechanisms 
to evade immune recognition and destruction54;55. These include both tumor intrinsic 
alterations, as well as the establishment of an immunosuppressive milieu (Figure 2). 
Defects in antigen processing and presentation
At the tumor level, antigen presentation can be disrupted by for instance down-regulation 
of antigen expression or selection of tumor cells lacking the immunogenic antigen54;56. 
1
Figure 1   Circle of tumor-reactive T cell activation and memory formation
Upon tumor antigen encounter, dendritic cells (DCs) home to the draining lymph node and  present 
the processed antigen to passing T cells. The T cells with the correct T cell receptor (TCR) become 
activated in the presence of co-signaling via CD28. Upon T cell activation also co-inhibitory receptors 
(CI-R) are up-regulated. The balance in positive and negative co-signaling into the T cell determines 
its activation state. Subsequently, the T cells acquire effector functions; they clonally expand and 
attack the tumor cells. After the effector phase, most cells will die through apoptosis and only a 
small pool of tumor-reactive memory cells remains. These have the potential to self-renew and can 
quickly respond to tumor recurrences. CI-L, co-inhibitory ligand; HLA, human leukocyte antigen.
Figure 2   Tumor cells hamper efficient anti-tumor immunity by using immunosuppressive 
mechanisms
Tumor cells prevent efficient immune recognition and destruction via multiple direct and indirect 
mechanisms. These include impaired antigen presentation, increased resistance to apoptosis, secre-
tion of immunosuppressive factors, recruitment of suppressive immune cells, and signaling via co-
inhibitory molecules. HLA, human leukocyte antigen; Bak, Bcl-2 homologous antagonist/killer; Bax, 
Bcl-2 associated X; Bcl-2, B cell lymphoma-2; Bcl-x
L
, B cell lymphoma extra long; Mcl-1, myeloid cell 
leukemia-1; Smac, small mitochondria-derived activator of caspases; XIAP, X-linked inhibitor of 
apoptosis; IDO, indoleamine 2,3-dioxygenase; IL-10, interleukin-10; sMIC-A, soluble major histocom-
patibility antigen class I polypeptide-related sequence A; TGF-β, transforming growth factor-β; NK, 
natural killer cell; Th2, T helper 2 cell; BTLA, B and T lymphocyte attenuator; CTLA-4, cytotoxic T 
lymphocyte associated antigen-4; PD-1, programmed death-1.
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recruited toward the tumor cells via amongst others the CCR4 chemokines CCL17 and 
CCL2265. Upon arrival in the tumor milieu, T
REG
 can exert their suppressive function via 
different mechanisms66, including direct inhibition of T cell activation and suppression of 
APC function via cell-cell contact, and secretion of IL-10 and TGF-β. Furthermore, they can 
also induce IDO production by APCs and thereby indirectly suppress effector T cell 
function. Moreover, T
REG
 are postulated to possess cytotoxic potential upon activation and 
may directly kill target cells via perforin- and granzyme-dependent pathways66;67. Notably, 
TGF-β in the tumor milieu can promote the conversion of effector T cells into T
REG
66. In 
addition, factors released in the tumor micro-environment attract monocytes and 
immature DCs, and mediate their differentiation into M2 macrophages, MDSCs and 
tolerogenic DCs68-70. These suppressive APCs secrete a variety of cytokines and growth 
factors, like TGF-β and IL-10, that facilitate tumor growth and motility, but also promote 
Th2 responses or induce immune tolerance. In addition, T cell proliferation and function is 
inhibited due to arginine deprivation and NO generation resulting from arginine 
catabolism by arginase-1 and iNOS, two enzymes highly expressed in M2 macrophages68 
and MDSCs69;70. Furthermore, high levels of reactive oxygen species produced by these 
suppressive APCs can also contribute to T cell suppression and tumorigenesis.
Signaling via co-inhibitory molecules
In the last decade, another powerful immunosuppressive mechanism exploited by cancer 
cells gained much attention: the repressive action of co-inhibitory molecules, which is 
described in more detail in Chapter 3. Normally, expression levels of co-inhibitory 
molecules like CTLA-4 and PD-1 are up-regulated upon T cell activation71. Ligation of these 
receptors to their corresponding ligands on APCs results in T cell inhibition, and via this 
natural feedback loop sustained T cell activation is prevented and the effector T cell 
response resolves. The balance in positive and negative co-signals determines the 
activation state of the T cells during immunity and tolerance. By down-regulating co- 
stimulatory molecules like CD80 and CD86, and up-regulating various co-inhibitory 
molecules tumor cells acquire an immune inhibitory phenotype48;72-75. Furthermore, 
tumor-reactive T cells can express high levels of the co-inhibitory receptors such as 
CTLA-4, PD-1 and BTLA76-79, as is described in Chapter 3, 4 and 5. It has been reported in 
chronic viral infections, that due to chronic antigen exposure these co-inhibitory 
molecules are up-regulated on the viral-specific T cells, and that sustained downstream 
signaling leads to T cell exhaustion80-83. This phenomenon may also occur in cancer, 
especially in case of refractory or relapsed disease, and by exploiting such negative 
regulatory pathways tumor cells effectively hamper T cell-mediated immunity. 
Boosting anti-tumor immune responses with immunotherapy
To cure hematological malignancies it is essential to explore therapeutic strategies that 
potently initiate and boost anti-tumor immune responses and induce tumor-specific 
can be caused by deletions in chromosome 6, where the HLA alleles are located, or due to 
mutations in the β2-microglobulin, an essential molecule for stable HLA expression on the 
cell surface. All these alterations contribute to invisibility of the tumor cells, thereby 
hampering efficient recognition by tumor-reactive T cells.
Resistance to immune-mediated cytotoxicity
Tumor cells can also become resistant to attack by cytotoxic immune cells via interference 
with signaling of death receptors, like Fas and TRAIL, or by directly impairing the perforin/
granzyme cytotoxic pathways58;59. Increased expression of anti-apoptotic molecules like 
Bcl-2, Bcl-x
L
, Mcl-1 or XIAP, which can be accompanied by reduced levels of pro-apoptotic 
molecules like Bax, Bak and Smac, render the cancer cells less sensitive to immune cell 
mediated apoptosis via inhibition of caspase activity60. Furthermore, oncogenic transcription 
factors like STAT3 can be constitutively activated in both the cancer cells and the immune 
cells present in the tumor milieu. STAT3 regulates various different processes, including 
tumor cell proliferation and survival, but also immunosuppression by inhibiting mediators 
required for immune activation61. These changes within the tumor cells can impede 
proper anti-tumor immune responses.
Secretion of immunosuppressive factors
Besides intrinsic alterations, the cancer cells can also create an immunosuppressive micro-
environment. For instance by secretion of immunosuppressive cytokines and soluble 
factors the function of surrounding immune cells can be modulated54;55. Depending on 
the tumor type different factors are secreted, amongst which IL-10, transforming growth 
factor (TGF)-β, prostaglandin (PGE)2 and MIC-A. IL-10 can suppress DC function and skew 
the T cell response towards the Th2 type, which is less effective in supporting 
tumor-reactive CTL formation and function than the Th1 counterparts. TGF-β inhibits DC 
activation as well, but also impairs T cell and NK cell function by diminishing T cell 
proliferation, down-regulating effector molecules such as perforin and IFN-γ, and blocking 
expression of the activating NK receptors NKp30 and NKG2D62. In addition, soluble MIC-A 
acts as a decoy factor mediating NK cell inhibition via occupation of the NKG2D receptor63. 
Another important factor secreted by tumor cells is indoleamine 2,3-dioxygenase (IDO), 
an enzyme that catalyzes the metabolization of the essential amino acid tryptophan via 
the kynurenine pathway64. This results in tryptophan depletion within the tumor micro-
environment, and subsequently induces cell cycle arrest and apoptosis of effector T cells.
 
Recruitment of suppressive immune cells
In addition to the direct immunosuppressive actions of the secreted soluble factors, these 
factors are also involved in recruitment of and differentiation into immunosuppressive 
immune cells, like regulatory T cells (T
REG
) and suppressive or tolerogenic APCs54;55. T
REG
 are 
characterized by the expression of CD25 and the transcription factor FOXP3, and are 
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cell lymphoma. Rituximab was approved in 1997, and both monotherapy and combination 
treatment with chemotherapy resulted in significantly increased progression-free survival 
and overall survival93;94. In chronic lymphoid leukemia (CLL) monotreatment with rituximab 
had low clinical activity, however in combination with fludarabine and cyclophospha-
mide prolonged progression-free survival was observed95. Importantly, the side effects of 
rituximab treatment are usually limited and reversible. 
 Antibody treatment can also be explored to improve immune effector expansion 
and function in vivo. T
REG
 present in the tumor micro-environment are known to suppress 
tumor-reactive T cell function. Therefore, anti-tumor immunity might be improved by 
depletion of these T
REG
. In order to do so different strategies have been developed that 
target the IL-2Rα chain, including denileukin diftitox (fusion protein of IL-2 and diphtheria 
toxin), LMB-2 (anti-CD25 immunotoxin) and daclizumab (anti-CD25 antibody)87. Recently, 
daclizumab was reported to reduce T
REG
 numbers and improve anti-tumor T cell responses 
following infusion with a cancer vaccine in patients with metastatic breast cancer96. 
However, in another study no improvement of anti-melanoma immunity was observed 
following daclizumab treatment, despite efficient depletion of T
REG
97. As activated effector 
T cells also express CD25, the protective anti-tumor responses are restrained as well. 
Hence, it is essential to transiently target the T
REG
 and limit the in vivo availability of 
daclizumab. Another exciting way to improve anti-tumor immune effector function is by 
favorably modulating the balance in co-stimulatory and co-inhibitory signals towards T 
cell stimulation. By administration of agonistic antibodies targeting co-stimulatory 
molecules, like CD28, 4-1BB and OX40, T cell activation and proliferation can be enhanced98. 
In addition, co-inhibitory interactions can be blocked using antagonistic antibodies 
targeting CTLA-4, PD-1 and BTLA to release the brake on T cell functionality79;98-101. The 
latter therapeutic strategy is described in more detail in Chapter 3, 4 and 5 of this thesis. 
Although, interference with these immune checkpoints seems a promising approach to 
increase anti-tumor immunity, one has to be careful not to elicit autoimmunity (i.e. GVHD 
in the allogeneic SCT setting).
Adoptive transfer of immune effector cells
The immune effector cells that play an important role in anti-tumor immunity are the T 
cells and NK cells102. Therefore, adoptive transfer of these potent effector cells is an 
appealing means to prevent or treat relapse of the tumor cells, and so far various strategies 
have been exploited. Nevertheless, specificity is crucial to avoid systemic toxicity. 
The major breakthrough for successful adoptive transfer was the implementation of an 
immunodepleting conditioning regimen prior to infusion103;104. Due to the resulting 
lymphopenia the infused cells are less easily rejected and can thus exert their effector 
function more efficiently. In addition, soluble factors, including IL-15, are released that 
promote survival of the transferred T and NK cells. One method to obtain sufficient 
numbers of T cells reactive against a TAA or MiHA is via isolation of these cells from the 
immune memory formation in order to prevent tumor relapse. Yet, severe treatment- 
related systemic toxicities should be avoided. Importantly, hematopoietic-restricted 
MiHAs, which are solely expressed by the redundant patient hematopoietic system and 
the hematological malignancy, hold the key to separate GVT and GVHD immunity after 
allogeneic SCT84;85. Currently, various immunotherapeutic strategies are being investigated 
to boost anti-tumor immunity, including systemic antibody treatment and cellular 
therapies like adoptive transfer of T cells and NK cells, and vaccination-based approaches 
using various antigen formulations or DCs. In addition to the exploration of these strategies 
as monotherapy, various combinations of antibody treatment, cellular therapy, 
chemotherapy and immunomodulatory drugs such as lenalidomide hold promise for 
future therapy of patients suffering from hematological malignancies.
Antibody treatment
Increasing numbers of clinical grade antibodies are being developed and investigated in 
the treatment of cancers. These antibodies can be applied as a monotherapy, but also in 
combination with other treatment modalities such as chemotherapy and cellular immuno-
therapy. Antibodies can mediate tumor clearance via various mechanisms86. Upon binding 
to the target molecule, the Fc-tail of the antibody can be recognized by Fc-receptors on 
NK cells resulting in subsequent NK degranulation and lysis of the target cell. Besides this 
antibody-dependent cell-mediated cytotoxicity (ADCC), cytolysis can also be mediated 
via activation of the complement system upon binding of complement components to 
the Fc-tail of the antibody. In addition, the antibody itself may directly affect signal 
transduction of the targeted molecule, or induce apoptosis. Furthermore, cytotoxic drugs 
or radionuclides can be coupled to the antibodies, thereby the target cells can be 
specifically damaged and patients will encounter less side effects than with regular 
treatment. Notably, this last approach requires internalization of the targeted molecule 
upon antibody crosslinking.
 For the treatment of hematological malignancies various monoclonal antibodies 
have been developed that target molecules highly expressed by the tumor cells. Amongst 
these are gemtuzumab (anti-CD33) and rituximab (anti-CD20)87;88. Notably, the expression 
of these target molecules is not restricted to malignant cells, and therefore also normal 
hematopoietic cells will be affected by antibody treatment. The gemtuzumab antibody 
was coupled to ozogamicin, a potent cytotoxic antibiotic, and has been used in the 
treatment of AML as in more than 80% of the patients CD33 is expressed by the leukemic 
blasts. Although, good overall response rates were observed in AML patients with relapsed 
disease89, this immunotoxin was withdrawn from the market in 2010 due to lack of benefit 
compared to standard chemotherapy, and treatment related toxicity90. Nevertheless, in 
certain patient subgroups treatment with adjusted doses of gemtuzumab ozogamicin 
had beneficial effects, and reassessment of this drug might be warranted91;92. In contrast, 
the anti-CD20 antibody rituximab is already part of standard treatment in patients with B 
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potential of this NK cell product is currently being explored in a phase I clinical trial in 
elderly AML patients who are not eligible for SCT.
Vaccination strategies
Patients can also be treated with tumor antigen presenting cell vaccines, either as 
monotherapy or in combination with T cell infusions and blockade of co-inhibitory 
signaling pathways, as these have the capacity to stimulate the tumor-reactive T cells in 
vivo. Another strategy is to infuse long peptides, which are engulfed, processed and cross-
presented by the patient’s DC subsets121. As these approaches allow in vivo antigen 
presentation, the natural cycle of T cell activation, expansion, contraction and memory 
formation is followed, ensuring long-term persistence of tumor-reactive T cell immunity. 
In the recent years, different vaccination strategies have been explored including vaccines 
of ex vivo generated DCs, DC fusions with tumor cells, and tumor cell lysates. 
 Nowadays, for immunotherapeutic purposes DCs are generally cultured from PB 
monocytes as high numbers of monocytes can be easily obtained from either patient or 
donor, and differentiated into mature DCs47;122. Depending on the tumor antigen, e.g. TAA 
or MiHA, against which T cell immunity should be elicited and its expression profile, the 
DCs might have to be loaded with the target antigen. In the setting of allogeneic SCT, re-
cipient-derived DCs express the MiHA endogenously and they can be infused without 
further modifications123. The advantage of this approach is that also currently unknown 
MiHAs are expressed by the DC vaccine, however these DCs can be compromised by the 
malignancy and treatment regimen. Another approach is the use of donor-derived DCs, 
which might be more potent and easier to obtain than those of the patient. Upon culture, 
donor-derived DCs have to be pulsed with the MiHA to be capable of eliciting MiHA-specific 
T cell responses. The advantage of using donor-derived DCs is that by exploiting hemato-
poietic-restricted MiHAs GVT immunity can be selectively boosted, without evoking 
severe GVHD124-126. Various antigen loading approaches have been developed, including 
co-culture of the DCs with tumor lysate, exogenous loading of the HLA molecules with a 
short peptide, and target antigen mRNA electroporation127-129. The limitation of peptide 
loading is that only one specific CD4+ or CD8+ T cell response can be induced, whereas DC 
pulsing with either tumor lysates or antigen mRNA allows natural processing and 
long-lasting presentation of a variety of different epitopes presented by both HLA class I 
and II molecules. In that way, the breadth of the elicited immune response could be 
strongly enlarged. 
 The feasibility and safety of DC-based vaccination in cancer patients has been shown 
for a number of malignant diseases, including melanoma, non-Hodgkin lymphoma and 
MM45;46;130-132. However, despite the induction of anti-tumor T cell responses and tumor 
regression in these DC-vaccinated patients, overall response rates and durable responses 
are not yet optimal. The magnitude of the anti-tumor immune responses, the functionality 
of the boosted T cells and the induction of long-term memory needs to be enhanced. 
effector repertoire of patients, followed by a fast expansion protocol105;106. However, the 
cytotoxic potential of these T cells might be suboptimal due to in vivo pre-exposure to 
immunosuppressive drugs and inhibitory factors in the tumor milieu. Another technique 
is the isolation and expansion of naive tumor-reactive T cells from a healthy donor by 
stimulation with peptide-presenting DCs107;108. However, this is a time-consuming and 
laborious process. The feasibility of both approaches has been demonstrated by several 
groups105-109. Importantly, one phase I trial reported in 5 out of 7 patients with relapsed 
leukemia a complete, but transient, remission upon adoptive transfer of MiHA-specific T 
cells expanded from post-transplant recipient PBMCs109. Unfortunately, the infused T cells 
failed to persist in vivo, which might be due to the terminal differentiation stage and, 
consequently, rapid exhaustion of these cells as a result of the extensive culture protocol. 
A third way to efficiently generate high numbers of tumor-reactive T cells with high-affinity 
TCRs is by gene transfer of the antigen-TCR α and β chains into donor T cells105;110. To 
prevent the induction of GVHD in patients treated with allogeneic SCT, the TCR genes 
should preferentially be transferred into donor T cells with a known specificity that cannot 
recognize and target GVHD-tissues, such as virus-specific T cells111. Another potential 
complication might be mispairing of the introduced and native TCR chains, thereby 
generating a new potentially harmful specificity112. Efforts are being made to prevent this 
mispairing, amongst which is the transfer of TCR α and β chains into γδ T cells. Successful 
TCR gene transfer and resultant cytolytic competence has been demonstrated for both 
TAAs and MiHAs113-116. Importantly, in the setting of allogeneic SCT matching of the HLA-
restriction allele between recipient and donor is no longer required, as with gene transfer 
the complete MiHA-TCR is introduced into the donor T cells. 
 In contrast to T cells, NK cell activation is only dependent on the balance of signals 
delivered by activating and inhibitory receptors. Since HLA class I molecules normally 
inhibit NK cell function, they will be activated and exert their cytolytic function in case of 
low HLA expression levels on the tumor cells. However, tumor cells can down-regulate 
surface expression of activating NK ligands, and secrete soluble decoy molecules that 
occupy the activating receptor NKG2D, and thereby interfere with the efficient 
NK-mediated recognition and elimination63. Importantly, anti-tumor responses have been 
observed in AML patients who received NK cell infusions, both in the allogeneic SCT and 
the non-transplant setting, without causing severe toxicity102;117. In addition, the infused 
NK cells even alleviated GVHD after allogeneic SCT. These characteristics designate NK 
cells as a promising immunotherapeutic strategy in the treatment of hematological 
malignancies118. Nevertheless, similar to the T cell infusions, long expansion and differen-
tiation culture protocols are required to obtain sufficient numbers of NK cells, and these 
might affect their in vivo functionality. Notably, in our group, a high log-scale expansion 
protocol was developed to culture large numbers of pure NK cells from umbilical cord 
blood CD34+ stem cells119. Upon differentiation, these NK cells expressed high levels of 
activating NK receptors and efficiently killed myeloid leukemia cells ex vivo119;120. The in vivo 
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clinical outcome post-transplantation. Importantly, we observed that disparity in 
autosomal MiHAs and detection of MiHA-specific T cell responses was associated with 
improved relapse-free survival, while the incidence and severity of GVHD was not affected.
 In Chapter 3 the role of co-inhibitory receptors in T cell immunity in hematological 
malignancies is reviewed. Numerous studies indicate that co-inhibitory pathways impair 
tumor-reactive T cell function in hematological and solid cancers, and contribute to tumor 
immune escape. Here, we discuss promising pre-clinical and clinical data of immunother-
apeutic approaches interfering with these co-inhibitory networks. In Chapter 4 we 
investigate whether the PD-1/PD-L pathway is involved in the functional impairment of 
GVT immune responses. We examine the expression levels of various co-stimulatory and 
co-inhibitory ligands on leukemic progenitor cells using flow cytometrical analysis. In 
addition, PD-1 expression on MiHA-specific T cells is analyzed. Finally, we stimulate these 
MiHA-specific T cells with peptide-loaded DCs in the presence of PD-1 blocking antibody. 
This resulted in enhanced MiHA-specific T cell expansion and cytokine production, 
especially in patients that developed relapsed disease. Beside PD-1, more co-inhibitory 
receptors may be involved in tumor immune escape. In Chapter 5 we study the role of 
the co-inhibitory receptor BTLA in the suppression of MiHA-specific T cell function after 
allogeneic SCT. First, we determine BTLA expression levels on MiHA-specific memory T 
cells using flow cytometry. Next, the expression of the BTLA ligand HVEM by various 
hematological malignancies is assessed. To investigate whether BTLA-HVEM signaling 
contributes to the functional impairment of MiHA-specific T cells we stimulate these T 
cells with DCs in combination with anti-BTLA and/or anti-PD-1 blocking antibody. 
Interestingly, some patients responded better to BTLA blockade, while others showed 
more pronounced effects following PD-1 blockade. The data in these chapters indicate 
that PD-1 and BTLA interactions contribute to the functional impairment of GVT immune 
responses, providing a rationale for incorporating co-signaling blockade against these 
receptors in post-transplant immunotherapy.
 However upon allogeneic SCT, the patient is in a highly activated immunological 
state due to chemotherapy-induced tissue damage and inflammation, especially in 
GVHD-prone target tissues such as skin and gut. Releasing immune checkpoints at this 
time could be dangerous, as T cells would home to the inflamed alloantigen-expressing 
GVHD sites and destroy healthy cells. Therefore, we developed another immunotherapeu-
tic strategy in Chapter 6. Here, we investigate whether we could augment MiHA-specific 
T cell responses by stimulation with PD-L1 and PD-L2 silenced monocyte-derived DCs. 
DCs are electroporated with PD-L1 and PD-L2 siRNA at the immature state, followed by 2 
days of maturation. Subsequently, we analyze DC phenotype and their capacity to 
stimulate either allogeneic or recall antigen T cell responses. Importantly, these PD-L 
knockdown DCs showed superior potential to expand ex vivo MiHA-specific CD8+ effector 
and memory T cells from leukemia patients. To generate a clinical-grade applicable DC 
vaccine with further improved immunogenic potential, we explore in Chapter 7 the 
Therefore, further improvement of DC vaccine potency is essential to increase the clinical 
benefit. The efficacy of DC vaccines is dependent on a variety of variables, including DC 
type, maturation status, antigen loading strategy, dosing and frequency of the vaccine 
infusions, and the route of administration130;133. Hence, more investigation is needed to 
improve these individual parameters to obtain the most optimal DC vaccine with high 
immunogenicity and potency to boost in vivo T cell responses. In this regard, we silenced 
the co-inhibitory molecules PD-L1 and PD-L2 and combined this with MiHA peptide or 
mRNA pulsing to improve DC immunogenicity, and demonstrated that these DCs exhibit 
superior potential to activate and expand naive and effector-memory MiHA-specific T cell 
responses (Chapter 6 and 7). The feasibility, safety and efficacy of vaccinating patients 
with these PD-L silenced DCs will be explored in an upcoming clinical study. Furthermore, 
strategies combining DC vaccination with other immunotherapeutic approaches such as 
DLI, transfer of MiHA-specific “stem cell-like” T cells, immunomodulatory drugs or blockade of 
negative regulatory pathways using antibodies are promising adjuvant treatment options 
in order to boost post-transplant GVT immunity.
Aims and outline of this thesis
Treatment of hematological malignancies with T cell-depleted allogeneic SCT followed by 
delayed add back of donor lymphocytes, has reduced the incidence and severity of GVHD 
and in that way has greatly improved the quality of life post-transplantation. Unfortunately, 
still too many patients relapse and even though in some patients MiHA-specific memory 
T cells are present, these T cells do not always efficiently respond to the recurring tumor 
cells. These observations suggest that the tumor cells suppress anti-tumor immune 
responses. For that reason, it is crucial to gain more knowledge on these immunosuppressive 
mechanisms exploited by the tumor cells in order to develop potent adjuvant immuno-
therapeutic approaches that can be applied after allogeneic SCT. The aim of this thesis is 
to explore the role of co-inhibitory molecules in the functional suppression of GVT 
immunity post-transplantation, and to investigate and explore different immunotherapeutic 
strategies that interfere with these negative signals to competently boost MiHA-specific T 
cell responses in order to prevent or treat recurrences of the tumor cells. 
 In Chapter 2, we sought to investigate further proof that MiHAs are crucial antigens 
in the beneficial GVT responses after allogeneic SCT. In a retrospective analysis, we 
assessed whether DNA disparity in either autosomal-encoded MiHAs or the ubiquitously-
expressed HY antigens is associated with less GVHD and improved relapse-free survival. 
Moreover, we zoom in on the importance of MiHA mismatching on post-transplant 
outcome of MM patients transplanted with a sibling graft. Finally, we study the 
immunogenic potential of MiHAs to induce specific T cell responses in mismatched 
patients, and analyze whether detection of these T cell responses correlates with better 
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Abstract
Allogeneic stem cell transplantation (allo-SCT) can induce remission in patients with 
hematological malignancies due to graft-versus-tumor (GVT) responses. This immune-
mediated anti-tumor effect, however, is often accompanied by detrimental graft-ver-
sus-host disease (GVHD). Both GVT and GVHD are mediated by minor histocompatibility 
antigen (MiHA)-specific T cells recognizing peptide products from polymorphic genes 
that differ between recipient and donor. In this study, we evaluated whether mismatches 
in a panel of seventeen MiHAs are associated with clinical outcome after partial T 
cell-depleted allo-SCT. Comprehensive statistical analysis revealed that DNA mismatches 
for one or more autosomal-encoded MiHAs was associated with increased relapse-free 
survival in sibling transplants (P =0.04), particularly in patients suffering from multiple 
myeloma (P =0.02). Moreover, mismatches for the ubiquitous Y chromosome-derived 
MiHAs resulted in a higher incidence of acute GVHD (grade 3-4; P =0.004), while 
autosomal MiHA mismatches, ubiquitous or restricted to hematopoietic cells, were not 
associated with severe GVHD. Finally, we demonstrated considerable differences 
between MiHAs in their capability to induce in vivo T cell responses using dual-color 
tetramer analysis of peripheral blood samples collected post-SCT. Importantly, detection 
of MiHA-specific T cell responses was associated with improved relapse-free survival in 
recipients of sibling transplants (P =0.01). Our findings provide a rationale to further 
boost GVT immunity towards autosomal MiHAs with a hematopoietic restriction to 
improve outcome after human leukocyte antigen-matched allo-SCT.  
Introduction
Allogeneic stem cell transplantation (allo-SCT) combined with donor lymphocyte infusion 
(DLI) is a potent treatment for patients with hematological malignancies1;2. Many clinical 
and experimental studies in human leukocyte antigen (HLA)-identical allo-SCT provide 
evidence that both the potentially curative graft-versus-tumor (GVT) effect and graft-ver-
sus-host disease (GVHD) develop as a result of donor T cell responses directed against 
disparate minor histocompatibility antigens (MiHAs)3-5. These MiHAs are polymorphic 
HLA-bound peptides derived from cellular proteins that can induce powerful alloreactive 
T cell responses. It has been demonstrated that emergence of MiHA-specific T cells 
precedes clinical remission in patients treated with DLI4;6;7. While various MiHAs, including 
Y chromosome-encoded MiHAs, are expressed ubiquitously, increasing numbers of auto-
somal-encoded MiHAs are being identified that are exclusively expressed by hematopoietic 
cells and their malignant counterparts8-10. The molecular identification of these GVHD- 
and GVT-associated MiHAs has made it possible to study the clinical impact of MiHA 
mismatches and their specific T cell responses post-transplantation.   
 Several studies in HLA-matched allo-SCT have reported an association between 
mismatches in MiHAs and clinical outcome. Mismatches in individual MiHAs, including 
HA-1, HA-2 and HA-8, have been associated with increased GVHD occurrence and lower 
relapse rates11-13, but other studies could not confirm these results14-16. Furthermore, 
previous studies have predominantly investigated cohorts of HLA-matched non-T 
cell-depleted transplants, and found only an increased rate of chronic GVHD (cGVHD) and 
reduced relapse rate upon HY MiHA disparity17;18. Moreover, investigation of the role of 
MiHA incompatibility in transplant outcome is hampered by the requirement to restrict 
studies to specific HLA types and low frequencies of particular MiHA alleles. Recently 
however, it was reported that HLA-A2+ chronic myeloid leukemia (CML) patients who 
developed acute GVHD (aGVHD) showed an improved overall survival (OS) and relapse-free 
survival (RFS) when receiving a transplant from a HA-1-mismatched donor19.
 In this study, we performed a retrospective analysis on the impact of a panel of 
seventeen immunogenic MiHA mismatches in a relatively large cohort of patients who 
received partial T cell-depleted allo-SCT. In sibling transplants, mismatches in one or 
more of the studied autosomal-encoded MiHAs resulted in an improved RFS (P =0.04), 
especially in multiple myeloma (MM) patients (P =0.02). In contrast, no significant 
association between autosomal MiHA mismatches and acute or chronic GVHD was 
observed, whereas the occurrence of a HY disparity led to more grade 3-4 aGVHD (P 
=0.004). Finally, this report describes for the first time the potential of disparate MiHAs 
to induce productive T cell responses post-transplantation. Tetramer analysis revealed 
that the ability of different MiHAs to mount specific CD8+ T cell responses post-trans-
plant varies strongly (0% - 60%). More importantly, presence of MiHA-specific T cell 
immunity was associated with improved RFS (P =0.01), without inducing severe aGVHD 
2
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months, and stopped at three months. Several patients received prophylactic or therapeutic 
DLI following transplantation. Prophylactic DLI was restricted to patients who had stopped 
CsA for at least three months, and had not developed aGVHD grade ≥2 or cGVHD.
Definition of outcome variables
Acute GVHD was graded according to the criteria of Przepiorka et al.24 and cGVHD was 
classified according to the revised Seattle criteria of Lee et al.25. Patient risk scores for 
outcome were determined according to the Gratwohl score26. OS, RFS, and non-relapse 
mortality (NRM) were defined according to the standard criteria proposed by the EBMT. 
MiHA genotyping using the KASPar system
HLA-matched SCT donor-recipient pairs were genotyped for a panel of 17 MiHAs with 
the KASPar assay system (KBioscience, Hoddesdon, UK), which is a fluorescence-based 
competitive allele-specific PCR using non-labeled primers. Details of this method can 
be found at http://www.kbioscience.co.uk. 
Tetramer staining and validation by T cell culture
PE- and APC-labeled MiHA tetramers were produced as described previously27. Tetramer 
stainings were performed directly on cryopreserved peripheral blood mononuclear 
cells (PBMCs) after thawing, and 7 days after ex vivo re-stimulation with the appropriate 
MiHA peptide28. For this, PBMCs were stimulated once with MiHA peptide-pulsed (10 
μM) Epstein-Barr virus lymphoblastoid cell lines (EBV-LCLs) on day 0. MiHA peptides 
were loaded on a corresponding EBV-LCLs stably transduced with either HLA-A2, -A3, or 
-B7. For additional HLA types (i.e. HLA-A24 and HLA-B8) matching healthy donor 
EBV-LCLs were used. After initial ex vivo re-stimulation, 100 IU/ml IL-2 (Chiron, Emeryville, 
CA) and 10 ng/ml IL-15 (Immunotools, Friesoythe, Germany) was added at days 2 and 5. 
For tetramer staining, ~1 x 106 cells were stained with 0.2 μg tetramer for 15 min at room 
temperature. The stability of all tetramers was verified using HPLC analysis in combination 
with a HLA-binding assay (MHC-ELISA or MHC-bead assay)29;30. In addition, the functional 
reactivity of all tetramers, except HEATR, was confirmed by staining cytotoxic T cell 
clones specific for the corresponding epitope, and subsequent flow cytometrical 
analysis. After tetramer staining, cells were washed with PBS/0.5% bovine serum albumin 
(BSA; Sigma, St Louis, MO, USA) and labeled with AlexaFluor700-conjugated CD8 
(Invitrogen, Carlsbad, CA, USA) in combination with FITC-conjugated CD4, CD14, CD16 
and CD19 (Beckman Coulter) for 30 min at 4°C. Finally, cells were washed and resuspended 
in PBS/0.5% BSA containing 0.2 μM Sytox Blue (Invitrogen) to allow dead-cell exclusion. 
Data acquisition was performed on a Cyan-ADP analyzer (Beckman Coulter) and 
analyzed using Kaluza 1.1 software (Beckman Coulter). CD8+ T cells were defined as 
viable Sytox Blue-negative, single-cell lymphocytes, CD8-positive and FITC (CD4, CD14, 
CD16, CD19) negative cells. Within the CD8+ T cell population, cells positive for both 
or cGVHD. Together, these data provide rationale for further boosting of GVT immunity 
towards autosomal hematopoietic-restricted MiHAs to improve relapse-free survival 
after HLA-matched allo-SCT.
Patients, materials and methods
Patients and donors
Three hundred and twenty-seven (N=327) adult SCT recipients and their donors were 
included in this study. They were selected from the total transplant cohort of our centre, 
treated between 1995 and 2010 with HLA-matched partial T cell-depleted allo-SCT for a 
hematological malignancy. HLA was typed using sequence-specific PCR. In sibling 
transplants, patients were transplanted with a HLA-identical sibling donor, and in 
matched unrelated transplants (MUD), patients were transplanted with an 8 to 10 out of 
10 HLA-matched voluntary donor, not considering HLA-DP. Only patient-donor couples 
with the HLA types HLA-A1, -A2, -A3, -A24, -B7, -B8 or -B44 were included, because the 
selected set of MiHAs was restricted to these HLA types. Furthermore, couples were 
selected based on the availability of both patient and donor material. The characteristics 
of patients, donors and SCT procedures are shown in Table 1. Patients and donors had 
given their informed consent to the prospective collection of data and samples for 
 investigational use, which was approved by the Radboud University Nijmegen Medical 
Centre’s Institutional Review Board. 
Treatment protocol
All patients were treated according to protocols described previously20-22. Myeloablative 
conditioning regimens consisted of cyclophosphamide (60 mg/kg for 2 days) in 
combination with either total body irradiation (TBI; 4.5 Gy for 2 days) or busulfan (4 mg/
kg for 4 days). Idarubicin (42 mg/m2 in 48 hours intravenously) was often added to 
reduce the risk of relapse in the setting of partial T cell-depleted SCT23. Non-myeloabla-
tive conditioning regimens consisted mainly of cyclophosphamide (1200 mg/m2 for 4 
days) in combination with fludarabine (30 mg/m2 for 4 days), sometimes only TBI (2 Gy). 
Patients receiving a MUD-graft received anti-thymocyte globulin (ATG) (2 mg/kg for 4 
days). After conditioning, patients received a partial T cell-depleted graft derived either 
from bone marrow (BM) or mobilized peripheral blood stem cells (PBSCs). The median 
number of CD34+ stem cells in the graft was 1.9 x 106 cells/kg (range 0.5-6.5) for BM and 
5.6 x 106 cells/kg (range 1.3-13.8) for PBSCs, and the median number of CD3+ T cells in BM 
grafts was 0.7 x 106 T cells/kg and in PBSC grafts 0.5 x 106 T cells (Table 1). GVHD prophylaxis 
consisted of cyclosporine A (CsA) only in almost all patients, and was dosed 1.5 mg/kg 
bidaily (bid) intravenously for the first two weeks, and thereafter 1 mg/kg bid intravenously 
or 2.5-3 mg/kg bid orally. Tapering of CsA was started in the absence of GVHD after two 
2
40 41
Chapter 2 MiHA disparity associates with RFS and GVHD after allo-SCT
tetramers (APC and PE) were quantified (Supplementary Figure 1). Patients were 
classified as having a positive tetramer response, when MiHA-specific CD8+ T cells 
(≥0.01% tetramer+ cells within the CD8+ T cell population) were found either directly 
after thawing, and/or 7 days after ex vivo peptide re-stimulation using peripheral blood 
samples obtained during the effector or memory phase of the immune response.
Statistical analysis
The outcome variables aGVHD and cGVHD, relapse, RFS, OS, and NRM after allo-SCT 
were analyzed in relation to MiHA disparity. Associations with RFS and OS were analyzed 
using Kaplan Meier curves and log-rank tests. Statistical differences in the RFS incidences 
at certain time points were analyzed using Kaplan Meier point estimates and their 
associated errors. Associations with cumulative incidences of aGVHD, cGVHD, relapse, 
and NRM were estimated respecting the presence of competing risks using the Gray 
test. As competing risks we considered death within 100 days from other toxicities or 
relapse for aGVHD, death after 100 days from other toxicities or relapse for cGVHD, NRM 
for relapse, and death from relapse for NRM.
 Furthermore, in case a P-value was ≤0.20 in univariable analyses, Cox regression 
analyses (for the endpoints RFS and OS) and Fine and Gray regression analyses (for the 
endpoints aGVHD, cGVHD, relapse, and NRM) were used to adjust for the following 
confounding risk factors: patient age, stem cell source, year of transplant, conditioning 
regimen, diagnosis-subgroup, CMV seropositivity of either recipient and/or donor, and 
2Table 1  Recipient, donor, and SCT characteristics (N=327)
Characteristic
Recipient age, years, mean (range) 46 (18-67)
Donor age, years, mean (range) 46 (11-71)
Recipient gender male, no (%) 195 (60%)
Donor gender male, no (%) 191 (58%)
Gender combination, no (%)
- Male patient/female donor
- Other
76 (23%)
251 (77%)
Donor relation, no (%)
- Matched sibling donor
- Matched unrelated donor
264 (81%)
63 (19%)
Disease category, no (%)
- AML/MDS
- ALL
- CML
- NHL/CLL
- MM
118 (36%)
34 (10%)
53 (16%)
67 (20%)
55 (17%)
Stem cell source
- Mobilized peripheral blood, no (%)
- CD34 x106/kg, median (range)
- CD3 x106/kg, median (range)
- Bone marrow, no (%)
- CD34 x106/kg, median (range)
- CD3 x106/kg, median (range)
175 (54%)
5.6 (1.3-13.8)
0.5 (0.04-1.7)
152 (46%)
1.9 (0.5-6.5)
0.7 (0.5-1.1)
SCT date, no (%)
- 1995-1999
- 2000-2004
- 2005-2010
98 (30%)
83 (25%)
146 (45%)
Conditioning regimens, no (%)
Myeloablative:
- (Ida)-Cy-Bus
- (Ida)-Cy-TBI
- Cy-ATG-Bus
- Cy-ATG-TBI
Non-myeloablative:
- Flu-Cy
- Flu-Cy-ATG
- TBI alone
18 (5.5%)
182 (55.5%)
8 (2.5%)
39 (12%)
50 (15.5%)
16 (5%)
14 (4%)
GVHD prophylaxis, no (%)
- Cyclosporine alone
- Cyclosporine/MMF
- None
305 (93%)
13 (4%)
9 (3%)
Disease status, no (%)
- Early
- Intermediate
- Advanced
193 (59%)
81 (25%)
53 (16%)
Table 1  Continued
Characteristic
Diagnosis before SCT, no (%)
- ≤ 1 year
- > 1 year
205 (62.5%)
122 (37.5%)
CMV status, no (%)
- Negative/negative
- Other combination
- Missing
76 (23%)
229 (70%)
22 (7%)
Gratwohl score, no (%)
- Score 0
- Score 1
- Score 2
- Score 3
30 (9%)
183 (56%)
93 (28.5%)
21 (6.5%)
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic 
leukemia; CML, chronic myeloid leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic lymphoid leukemia; MM, 
multiple myeloma; SCT, stem cell transplantation; Ida, idarubicin; Cy, cyclophosphamide; Bus, busolfan; TBI, total 
body irradiation; ATG, anti-thymocyte globulin; Flu, fludarabine; MMF, mycophenolate mofetil; GVHD, graft-versus-
host disease; CMV, cytomegalovirus. 
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Autosomal MiHA disparity is associated with improved relapse-free survival in 
sibling transplants
Statistical analysis revealed that mismatches in the studied MiHAs did not have an 
impact on relapse-free survival in the complete transplant cohort (Figure 3A). Because 
recipients transplanted with a MUD graft might have a HLA-DP mismatch, as well as a 
higher rate of unknown MiHA mismatches, we separately analyzed the effect of disparities 
in known MiHAs on clinical outcome in the sibling cohort (N=264). Interestingly, 
recipients transplanted with an autosomal MiHA-mismatched sibling graft showed 
significantly better RFS in multivariable analysis (HR 0.68, 95%CI: 0.48-0.98, P =0.04; 
Figure 3B, Table 3). This beneficial effect of autosomal MiHA disparity on RFS could be 
aGVHD grade 2-4. Analyses were performed using SAS 8.2 software and the cmprsk 
package of open source language R version 2.6.2. (www.r-project.org). P-values <0.05 
were considered statistically significant. MiHA mismatch parameters were defined as 
disparate HY (HY MiHAs restricted to HLA-A2, -B7 or -B8), disparate HA-1, and disparate 
autosomal MiHAs (mismatched for one or more MiHAs listed in Table 2, excluding for HY).
Results
Clinical outcome parameters after HLA-matched allo-SCT
We analyzed the clinical outcome after partial T cell-depleted allo-SCT in patients 
(N=327) suffering from a hematological malignancy. The median follow-up of patients 
alive at last follow-up was 7.1 years (range 0.5-17), and 1.1 years (range 0.05-12.6) in those 
who died. In Figure 1A-B, the survival curves for OS (5 year: 68%) and RFS (5 year: 44%) 
are depicted for the complete cohort. NRM after 5 years was 15.6% (i.e. 43.4% of all 
deaths, Figure 1C) and 40.4% of the patients experienced relapse. Acute GVHD occurred 
in 19.6% of patients and was severe (grade 3-4) in only 6.5%. Of all evaluable patients, 
22.7% developed limited cGVHD and 14.2% extensive cGVHD.  
MiHA allele frequency and phenotype disparity rate 
To determine the MiHA allele frequency and disparity rates, recipient and donor DNA 
was typed. Paired couples were only genotyped when the appropriate HLA molecule 
was expressed to which the MiHA is restricted, leading to actual immunogenic disparity 
rates. HY.A2, HY.B7 or HY.B8 disparity was scored when a female-donor-male-recipient 
(FDMR) transplantation was performed. The highest disparity rates, within the restricting 
HLA type, were observed for all Y chromosome-derived MiHAs (20.9%-26.5%), as well as 
for ACC-2 (25.0%), LRH-1 (19.6%) and HA-1 (16.4%). Overall, 60 (18.2%) and 137 (41.6%) of 
the 327 pairs were disparate for Y-chromosome or autosomal chromosome encoded 
MiHAs, respectively (Table 2).
HY disparity is associated with increased aGVHD 
In HY mismatched patients a significantly higher grade 3-4 aGVHD incidence of 19% at 
day 100 after SCT was observed than in HY matched patients (4%; univariable analysis 
P <0.001) when respecting for the presence of competing risks. Multivariable analysis 
confirmed this association for HY incompatibility with the increased risk to develop 
aGVHD grade 3-4 (hazard ratio (HR) 4.1, 95% confidence interval (CI): 1.6-10.3, P <0.001 
Figure 2A). Notably, none of the non-sex linked MiHA mismatched categories (HA-1 or 
autosomal MiHAs mismatched) showed an association with acute or chronic GVHD 
(Figure 2A-B), possibly due to the hematopoietic-restricted tissue expression pattern of 
the majority of the autosomal MiHAs tested.
2
Figure 1   Clinical outcome parameters after partial T cell-depleted allo-SCT
Within the complete cohort of allo-SCT recipients, (A) overall survival, (B) relapse-free survival and 
(C) the cumulative incidence of non-relapse mortality (NRM) was analyzed using Kaplan Meier 
analysis. Allo-SCT, allogeneic stem cell transplantation.
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MM patients show improved RFS upon transplantation with a MiHA-mismatched 
sibling graft
Interestingly, our multivariable analysis including the correction for diagnosis subgroups 
revealed an association between autosomal MiHA disparity and improved RFS in 
HLA-matched sibling transplantation, which indicates a diagnosis independent effect. 
To study which patients benefit the most from a disparity in the studied MiHAs, we 
separately analyzed the influence of MiHA mismatches on clinical outcome in different 
diagnosis subgroups. Notably, we were only able to confirm the significant correlation 
between the occurrence of a disparate autosomal MiHA and clinical outcome in the MM 
subgroup. Of the 22 mismatched MM patients, 15 patients were mismatched for 1 MiHA, 
6 patients for 2 MiHAs and 1 patient for 4 MiHAs. Importantly, transplanted MM patients 
showed improved RFS when at least one autosomal MiHA mismatch was present (HR 
0.41, 95%CI: 0.19-0.89, P =0.02, Figure 4A). In addition, patients with an autosomal MiHA 
mismatch developed significantly less relapse as observed in univariable Fine and Grey 
competing risk analysis (HR 0.46, 95%CI: 0.21-1.00, P =0.049, Figure 4B). The occurrence 
attributed to both a trend in improved NRM (HR 0.59, 95%CI: 0.29-1.25, P =0.19) and less 
relapse (HR 0.77, 95%CI: 0.50-1.11, P =0.14) as assessed in multivariable Fine and Gray 
competing risk analyses. Furthermore, also in sibling allo-SCT HY disparity was associated 
with a higher incidence of grade 3-4 aGVHD (HR 4.2, 95%CI: 1.6-10.9, P =0.004, Table 3). 
Analysis of clinical outcome in recipients of a MUD graft (N=61) showed no significant 
associations of MiHA disparity with neither RFS (Figure 3C) nor aGVHD (data not shown). 
Taken together, these data indicate that recipients of a HLA-identical sibling donor stem 
cell graft that is mismatched for the studied autosomal MiHAs may induce beneficial GVT 
immunity post-SCT.
2
Table 2   MiHA disparity rate
MiHA HLA 
restriction
Peptide 
sequence
Reference NA Number of disparate 
pairs (rates)B
HA-3 A1 VTEPGTAQY 40 82/87 3 (3.7%)
HA-1 A2 VLHDDLLEA 41 195/197 32 (16.4%)
HA-2 A2 YIGEVLVSV 42;43 195/197 6 (3.1%)
HA-8 A2 RTLDKVLEV 44 194/197 22 (11.3%)
HY A2 FIDSYICQV 9 197/197 42 (21.3)
ADIR A2 SVAPALALAFPA 45 195/197 30 (15.4%)
HwA11 A2 CIPPDSLLFPA 46 195/197 6 (3.1%)
SP110 A3 SLPRGTSTPK 47 92/93 7 (7.6%)
PANE1 A3 RVWDLPGVLK 48 92/93 5 (5.4%)
ACC-1 A24 DYLQYVLQI 49 54/54 6 (11.1%)
ACC-2 B44 KEFEDDIINW 49 64/65 16 (25.0%)
LRH-1 B7 TPNQRQNVC 35 97/98 19 (19.6%)
HY B7 SPSVDKARAEL 8 98/98 26 (26.5%)
ECGF B7 RPHAIRRPLAL 50 97/98 5 (5.2%)
ZAPHIR B7 IPRDSWWVEL 51 97/98 12 (12.4%)
HY B8 LPHNMTDL 52 67/67 14 (20.9%)
HEATR B8 ISKERAEAL 53 64/67 8 (12.5%)
AN, number of patient donor couples typed, within the total number of couples presenting the correct HLA 
molecule. BThe number of disparate pairs and disparity rates of a particular MiHA were determined within all typed 
couples presenting the correct HLA molecule.
Figure 2   Occurrence of GVHD following MiHA-mismatched transplantation
Within the complete cohort, the incidence of (A) aGVHD grade 3-4 and (B) limited/extensive cGVHD 
was analyzed using Fine and Gray competing risk regression models. Groups were categorized 
based on MiHA disparity in mismatched and matched at the DNA level. GVHD, graft-versus-host-
disease; MiHA, minor histocompatibility antigen.
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of a disparate MiHA was also correlated with an increase in limited cGVHD (univariable 
analysis P =0.03, Figure 4C). Notably, the effects on clinical outcome parameters were 
not a result of differences in disease status between MiHA matched and mismatched 
patients (Figure 4D). Interestingly, 22.6% of the MiHA mismatched MM patients had a 
HA-1 disparity (Figure 4E). HA-1 disparity was previously reported to be associated with 
improved RFS in CML patients who developed aGVHD19. Altogether, these data suggest 
that mismatches in the studied MiHAs induce improved graft-versus-myeloma immunity 
following partial T cell-depleted sibling allo-SCT. 
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s. Figure 3   Autosomal MiHA disparity is associated with increased relapse-free survival 
after transplantation with a sibling graft
Relapse-free survival was analyzed for (A) the complete cohort of recipients versus patients trans-
planted with (B) a sibling graft or (C) an unrelated graft using the log-rank test. Groups were cate-
gorized based on autosomal MiHA disparity in mismatched (black line) and matched (grey line) at 
the DNA level. Allo-SCT, allogeneic stem cell transplantation; N, number of patients within the 
group; MiHA, minor histocompatibility antigen. a P-value of multivariable analysis is given.
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Ability to induce tetramer+ MiHA-specific T cell responses varies among MiHAs
Although genetic MiHA incompatibility shows significant differences on clinical outcome 
post-SCT, this does not necessarily mean that corresponding T cell responses actually 
occur. Therefore, we investigated the potential of 15 of the 17 studied MiHAs to induce 
productive MiHA-specific T cell responses in vivo. For this, we analyzed recipient PBMC 
material obtained at a median of 9 months (range 2-70 months) after allo-SCT using a 
dual-color MiHA-multimer approach. Patients were classified as having a positive 
tetramer response, when MiHA-specific CD8+ T cells were detected directly after thawing 
and/or after one ex vivo peptide re-stimulation. Although we were unable to analyze all 
patients at the same time interval, we believe that a positive detection of MiHA tetramer+ 
CD8+ T cells at variable time points reflects either an ongoing effector immune response, 
or a sustained effector-memory response after immune contraction. In Figure 5A, 
representative tetramer screenings of three different allo-SCT recipients are depicted. 
Already in freshly thawed samples low numbers of MiHA-specific CD8+ T cells were 
observed in 27 out of 40 (67.5%) MiHA T cell responsive patients. In addition, in 13 out of 
40 (32.5%) responsive patients, tetramer+ T cells were detectable after 1 week stimulation 
with MiHA peptide-pulsed EBV-LCLs. Notably, when examining the whole cohort of 
MiHA-mismatched recipients, certain MiHA-specific T cell responses were observed 
more frequently than others (Figure 5B). Especially, disparity for HA-1, HA-2, PANE1, 
LRH-1, ACC-1 and the HY-chromosome encoded antigens HY.A2 and HY.B7 resulted in 
MiHA-specific CD8+ T cell responses in 25-60% of the MiHA-mismatched patients. HA-8-, 
SP110- and ZAPHIR-specific CD8+ T cells were found in 10-20%. In contrast, no productive 
CD8+ T cell responses against ADIR, HwA11, ECGF, HEATR and HY.B8 were observed, 
despite genetic disparity. These results indicate that certain MiHAs appear relatively 
more productive in inducing MiHA-specific CD8+ T cell responses after partial T 
cell-depleted allo-SCT than others. 
 Finally, we examined whether presence of a MiHA-specific T cell response, including 
those targeting autosomal MiHAs (N=25 in the complete cohort, and N=20 in the SIB 
cohort) or HY (N=15 in both the complete cohort and the SIB cohort), was associated 
with improved outcome post-transplantation. When analyzing the whole RFS curves 
no significant differences were observed (complete cohort: HR 0.82, 95%CI: 0.52-1.30, 
P =0.39; SIB cohort: HR 0.73, 95%CI: 0.44-1.22, P =0.23). Nevertheless in the first years 
after allo-SCT, the RFS of patients with and without a MiHA-specific T cell response 
clearly differs. Therefore, the RFS incidences at 3 years post-transplant were compared 
and we found that detection of MiHA-specific T cell responses was associated with 
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Figure 4   Multiple myeloma patients transplanted with a related MiHA-mismatched 
graft show improved relapse-free survival
Multiple myeloma patients transplanted with a sibling graft were grouped based on autosomal 
MiHA disparity in mismatched and matched at the DNA level. Between these subgroups differences 
in (A) relapse-free survival and (B) relapse were analyzed using the log-rank test and Fine and Gray 
competing risk regression model, respectively. N, number of patients within the group. P-values of 
univariable analyses are given. (C) The incidence of cGVHD and (D) disease status was analyzed 
using the Fisher Exact test. (E) Within the total of mismatched MiHAs, the relative contribution of 
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improved RFS in both the complete cohort (RFS incidence of 69% vs. 51%, univariable 
analysis P =0.03, Figure 5C), as well as in the sibling transplants (RFS incidence of 73% vs. 
52%, univariable analysis P =0.01, Figure 5D). Notably, this association with improved RFS 
at 3 years after allo-SCT can be mainly attributed to less relapse in patients with a 
MiHA-specific T cell response (complete cohort: relapse incidence of 26% vs. 39%, P 
=0.09; SIB cohort: relapse incidence of 24% vs. 40%, P =0.047), and to a smaller extent to 
improved NRM (complete cohort: NRM incidence of 5% vs. 10%, P =0.26; SIB cohort: 
NRM incidence of 3% vs. 9%, P =0.10) as assessed in univariable Fine and Gray competing 
risk analyses. Despite inclusion of T cell responses against ubiquitously expressed MiHAs, 
including HA-8 and HY (i.e. 17 out of 40 or 35 in the complete and the SIB cohort 
respectively), the incidence of neither grade 3-4 aGVHD (P >0.7) nor limited/extensive 
cGVHD was affected (P >0.2; both univariable Fine and Grey competing risk analysis). To 
conclude, these results indicate that productive MiHA-specific T cell responses 
contribute to the beneficial GVT immunity following partial T cell-depleted allo-SCT.
Discussion
As the dominant target antigens in HLA-matched allo-SCT, MiHAs play a pivotal role in 
both GVT responses, as well as GVHD. Precise understanding of involved MiHA-specific 
T cell responses may not only lead to a better prediction of clinical outcome in allo-SCT 
recipients, but also provide a rationale for the selection of the most potent MiHAs in 
post-transplant immunotherapy. Interestingly, our statistical analyses of immunogenic 
MiHA disparity rates in sibling transplants revealed that DNA mismatches in autosomal-
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Figure 5   Detection of tetramer+ MiHA-specific CD8+ T cell responses is associated with 
improved RFS after allo-SCT
Recipient PBMC samples obtained after allo-SCT were analyzed for presence of MiHA-specific CD8+ 
T cells using the dual-color MiHA-multimer flow cytometry assay. Patients were classified as having 
a positive tetramer response, when MiHA-specific CD8+ T cells were found directly after thawing, or 
7 days after stimulation with peptide-loaded EBV-LCLs. (A) The number in the dot plots indicates 
the percentage of MiHA-specific cells positive for both tetramers (PE and APC) within the CD8+, 
CD4-, CD14-, CD16-, CD19- T cell population. Three representative examples are shown. (B) For each 
disparate MiHA, the number of tetramer+ responses (white bars) within the total number of scree-
nings (grey bars) is depicted for the complete cohort of MiHA-mismatched recipients. Percentages 
indicate the relative number of productive responses. (C-D) Relapse-free survival was analyzed for 
(C) the complete cohort of recipients versus (D) patients transplanted with a sibling graft using the 
log-rank test. Groups were categorized based on detection of MiHA-specific T cell responses (black 
line) vs. no MiHA-specific T cell responses or no mismatching for any of the studied MiHAs (grey line) 
after allo-SCT. Allo-SCT, allogeneic stem cell transplantation; N, number of patients within the group; 
MiHA, minor histocompatibility antigen. Statistical differences in RFS incidences were analyzed 
using Kaplan Meier point estimates and their associated errors, univariable P-values are given.
52 53
Chapter 2 MiHA disparity associates with RFS and GVHD after allo-SCT
independent effect. However, we could only confirm the observed significant correlation 
between the occurrence of disparate autosomal MiHAs and improved RFS in the MM 
subgroup. The reason why we did not observe similar effects in the other diagnosis-
subgroups could be related to differences in the immune susceptibility of the various 
malignancies and the number of patients included in this study. Furthermore, partial T 
cell-depleted SCT results in a low incidence of acute and chronic GVHD, which might 
have downgraded the clinical impact of MiHA mismatches. When focusing on patients 
suffering from MM within the sibling cohort, an evident role for disparate MiHAs on 
both relapse incidence, as well as RFS was observed independent of disease status. 
Moreover, the occurrence of disparate MiHAs was also associated with a higher 
incidence of limited cGVHD. These results show that especially MM patients can benefit 
from a MiHA-driven GVT effect in the presence of an acceptable degree of cGVHD. It is 
well known that MM is an immunogenic tumor and that patients can respond well to 
DLI33;34. This phenomenon could be the result of multiple factors, likely including high 
antigen presentation, good susceptibility to killing, and possibly a good window for 
immune recognition and killing due to the relatively slow tumor growth. Furthermore, 
post-transplant treatment with immunomodulatory drugs such as lenalidomide has a 
promoting impact on GVT immunity. 
 Overall, we observed low incidence of aGVHD (6.5% grade 3-4) in our partial T 
cell-depleted setting, even when ubiquitous expressed MiHA mismatches were present. 
This indicates that there is a potential safe clinical application for transplant mismatching 
of certain strongly immunogenic MiHAs in allo-SCT. Previously, the MiHAs HA-1, HA-2, 
LRH-1 and ACC-1 have been implicated to selectively induce a GVT effect without 
GVHD7;35-37. We show that they are also potent in inducing MiHA-specific T cell responses 
in vivo, adding to the promise of these MiHAs not only in transplant mismatching but 
also in vaccination or adoptive T cell strategies. However, timing of the tetramer-based 
analysis of post-transplant PBMC samples is crucial in detecting MiHA-specific T cell 
responses, and our study had a rather wide time frame of sampling after allo-SCT, which 
probably resulted in underscoring of the frequency of positive responses. In addition, 
some of the MiHA-specific T cell responses could be masked (subdominant) by other 
(un)known MiHAs. Moreover, the underlying malignancy might skew the MiHA-specific 
T cell repertoire towards a particular hematopoietic compartment such as the BM, 
which may prevent the detection of MiHA-specific T cells in peripheral blood. Therefore, 
absence of tetramer+ T cells during analysis does not necessarily mean a complete lack 
of MiHA-specific T cells in vivo. Nevertheless, we observed that presence of MiHA-specific 
T cell responses resulted in improved RFS at 3 years after allo-SCT despite heterogeneity 
of the cohort. However, after 5 years the RFS curves of patients with and without 
MiHA-specific immunity no longer differ. As the group size is relatively limited at start 
and becomes even smaller in time due to positive events or censoring of patients, the 
data are likely less reliable at late time-points. Furthermore, due to the heterogeneity of 
encoded MiHAs are associated with improved clinical outcome. In particular, MM 
patients showed a lower incidence of relapse and increased RFS when transplanted 
with a MiHA-mismatched sibling transplant. In addition, we demonstrated considerable 
variance in the relative immunogenicity of different MiHAs in inducing productive T cell 
responses post-transplantation. Most importantly, presence of these MiHA-specific T 
cell responses was associated with improved GVT immunity after partial T-cell depleted 
allo-SCT.
 Characteristics of all recipients and their corresponding donors were analyzed for 
clinical outcome parameters (Table 3). Importantly, we observed that mismatched 
autosomal MiHAs, including those with a ubiquitous expression pattern, were not 
correlated with higher incidences of severe acute or chronic GVHD after partial T 
cell-depleted SCT. In accordance with previous reports, only the HY MiHA was associated 
with increased frequency of grade 3-4 aGVHD. Similar findings were previously reported 
by Gratwohl et al.18 and Stern et al.31 who used female-to-male alloreactivity as a model 
for MiHA HY mismatches. However, not only MiHAs play an important role in the FDMR 
transplants, also non-inherited maternal/paternal antigens (NIMA and NIPA) are involved. 
In non-T cell-depleted haploidentical sibling NIMA-mismatched allo-SCT, lower aGVHD 
rates were observed than in NIPA-mismatched recipients32. In our current study, we have 
no information on the NIMA or NIPA status of the transplant couples and cannot exclude 
the influence of these antigens on clinical outcome after partial T cell-depleted allo-SCT. 
Moreover, unknown MiHAs not present in our panel and other general genetic 
disparities might be important as well. Therefore, we analyzed patients transplanted 
with a sibling donor separately, thereby circumventing the higher likelihood of unknown 
polymorphic differences between recipients and donors. Analysis showed again a role 
for a disparate HY MiHA, and although more cases of severe aGVHD (grade 3-4) were 
observed, this gender mismatch showed a trend towards a lower incidence of relapse 
(P =0.095; Table 3), which was previously reported by Gratwohl et al.18. 
 Our findings indicate that a disparity in at least one known autosomal MiHA was 
associated with higher RFS, without increasing aGVHD incidence or severity after partial 
T cell-depleted allo-SCT. This contribution of autosomal MiHA mismatches to improved 
RFS in the sibling transplant setting becomes even more apparent when compared 
with patients transplanted with a MUD graft. In the MUD cohort, effects of mismatched 
MiHAs on RFS could not be observed, which might be attributed to the smaller size of 
this cohort. Furthermore, these MUD patients receive ATG treatment20, which results in 
an additional in vivo T cell depletion, thereby reducing the chance of inducing 
tumor-reactive MiHA-specific T cell responses. 
 Besides the role of alloreactive T cells in the GVT response, the underlying 
malignancy of the recipients might also be important. We found that autosomal MiHA 
disparity in sibling transplants was associated with improved RFS in multivariable 
analysis, which included the correction for diagnosis subgroups, suggesting a diagnosis 
2
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the cohort, over time the patient group is likely skewed toward late-relapsing malignancies 
with low immunogenicity. It could also well be that the patients that develop late 
relapses have impaired MiHA-specific T cell immunity due to immune escape mechanisms 
exploited by surviving tumor cells, like the PD-1/PD-L1 and BTLA/HVEM co-inhibitory 
pathways as we have reported previously38;39. Due to this negative signaling T cells can 
become exhausted in time, and patients may lose the advantage of having MiHA-specific 
immunity post-transplantation. 
 Importantly, occurrence of these in vivo MiHA-specific T cell responses, including 
those recognizing ubiquitously expressed MiHAs, amongst which the HY antigens, was 
not associated with an increased incidence of severe acute or chronic GVHD. 
Unfortunately, the group of patients having MiHA-specific T cell immunity was too small 
to focus on diagnosis subgroups or perform multivariable analyses. Therefore, these 
observations should be confirmed in a larger and more homogenous cohort of allo-SCT 
recipients with longer follow-up. 
 In conclusion, this study shows that the occurrence of MiHA mismatches is associated 
with improved clinical outcome after partial T cell-depleted HLA-matched allo-SCT, 
particularly in MM patients but likely also in other hematological malignancies. The 
observed positive effects might be attributed to MiHA-specific CD8+ T cells inducing 
GVT responses. However, not all MiHAs seem to have the same potential to induce 
MiHA-specific T cells as was shown by tetramer analysis of PBMC samples collected 
post-transplant. By further studying the MiHAs that are most productive in this respect, 
we can select hematopoietic-restricted MiHAs as safe and potent target antigens in 
allo-SCT in order to prevent or treat tumor recurrences with post-transplant immuno-
therapeutic strategies.
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Supplementary Figure 1   
Gating strategy for detection of tetramer+ MiHA-specific T cell responses
Recipient PBMC samples, obtained after allo-SCT or DLI were stained with MiHA-tetramers in PE and 
APC, CD8-AlexaFluor 700, CD4-, CD14-, CD16- and CD19-FITC and Sytox Blue. Subsequently, cell 
 populations were analyzed by flow cytometry. Sytox blue- single cells were selected and gated on 
CD8+FITC - lymphocytes. Within this population the percentage of cells positive for both tetramers 
was determined.
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Abstract
The adaptive immune system can be a potent defense mechanism against cancer, 
however it is often hampered by immune suppressive mechanisms in the tumor micro-
environment. Co-inhibitory molecules expressed by tumor cells, immune cells and stromal 
cells in the tumor milieu can dominantly attenuate T cell responses against cancer cells. 
Today, a variety of co-inhibitory molecules, including CTLA-4, PD-1, BTLA, LAG3, TIM-3 and 
CD200R, have been implicated in immune escape of cancer cells. Sustained signaling via 
these co-inhibitory molecules results in functional exhaustion of T cells, during which the 
ability to proliferate, secrete cytokines and mediate lysis of tumor cells is sequentially lost. 
In this review, we discuss the influence of co-inhibitory pathways in suppressing autologous 
and allogeneic T cell-mediated immunity against hematological malignancies. In addition, 
promising pre-clinical and clinical data of immunotherapeutic approaches interfering 
with negative co-signaling, either as monotherapy or in conjunction with vaccination 
strategies, are reviewed. Numerous studies indicate that co-inhibitory signaling hampers 
the clinical benefit of current immunotherapies. Therefore, manipulation of co-inhibitory 
networks is an attractive adjuvant immunotherapeutic intervention for hematological 
cancers after standard treatment with chemotherapy and hematopoietic stem cell 
 transplantation.
Introduction
Despite the powerful aspects of immune reactions, most often tumor cells are able to 
evade immune recognition and destruction. Mechanisms exploited by tumor cells to 
escape T cell-mediated immunity include disruption of antigen presentation, down- 
regulation of HLA molecules, secretion of immune suppressive cytokines, as well as 
recruitment of regulatory T cells (T
REG
) and myeloid-derived suppressor cells1. In the last 
decade, another powerful immune suppressive mechanism gained much attention: the 
repressive action of co-inhibitory molecules2. Activation of T cells is predominantly 
dependent on both co-stimulatory and co-inhibitory molecules, including members of 
the B7/CD28 family. The balance between positive and negative co-signals determines the 
functionality of T cells during immunity and tolerance. In addition to the native role of 
co-signaling, tumor cells can evade immune control by down-regulating co-stimulatory 
molecules such as CD80 and CD86, and up-regulating various co-inhibitory ligands, 
thereby limiting the therapeutic potential of current immunotherapy against cancer. 
 Standard treatment for hematological cancers includes chemotherapy and radio -
therapy, which reduce tumor burden and can induce long-term remission. Moreover, in 
the past years new therapeutics, including imatinib, dasatinib, rituximab, bortezomib and 
lenalidomide, have been developed that target tumor cells. However, drug resistance and 
relapse remain major problems. In addition, cellular immunotherapy is an attractive 
treatment option to cure hematological malignancies. Such cell-based immunotherapies 
include allogeneic stem cell transplantation (allo-SCT), T cell and NK cell adoptive transfer, 
and vaccination-based approaches using various antigen formulations or dendritic cells 
(DCs). Allo-SCT can be regarded as the most powerful cell-based immunotherapy, due to 
the graft-versus-tumor (GVT) responses constituted by alloreactive T cells3. These 
alloreactive T cell responses eradicate the malignant cells upon recognition of polymorphic 
HLA-presented peptides, known as minor histocompatibility antigens (MiHAs). Allo-SCT 
greatly enhanced the cure rate for aggressive hematological cancers, although many 
patients fail to launch productive immune responses and develop relapses. Moreover, a 
major drawback of allo-SCT is the occurrence of graft-versus-host disease (GVHD), a 
potentially life-threatening side effect predominantly caused by alloreactive T cells 
recognizing healthy tissues, notably the skin, liver and gastrointestinal tract. Since hemato- 
restricted MiHAs are solely expressed by the redundant patient hematopoietic system 
and the hematological malignancy, they hold the key to separate GVT from GVHD4. 
Studies by us and others demonstrated that the cellular immunotherapies described 
above are often hampered by the action of co-inhibitory molecules that attenuate 
tumor-reactive T cell responses, resulting in sub-optimal clinical results. This review will 
address the role of co-inhibitory molecules in immune evasion by hematological 
malignancies, and discuss options to circumvent T cell inhibition without severe adverse 
effects. In addition, we address whether a differential effect of co-inhibitory molecules 
3
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exists in GVT and GVHD, creating an opportunity to limit GVHD toxicity without dampening 
anti-tumor immunity.
Co-inhibitory molecules in hematological malignancies
Today a variety of co-inhibitory molecules have been implicated in immune escape of 
cancer. Here, we will discuss the co-inhibitory molecules involved in suppressing 
anti-tumor immunity against hematological malignancies (summarized in Table 1).  
CTLA-4
Expression and function of CTLA-4
Cytotoxic T lymphocyte associated antigen-4 (CTLA-4; CD152) was the first co-inhibitory 
molecule identified, and is partly similar to the co-signaling molecule CD285. However, 
while CD28 is constitutively expressed on the membrane of naive T cells, CTLA-4 is 
primarily localized in intracellular compartments and rapidly translocates to the cell 
membrane upon T cell activation. The inhibitory function of CTLA-4 was revealed in 
knockout mice, which developed lethal lymphoproliferative disease with multiorgan T cell 
infiltration6. Like CD28, CTLA-4 has an extracellular domain containing the MYPPPY binding 
motif, enabling both receptors to interact with CD80 (B7-1) and CD86 (B7-2) expressed by 
antigen-presenting cells (APCs). However, the binding affinity of CTLA-4 for these ligands 
is 10-100 fold higher, thereby outcompeting CD28 and promoting immune inhibition7.
 As CTLA-4 is up-regulated upon T cell receptor (TCR) ligation, it plays an important 
role in dampening effector T cell activation and regulating immune homeostasis. 
Additionally, CTLA-4 signaling in immunosuppressive T
REG
 mediates the control of 
auto-reactive T cells, as in vivo interference with CTLA-4 on these cells elicited pathological 
autoimmunity8. The effect of CTLA-4 interference could either be due to depletion and/or 
inhibition of T
REG
. Wing et al. showed that T
REG
-specific CTLA-4 deficiency resulted in 
impaired suppressive T
REG
 function, since CTLA-4 enables the down-regulation of CD80/
CD86 on APCs9, which can be partly due to endocytosis of CD80 and CD86 by T
REG
10. This 
renders a less stimulatory APC, resulting in a lasting cell-extrinsic inhibitory effect. CTLA-4 
signaling can attenuate adaptive immune responses in chronic viral infections and cancer. 
CTLA-4 as such is not a marker of exhausted cells, but elevated levels on viral antigen-
specific T cells correlated with their dysfunction in patients with chronic viral infections, 
which could be restored by CTLA-4 blockade11. Also in cancer, high expression of CTLA-4 
was correlated with antigen-specific T cell dysfunction in metastatic melanoma12. In 
various CD80- and CD86-positive solid tumor models, monotherapy with CTLA-4 blocking 
antibody resulted in elimination of established tumors and long-lasting anti-tumor 
immunity13. Several clinical trials have been performed with anti-CTLA-4 antibodies, 
mostly with ipilimumab in melanoma. Interestingly, an increase in overall survival of 
melanoma patients has been observed14. However, not all patients gain clinical benefit 
and individual responses are hard to predict. Furthermore, occurrence of adverse toxic 
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resulted in clinical responses in 2 patients, and in a number of patients enhanced T cell 
responses against KLH and tetanus toxoid were observed25. Overall toxic effects were 
limited in these studies, and although durable responses were rare, the response rates 
resembled those of the first clinical trials in solid cancers. Since only small numbers of 
patients with hematological malignancies have been treated so far, more research is 
warranted to draw conclusions.
 Allogeneic T cell function after allo-SCT is also strongly influenced by co-inhibitory 
molecules. The importance of CTLA-4 in modulating allogeneic immune responses has 
been confirmed by association of certain CTLA-4 genotypes with the incidence of leukemia 
relapse and overall survival after allo-SCT26. Although not all functional consequences of 
reported polymorphisms have been elucidated, the CT60 single nucleotide polymorphism 
is postulated to influence the transcription of the sCTLA-4 variant, hampering normal 
CTLA-4 function27. Interestingly, it was demonstrated that CTLA-4 blockade shortly after 
allo-SCT increased GVHD in a CD28-dependent manner28. However, when anti-CTLA-4 was 
administered at later time points after allo-SCT, the GVT effect was boosted without signs of 
GVHD. Shortly after allo-SCT, conditioning-related mucosal barrier injury, leading to a pro-
inflammatory cytokine storm, tissue damage and inflammation, may induce major T cell 
activation in GVHD tissues. However, at later time points these inflammatory events have 
diminished, and there is no general T cell activation. In patients, ipilimumab administration 
at late time points after allo-SCT has been explored in one phase I trial29. Following a single 
infusion of ipilimumab in 29 allo-SCT patients with a recurrent or progressive hematological 
malignancy, 3 clinical responses were observed. Importantly, no induction or exacerbation 
of clinical GVHD was reported, although similar to other CTLA-4 blockade trials 14% of 
the patients showed organ-specific immune adverse events. The lack of GVHD induction is 
likely attributed to the median interval of 1 year between last donor cell infusion and 
ipilimumab administration. This provides a window for anti-tumor immunotherapy in the 
post-transplantation setting and emphasizes the importance of appropriate timing.
PD-1
Expression and function of PD-1
Programmed death-1 (PD-1; CD279) is another immunoreceptor belonging to the B7/
CD28 family30. In 1992, PD-1 was identified on hybridoma T cells undergoing apoptosis and 
was believed to be a programmed cell death-induced gene31. Further characterization 
demonstrated that PD-1 is inducibly expressed on stimulated CD4+ T cells, CD8+ T cells, B 
cells and monocytes32. PD-1 binds two B7 family ligands, PD-L1 (B7-H1; CD274) and PD-L2 
(B7-DC; CD273)33. Their interaction with PD-1 differs in affinity34 and type, due to a 
conformational transition in PD-L1, but not PD-L2, upon binding35. While PD-L2 expression 
is mainly restricted to APCs, like DCs and macrophages, PD-L1 is expressed on many 
non-lymphoid tissues as well36. Furthermore, multiple tumor types express PD-L1 and its 
expression is elevated following IFN-γ exposure37. PD-L1 molecules on tumor cells can 
effects remains a problem. Interestingly, in one trial patients responding to ipilimumab 
were reported to have high titers of anti-MICA-antibodies, probably because of enhanced 
CD4+ T cell function resulting in increased antibody responses. These antibodies may 
revert the functional inhibition of natural killer (NK) and CD8+ T cells induced by 
tumor-secreted MICA. In 2011, the FDA and EMA approved ipilimumab treatment for 
advanced melanoma, paving the way for further exploration of therapies targeting 
co-inhibitory molecules in cancer15. Although anti-CTLA-4 treatment works in vivo, either 
alone or in combination with vaccines, in vitro CTLA-4 blockade has not been very 
successful in reversing T cell dysfunction. This might be due to limitations of the in vitro 
models, as CTLA-4 blockade probably exerts its in vivo action via multiple immune 
mediators (e.g. effector T cells, T
REG
, antibody responses)16.
CTLA-4 in hematological malignancies
Numerous experimental and clinical studies have demonstrated that co-inhibitory 
molecules hamper T cell immunity against hematological cancers in both the autologous 
and allogeneic setting (Table 2 and 3). For instance, a causal relationship between CTLA-4 
and T
REG
 was demonstrated in lymphoma patients17. A large proportion of the lymphoma-
infiltrating lymphocytes was identified as CTLA-4+ T
REG
, and T
REG
-mediated T cell 
suppression could be abrogated by CTLA-4 blockade. Additionally, CTLA-4:CD80/CD86 
interactions also take place between T cells and tumor cells. In multiple myeloma (MM) 
patients, CD86 but not CD80 was expressed by tumor cells, while CTLA-4 was up-regulated 
on T cells, resulting in anergy of tumor-specific T cells18. In concordance with these results, 
T cells from chronic lymphoid leukemia (CLL) patients responded to anti-CD3 activation 
by a decrease in CD28 and an increase in CTLA-4 expression, resulting in an inhibitory 
phenotype19. Similar to MM, we and others showed that acute myeloid leukemia (AML) 
cells heterogeneously express CD86, but CD80 levels are generally low or absent20;21. As 
CD80 and CD86 can mediate either T cell stimulation via CD28 or T cell inhibition via 
CTLA-4, their role in the induction of tumor-specific T cell immunity was investigated in an 
AML model22. Expression of CD86 on AML resulted in tumor rejection, whereas CD80+ 
AML tumors grew progressively. The latter observation was shown to be CTLA-4 
dependent, as blockade with anti-CTLA-4 resulted in clearance of CD80+ AML cells. 
 Because of their potent suppressive function, co-inhibitory molecules became major 
targets of preclinical and clinical blocking studies. For example, in a murine thymoma 
model, CTLA-4 blockade after DC vaccination improved survival and resulted in a 
sustained increase in the number of antigen-specific T cells23. In a phase I study that 
included four non-Hodgkin lymphoma (NHL) patients, two subjects developed a clinical 
response upon ipilimumab treatment24. No enhanced T cell-mediated anti-tumor 
reactivity could be observed, although T
REG
 levels decreased, suggesting that CTLA-4’s 
effectiveness may be attributed to T
REG
 depletion via antibody-dependent cell-mediated 
cytotoxicity (ADCC). In a follow-up study with 18 NHL patients, ipilimumab administration 
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 It has been well demonstrated that PD-1 plays a crucial role in T cell regulation in 
various immune responses such as peripheral tolerance, autoimmunity, infection and 
anti-tumor immunity36. Elevated PD-1 expression on viral antigen-specific CD8+ T cells in 
chronic viral infections was recognized as a hallmark for T cell dysfunction upon antigen 
re-stimulation43. This phenomenon known as exhaustion is characterized by the sequential 
deliver negative signals towards PD-1-expressing tumor-reactive T cells, thereby inhibiting 
anti-tumor immunity38. Indeed, PD-L1 expression has been associated with poor prognosis 
in solid tumors37;39. Interestingly, PD-L1 is also able to bind CD80, mediating T cell 
inhibition40. In addition to downstream signaling of PD-L141, also engagement of PD-L2 
resulted in T cell inhibition, further illustrating the complexity of these interactions42.
3
Table 2  Outcome of interference with murine co-inhibitory molecules 
Molecule Therapy Tumor Outcome Ref
Autologous
CTLA-4 Anti-CTLA-4 + ova-DC vaccination Thymoma Improved tumor rejection, enhanced antigen-specific T cell responses 23
CTLA-4 Anti-CTLA-4; CTLA-4 deletional knockout AML Increased survival and improved tumor rejection 22
CTLA-4 Anti-CTLA-4 AML Enhanced T cell response, prolonged survival 54
PD-1 Anti-PD-L1; PD-1 knockout MM Delayed tumor growth; complete tumor rejection in PD-1 knockout 49
PD-1 HSCT + whole cell vaccination + anti-PD-L1 MM Increased survival 52
PD-1 Anti-PD-L1; PD-1 knockout AML Enhanced T cell response, improved tumor rejection, increased survival 50
PD-1/TIM-3 Anti-PD-L1 and/or mTim-3 hFc AML Delayed tumor growth upon monotherapy, improved tumor rejection upon 
combined blockade
93
CD200 Anti-CD200 AML Increased survival 86
CD200 Anti-CD200 B-CLL Improved tumor rejection 87
CD200 Anti-CD200 B-cell lymphoma Delayed tumor growth 88
Allogeneic
CTLA-4 Anti-CTLA-4 AML Enhanced T cell response and GVHD early after BMT; enhanced tumor-specific T cell 
response later after BMT with low GVHD
28
PD-1 Anti-PD-L1 Lymphoma Enhanced T cell response 63
PD-1 Anti-PD-L1 None Enhanced alloreactive T cell response, no GVHD 64
PD-1 Anti-PD-L1; PD-1 knockout CML Increased survival 65
BTLA BTLA agonist B-cell lymphoma Early after BMT: prevention of GVHD; later after BMT: no effect on GVHD; effective GVT 
response
78
BTLA BTLA agonist Mastocytoma/T-cell 
lymphoma
Inhibition of alloreactive T cell response, prevention from GVHD 79
HVEM Specific blockade of BTLA binding None Prevention from acute GVHD 80
PD-1H/VISTA PD-1H/VISTA agonist None Prevention from acute GVHD 103
AML, acute myeloid leukemia; B-CLL, B-cell chronic lymphoid leukemia; CML, chronic myeloid leukemia; MM, 
multiple myeloma; BMT, bone marrow transplantation; HSCT, hematopoietic stem cell transplantation; GVHD, 
graft-versus-host-disease; GVT, graft-versus-tumor.
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to these signaling effects, the PD-1 gene itself is subject to epigenetic regulation, as 
increased PD-1 expression on activated CD8+ T cells results from demethylation of the 
Pdcd1 locus48. During conversion to functional memory T cells remethylation of Pdcd1 
occurs, whereas in exhausted T cells the Pdcd1 regulatory region remains demethylated. 
PD-1 in hematological malignancies
In addition to CTLA-4, PD-1/PD-L interactions were shown to be of importance in hemato- 
logical malignancies. For instance, PD-L1 overexpression enhanced MM invasiveness and 
rendered tumor cells less susceptible to cytotoxic T lymphocytes (CTLs)49. This effect was 
loss of the ability to proliferate, secrete cytokines and lyse target cells. Especially in HIV 
infection, T cell impairment could be relieved by PD-1 blockade both in vitro and in animal 
models44;45. Exhausted T cells have increased expression of multiple co-inhibitory receptors 
and a distinct gene signature, different from anergic cells, resulting in changes in T cell 
receptor (TCR) and cytokine signaling pathways46. Indeed, an exhaustion-specific gene 
signature, recently defined by Quigley et al., demonstrated that PD-1 downstream 
signaling effects play an important role in the exhaustion of HIV-specific T cells47. 
Furthermore, they showed that the transcription factor BATF (basic leucine zipper 
transcription factor, ATF-like) appears essential for downstream PD-1 signaling. In addition 
3
Table 3  Outcome of interference with human co-inhibitory molecules
Molecule Therapy Tumor Outcome Ref
CTLA-4 Ipilimumab, in vivo NHL 2/4 tumor regression, no increase in vaccine-specific T cell responses, reduction in T
REG
 
number early after treatment. Toxicity: mainly grade 1-2, 1x grade 3
24
CTLA-4 Ipilimumab, in vivo Relapsed/refractory B 
cell NHL
2/18 clinical response, 5/16 enhanced T cell response to recall antigen. Toxicity: mainly 
grade 1-2, 6/18 grade 3
25
CTLA-4 Ipilimumab after allo-SCT, in vivo AML, CML, CLL, HL, 
NHL, MM
3/29 clinical response. Toxicity: no induction of GVHD, 4/29 organ-specific immune 
adverse events
29
CTLA-4 Anti-CTLA-4, ex vivo HL Abrogated T
REG
 suppression 17
CTLA-4 Anti-CTLA-4, ex vivo CLL Enhanced tumor-specific T cell response 109
PD-1 BMS-936,558, ex vivo ALL, AML, CML, NHL, 
MM
Enhanced alloreactive T cell response 20
PD-1 Anti-PD-L1, ex vivo NHL Enhanced T cell response 52
PD-1 Anti-PD-L1 and anti-PD-L2, ex vivo HL Restored T cell response 53
PD-1 Anti-PD-L1, ex vivo HCV-lymphoma Abrogated T
REG
 suppression, reduction in T
REG
 number 55
PD-1 CT-011, in vivo AML, CLL, HL, NHL, 
MDS, MM
6/17 clinical response, 1 complete remission, no toxicity 57
PD-1 CT-011 w/wo lenalidomide, ex vivo MM Enhanced NK cytotoxicity, additive effect of lenalidomide 58
PD-1 CT-011 + tumor/DC vaccination, ex vivo MM Reduction in T
REG
 number, enhanced T cell response 59
PD-1 DC vaccination with PD-L silencing, ex vivo AML, CML Enhanced alloreactive T cell response 105
BTLA Anti-BTLA, ex vivo ALL, AML, CML, NHL, 
MM
Enhanced alloreactive T cell response 67
CD200 Anti-CD200, ex vivo AML Enhanced NK cytotoxicity 84
CD200 Anti-CD200, ex vivo CLL Enhanced antigen-specific T cell responses, reduction in T
REG
 number 85
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoid leukemia; CML, 
chronic myeloid leukemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic 
syndrome; MM, multiple myeloma; HCV, hepatitis-C virus; T
REG
, regulatory T cell; NK, natural killer cell; MiHA, minor 
histocompatibility antigen; GVHD, graft-versus-host-disease; GI, gastro-intestinal tract.
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serious adverse event, inflammatory colitis, was reported60. Follow-up reports presented 
at ASCO 2010 and GU ASCO 2011 showed that persistent clinical responses were observed 
in approximately 30% of patients with renal cell carcinoma, prostate cancer, melanoma 
and lung cancer upon treatment with repetitive doses of anti-PD-1 antibodies61;62. The lack 
of strong toxic effects in this study holds promise that PD-1 blockade might have a more 
subtle effect than CTLA-4 blockade, thereby highlighting anti-PD-1 antibodies as 
interesting candidates for cancer therapy.
 The role of PD-1 in allo-SCT has been investigated both in mice and men. In two 
similar murine studies dissecting the role of alloantigens in GVT and GVHD reactivity, it 
was found that alloreactive T cells recognizing antigens on GVHD-prone tissues are driven 
into dysfunction and apoptosis63. Furthermore, the interaction of non-hematopoietic cells 
with alloreactive T cells prevented the formation of proper alloreactive memory cells by 
exploiting the PD-1/PD-L pathway64. This means that in addition to the detrimental effect 
of GVHD as such, also the beneficial GVT effect is hampered as alloreactive T cells become 
functionally impaired. Notably, PD-L1 blockade late after allo-SCT may partly restore the 
GVT reactivity without inducing GVHD. Moreover, these results support the importance of 
targeting hematopoietic-restricted MiHAs, since these are solely expressed by 
hematopoietic tumor cells and residual healthy immune cells of the recipient, but not by 
GVHD-prone tissues. In one of the few studies investigating chronic myeloid leukemia 
(CML), using a retrovirus-induced CML model, it was demonstrated that tumor-specific T 
cells can become exhausted65. In this model, consisting of PD-1+ tumor-specific T cells and 
PD-L1+ CML cells, exhaustion was overcome by either using PD-1 deficient cells or 
anti-PD-L1 administration. We and others have investigated the role of PD-1 in GVT 
immunity in allo-SCT patients. High PD-1 expression was observed on alloreactive CD8+ 
T
EM
 cells that specifically recognize hematopoietic-restricted MiHAs in myeloid leukemia 
patients20. In agreement, Mumprecht et al. showed that the total T cell population from 
CML patients had elevated levels of PD-165. Also CD117+ progenitor AML cells displayed low 
levels of CD80 and CD86, whereas PD-L1 was highly expressed, especially under 
inflammatory conditions20. Since these observations were made in allo-SCT patients who 
relapsed after initial powerful MiHA-specific T cell responses, we postulated that PD-1 
expression is involved in T cell exhaustion. By stimulation with MiHA-loaded DCs ex vivo, 
we aimed at activating these PD-1+ MiHA-specific T
EM
 cells, however results were 
suboptimal, suggesting an impaired state. Importantly, upon treatment with anti-PD-1 or 
anti-PD-L1 blocking antibodies we were able to reinvigorate MiHA-specific T
EM
 proliferation. 
Notably, the effect of PD-1 blockade on MiHA-specific T
EM
 cells from relapsed patients 
compared to patients in long-term remission was significantly stronger, indicating the 
function of PD-1 in T cell exhaustion and subsequent tumor immune evasion.
alleviated in PD-1 knockout mice or by anti-PD-L1 antibody treatment, demonstrating the 
importance of the PD-1/PD-L pathway in this process. This role of PD-1 was also confirmed 
in an AML model, and interestingly, PD-L1 expression was elevated on tumor cells in vivo 
compared to in vitro50. In another report, an increased level of PD-L1 on MM cells together 
with enhanced PD-1 expression on exhausted T cells was demonstrated51. As expected, in 
mice PD-L1 blockade improved survival after autologous SCT and whole cell vaccination 
from 0% to 40%. In humans, PD-L1 expression was observed on NHL tumor cells, and 
blockade greatly enhanced cytokine production of autologous tumor-reactive T cells52. 
Furthermore, it was shown that tumor cells of Hodgkin lymphoma (HL) patients can 
express both PD-L1 and PD-L2, and PD-1 expression was elevated on HL-infiltrating T 
cells53. Also in this case, blockade of PD-Ls mediated increased cytokine secretion by the 
infiltrated T cells. Additionally, long-term persistent murine leukemia cells were shown to 
sequentially up-regulate PD-L1 and CD80, thereby conferring protection against immune 
destruction54. Upon PD-L1 or CTLA-4 blockade, CTL-mediated lysis of these persistent 
AML cells was improved. Similar to the link of CTLA-4 and T
REG
, an elevated number of T
REG
 
exhibiting high PD-1 expression was described in HCV-associated lymphoma55. In addition 
to PD-1 expression on CD8+ T cells and T
REG
, PD-L1 expression on APCs was important for 
tumor persistence of murine AML. Combining PD-L1 blockade with T
REG
 depletion showed 
superior efficacy in clearance of AML, due to alleviation of PD-1-dependent T
REG
-mediated 
suppression56. 
 Although clinical PD-1 blockade has not been as extensively tested as ipilimumab for 
CTLA-4, multiple clinical grade antagonistic anti-PD-1 antibodies have been developed, 
i.e. CT-011, BMS-936,558 and MK-3475 (NCT01295827). Furthermore, two anti-PD-L1 
antibodies, BMS-936,559 (NCT00729664) and MPDL2180A (NCT01375842), one anti-PD-L2 
antibody (NCT00658892) and a PD-L2 fusion protein AMP-224 (NCT01352884) are being 
tested in phase I clinical trials. Three studies involving hematological cancers were 
performed with CT-011. One phase I clinical trial was conducted in patients with varying 
hematological malignancies, and showed a clinical response in 6 out of 17 patients, with 
few adverse events57. Although the CD4+ T cell count was elevated in the treated patients, 
no additional evidence of T cell activation was found. In a pre-clinical study, ex vivo 
treatment with CT-011 enhanced the functionality of NK cells against autologous primary 
MM cells58. In addition, the drug lenalidomide down-regulated PD-L1 levels, and an 
additive effect was shown by combining lenalidomide with CT-011, rendering this 
combination a promising therapy for MM patients. Another study examined whether 
PD-1 blockade improves the effectiveness of myeloma/DC vaccination therapy, since it is 
known that both myeloma cells and myeloma/DC hybridomas highly express PD-L159. 
Indeed, ex vivo addition of CT-011 resulted in enhanced myeloma lysis by T cells, as well as 
a reduction in the number of T
REG
. However, until now the most promising effects have 
been obtained with the monoclonal human anti-PD-1 antibody BMS-936,558 (MDX-1106; 
ONO-4538). Administration to patients with solid tumors was well tolerated and only one 
3
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that BTLA was also highly expressed on MiHA-specific T
EM
 cells. Moreover, in 7 out of 11 
patients BTLA blockade resulted in increased outgrowth of MiHA-specific T
EM
 cells of 
transplanted patients. Interestingly, in 3 patients BTLA blockade effects were more 
prominent than those of PD-1, indicating that BTLA has a non-redundant function to PD-1, 
and therefore it holds promise in post-SCT therapies. 
New co-inhibitory players 
In addition to the afore discussed molecules, CD200R, TIM-3, LAG3 and PD-1H/VISTA were 
recently shown to contribute to T cell inhibition and/or exhaustion in hematological cancers. 
 CD200 receptor (CD200R) is an inhibitory receptor previously thought to be most 
important on myeloid cells, but it is also expressed in the lymphoid lineage such as NK, 
CD4+ and CD8+ T cells, especially upon stimulation81. Its ligand, CD200 (OX2) is a 
glycoprotein expressed on a broad number of cell types, including solid tumors and 
hematological malignancies82;83. In addition to the previously discussed co-inhibitory 
molecules, CD200R inhibits both T and NK cell functionality84;85. Furthermore, CD200/
CD200R interactions are involved in tumor immune evasion, as CD200 expression on AML 
cells promoted tumor growth in mice86. Interestingly, patients with CD200+ AML cells 
displayed a lower number of activated NK cells, and the effect on NK functionality was 
correlated to CD200 expression on the leukemia cells84. In concordance with this, blockade 
of CD200 enhanced IFN-γ release and cytotoxicity by NK cells. Moreover, CD200 blockade 
restored T cell proliferation and tumor control by immune cells for human CD200+ CLL 
both in vitro85 and in a humanized mouse model87. However, in a follow-up report 
treatment with anti-CD200 antibody caused loss of T cell-mediated tumor control due to 
clearance of the T cells88. This was attributed to ADCC of CD200+ T cells caused by the IgG1 
variant of anti-CD200, which was not observed for the IgG4 isotype. Therefore, blocking 
strategies should be carefully designed before proceeding to the clinic.
 In addition, the co-signaling receptor TIM-3 is expressed on Th1 CD4+ and CD8+ T 
cells, and is involved in co-inhibition. In mice, the interaction of TIM-3 with its ligand 
Galectin-9 was demonstrated to be inhibitory in autoimmune diseases and malignancies89. 
Furthermore, in HIV90 and melanoma patients91, dysfunctional T cells have been shown to 
co-express TIM-3. In this regard interference with TIM-3 signaling is an interesting 
treatment option, and enhanced tumor vaccine efficacy has been observed by TIM-3 
blockade92. Interestingly, both TIM-3 and PD-1 were expressed on a subset of exhausted 
CD8+ T cells in a murine AML model and expression increased during tumor progression93. 
While either TIM-3 or PD-L1 blockade alone was not sufficient to improve survival, a 
combination of the two antibodies decreased tumor burden and enhanced survival. 
Furthermore, in human lymphoma an interesting role for TIM-3 has been described on 
tumor endothelium94. TIM-3 expressed on these endothelial cells mediated impaired 
CD4+ T cell responses, and thereby promoted lymphoma onset, growth, and dissemination. 
In contrast, a stimulatory role for TIM-3 and Galectin-9 has been reported in the interaction 
BTLA
Expression and function of BTLA
B and T lymphocyte attenuator (BTLA), i.e. CD272, was identified in 2003 as an inhibitory 
receptor with structural similarities to CTLA-4 and PD-166. BTLA is mainly expressed by 
immune cells, including T and B cells, DCs and myeloid cells67;68. In contrast to other B7/
CD28 family members, BTLA binds a member of the tumor necrosis factor receptor (TNFR) 
superfamily, namely Herpes virus entry mediator (HVEM)69. Though, HVEM is part of an 
intricate signaling network as it has at least four additional binding partners that 
distinctively mediate T cell responses: i.e. CD160, LIGHT (for Lymphotoxin-like, exhibits 
inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor 
expressed by T lymphocytes), Lymphotoxin-α (LT-α) and Herpes simplex virus glycoprotein 
D (gD)70. BTLA or CD160 signaling upon HVEM binding result in T cell inhibition69;71. 
However, HVEM present on T cells acts as a co-stimulatory receptor72, thereby constituting a 
bidirectional pathway. Interestingly, naive T cells express both HVEM and BTLA, and these 
molecules form a T cell intrinsic heterodimer complex73. Due to formation of this complex, 
HVEM is unavailable for extrinsic ligands, and no co-stimulatory signal is transduced. 
Studies in BTLA-deficient mice revealed a predisposition to experimentally induced 
autoimmune encephalomyelitis66. Furthermore, these mice develop late-onset 
spontaneous autoimmune hepatitis-like disease and multi-organ lymphocyte infiltration74, 
implying the involvement of BTLA in maintaining self tolerance. In humans, persistent 
expression of BTLA was observed on EBV- and CMV-specific CD8+ T cells, negatively 
affecting T cell function75;76. Furthermore, in melanoma patients high BTLA expression 
correlated with impaired tumor-specific T cell function12;75. These tumor-specific T cell 
responses could be restored in vitro by interference with the BTLA/HVEM pathway in 
combination with vaccination therapy. In addition, co-expression of PD-1, BTLA and T-cell 
immunoglobulin and mucin domain-3 (TIM-3) rendered melanoma-specific CD8+ T cells 
highly dysfunctional, which could be restored by combined blockade of all three 
co-inhibitory molecules77.
BTLA in hematological malignancies
A single administration of agonistic anti-BTLA antibody directly after allo-SCT in mice 
completely prevented GVHD, while this treatment did not hamper GVT responses78;79. 
Moreover, when using an antibody that specifically blocked the interaction of HVEM with 
BTLA, but not LIGHT, GVHD was attenuated80. This suggests that in this model the 
co-stimulatory function of HVEM was dominant over its co-inhibitory activity. Since both 
HVEM and BTLA can be expressed by T cells, bidirectional signaling can occur. Therefore, 
combining specific blocking antibodies with cell-specific knockout models for these 
molecules will be necessary to further unravel the intricate interactions between HVEM, 
BTLA, CD160 and LIGHT. In addition, we investigated the effect of a BTLA blocking antibody 
on MiHA-specific T cell function in allo-SCT patients67. As shown for PD-1, we observed 
3
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blocking antibodies or siRNA knockdown of co-inhibitory molecules to boost anti-tumor 
immunity, or by administration of agonistic antibodies against co-inhibitory molecules 
implicated in GVHD, adverse effects may be reduced (Figure 1).
 Although anti-CTLA-4 and anti-PD-1 monotherapy have shown promising results, 
combination therapy with other treatment modalities such as immunomodulatory 
anti-cancer agents, vaccines or T
REG
 depletion is potentially necessary to effectively cure 
hematological cancers. At the moment, several clinical trials are underway that target 
co-inhibitory receptors in hematological cancers. The effectiveness of CTLA-4 blockade 
by ipilimumab is investigated in lymphoma patients (NCT00047164), and the anti-PD-1 
of CD8+ T cells and DCs95. This discrepancy is reflected in research investigating its 
mechanism of action, where T cell receptor stimulation is enhanced upon TIM-3 signaling96. 
This might be explained by the fact that T cell exhaustion could be caused by prolonged 
TCR signaling, and TIM-3 accelerates this process. Another explanation is that depending 
on which ligand binds to TIM-3, different modes of signaling are initiated. Therefore, TIM-3 
may act as either a co-stimulatory or a co-inhibitory factor, similar to BTLA.
 Lymphocyte-activation gene 3 (LAG3; CD223) is a co-inhibitory receptor highly similar 
to CD4 and binds HLA class II molecules97;98. Importantly, LAG3 was implicated to inhibit T 
cell function in HL patients97;99. LAG3 seems to be non-redundant from PD-1, as both are 
expressed on distinct populations of CD8+ T cells.100 Recently, it was shown that in mice 
PD-1 and LAG3 act synergistically in the onset of autoimmune diseases and tumor 
escape101;102. Furthermore in HL, both T
REG
 and LAG3+ CD4+ T cells were shown to be 
involved in tumor immune evasion, since the expression of FoxP3 and LAG3 coincided 
with the impairment of tumor-specific T cell responses99. Therefore, LAG3 is an interesting 
candidate to combine with therapies that utilize T
REG
  depletion or PD-1 blockade.
 Recently another immunoregulatory molecule with similarities to PD-1, as well as to 
PD-L1 was simultaneously discovered by two groups: PD-1H (PD-1Homolog)103 or VISTA 
(V-domain Ig suppressor of T cell activation)104. This molecule is broadly expressed on 
hematopoietic cells and is up-regulated on APCs and T cells upon activation. Mice treated 
with a single dose of PD-1H/VISTA-antibody did not develop GVHD after allo-SCT, however 
the mechanism of action was not elucidated103. Another study identified PD-1H/VISTA as 
an inhibitory ligand on APCs and tumor cells104. Here, PD-1H/VISTA Ig-fusion protein 
conveyed a lasting negative signal to T cells, and expression of the protein on APCs 
suppressed T cell proliferation. Importantly, PD-1H/VISTA expression on tumor cells 
resulted in diminished anti-tumor immunity. The human ortholog was determined on the 
genomic level, and due to the important role of this immunoregulatory molecule in GVHD 
and tumor escape, PD-1H/VISTA is anticipated to be a potential therapeutic target. 
Future prospects
Several therapeutic strategies to interfere with the function of co-inhibitory molecules are 
being explored in order to enhance anti-tumor T cell immunity. The challenge of 
interference with immune checkpoints is to boost anti-tumor reactivity while avoiding 
systemic toxicity. This could potentially be achieved by 1) combining the alleviation of 
co-inhibition with other therapeutic options, 2) blocking co-inhibitory molecules that are 
intrinsically skewed towards anti-tumor responses rather than GVHD or autoimmune effects 
and 3) optimal dosage and timing of antibody administration. Appealing combinations 
are the simultaneous targeting of multiple co-inhibitory receptors, or incorporation in 
existing cellular therapies. For example, DC vaccination may be applied together with 
3
Figure 1   Therapeutic strategies for interfering with co-inhibitory molecules
First, blocking antibodies can be used to abrogate binding between co-inhibitory molecules on the 
tumor-reactive T cell and tumor cells, thereby enhancing T cell responses. In addition, DC therapy 
can be combined with antagonistic antibodies to boost the tumor-specific effect of DC vaccination. 
Another method to circumvent co-inhibitory signaling during DC vaccination is silencing of 
 co-inhibitory molecules. Delivery of siRNA can be achieved either by electroporation or via lipid 
nanoparticles. Finally, co-inhibitory molecules which are differentially more involved in GVHD can 
be stimulated by agonistic antibodies. This will attenuate GVHD-specific T cell responses, thereby 
preventing attack of GVHD-prone tissue.
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knowledge of a growing number of co-inhibitory molecules, novel mono- and combinatorial 
treatment options become available. In the end, this could lead to optimized immuno -
therapy against hematological cancers, with limited risk of adverse events like the 
induction of autoimmune diseases and GVHD. 
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monoclonal antibody CT-011 is combined with three different therapies. In lymphoma 
patients, CT-011 is administered following autologous SCT (NCT00532259) and combined 
with rituximab (NCT00904722). Furthermore, the combination of CT-011 with a DC/AML 
fusion vaccine is being investigated as a therapy for AML patients (NCT01096602). Recently, 
we explored another treatment option in which an antigen-specific stimulation is 
combined with interference of co-inhibition. We demonstrated that stimulation with 
PD-L1/L2 silenced MiHA-loaded DCs boosted the expansion of MiHA-specific T cells ex 
vivo105. Following these promising results, we will start a clinical trial shortly combining DLI 
with vaccination of PD-L1/L2 silenced donor DCs loaded with hematopoietic-restricted 
MiHA (CCMO-trial no. NL37318). We believe that these clinical studies provide a platform 
for incorporating blockade of co-inhibitory molecules in adjuvant therapy of hematological 
malignancies, with numerous options for combination therapies. Importantly, the risk of 
breaking tolerance systemically by blockade of one co-inhibitory molecule could be 
prevented by using lower levels of multiple blocking antibodies targeting different 
inhibitory molecules simultaneously, since together these may boost immune responses 
in a non-redundant manner. This is stressed by the fact that exhausted T cells are known 
to display multiple different co-inhibitory receptors106. By analyzing the downstream 
pathways of different co-inhibitory receptors one could limit these options and exclude 
combinations of receptors that have redundant effects, and focus on synergistic 
combinations. Notably, a clinical trial in solid tumors has started which combines blocking 
antibodies against PD-1 en CTLA-4 (NCT01024231), harnessing the power of these two 
non-redundant immune checkpoints.
 The crux in allo-SCT is the separation of GVT and GVHD reactivity. Although CTLA-4 
and PD-1 clearly contribute to T cell exhaustion, their activation might have too broad 
consequences early after allo-SCT, and interfering with their signaling might deteriorate 
GVHD. Interestingly, anti-BTLA was recently reported to impair GVHD while allowing GVT 
reactions78;107. Whether or not this important distinction in alloreactive responses also 
exists in humans needs to be evaluated, but it renders BTLA an important candidate for 
post-transplantation immunotherapy. Furthermore, the timing of co-receptor blockade 
seems to be essential to boost GVT without causing GVHD28;64. Early after allo-SCT, the 
patient is in a highly activated immunological state, due to chemotherapy-induced tissue 
damage and subsequent inflammation, especially in GVHD-target tissues such as skin and 
gut. To release immune checkpoints at this time would be dangerous, since T cells would 
home to these inflamed alloantigen-expressing GVHD sites and destroy healthy cells. 
However, a delayed treatment window following allo-SCT is possible, when there is no 
systemic ‘inflammatory’ state. However, at the tumor site where the inflammation is 
sustained anti-tumor MiHA-specific T cells may be specifically boosted, resulting in 
renewed GVT effects.
 Altogether, co-inhibitory molecules play a pivotal role in natural and immunotherapy- 
induced T cell-mediated immunity against hematological cancers. With increasing 
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Abstract
Tumor relapses remain a serious problem after allogeneic stem cell transplantation 
(allo-SCT), despite the long-term persistence of minor histocompatibility antigen (MiHA)-
specific memory CD8+ T cells specific for the tumor. We hypothesized that these memory 
T cells may lose their function over time in transplanted patients. Here, we offer functional 
and mechanistic support for this hypothesis, based on immune inhibition by programmed 
death-1 (PD-1) expressed on MiHA-specific CD8+ T cells and the associated role of the PD-1 
ligand PD-L1 on myeloid leukemia cells, especially under inflammatory conditions. PD-L1 
was highly up-regulated on immature human leukemic progenitor cells, whereas 
co-stimulatory molecules such as CD80 and CD86 were not expressed. Thus, immature 
leukemic progenitor cells seemed to evade the immune system by inhibiting T-cell 
function via the PD-1/PD-L1 pathway. Blocking PD-1 signaling using human antibodies led 
to elevated proliferation and IFN-γ production of MiHA-specific T cells co-cultured with 
PD-L1-expressing leukemia cells. Moreover, patients with relapsed leukemia after initial 
MiHA-specific T-cell responses displayed high PD-L1 expression on CD34+ leukemia cells 
and increased PD-1 levels on MiHA-specific CD8+ T cells. Importantly, blocking PD-1/PD-L1 
interactions augment proliferation of MiHA-specific CD8+ memory T cells from relapsed 
patients. Taken together, our findings indicate that the PD-1/PD-L pathway can be hijacked 
as an immune escape mechanism in hematological malignancies. Furthermore, they 
suggest that blocking the PD-1 immune checkpoint offers an appealing immunothera-
peutic strategy following allo-SCT in patients with persisting or relapsed disease.
Introduction 
Alloreactive CD8+ T cells play a crucial role in the graft-versus-tumor (GVT) response 
following allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusion 
(DLI)1. In human leukocyte antigen (HLA)-matched allo-SCT, these alloreactive CD8+ T cell 
responses are directed against minor histocompatibility antigens (MiHAs)2. Previously, we 
have characterized CD8+ T cell immunity toward a hematopoietic-restricted MiHA, 
designated LRH-1, which is presented by HLA-B7 and encoded by the P2X5 purinergic 
receptor gene3. LRH-1-specific CD8+ T cell responses can be frequently detected in 
myeloid leukemia patients following DLI, and has been associated with leukemic 
remission3;4. Moreover, we showed that CD34+ myeloid leukemia progenitor cells can be 
efficiently targeted in vitro by LRH-1-specific CD8+ cytotoxic T lymphocytes (CTLs), 
indicating that these CTLs play a significant role in GVT-specific immunity against myeloid 
leukemia. However, we have observed that despite the presence of LRH-1-specific CD8+ 
memory T (T
mem
) cells for many years, late relapses do occur in patients with advanced 
myeloid leukemia. Furthermore, we noted that LRH-1-specific CD8+ T
mem
  cells do not 
always efficiently expand with recurrence of leukemia cells, suggesting that these T cells 
become functionally impaired. 
 Mechanisms exploited by tumor cells to inhibit CD8+ T cell-mediated immunity 
include disruption of antigen presentation, down-regulation of HLA molecules, and 
induction of immune suppressive components such as Programmed death-1 (PD-1) 
signaling5;6. PD-1 plays a crucial role in T cell regulation in various immune responses and 
is involved in peripheral tolerance, autoimmunity, infection and anti-tumor immunity7. 
Elevated PD-1 expression on antigen-specific CD8+ T cells in chronic viral infections has 
been recognized as a hallmark for T cell exhaustion resulting in diminished cytokine 
production, proliferation and cytotolytic activity upon antigen restimulation8. PD-1 binds 
two ligands, PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273)7. Although PD-L2 expression 
is mainly restricted to antigen presenting cells (APCs) like dendritic cells (DCs) and 
macrophages, PD-L1 is also expressed by many non-hematological cell types7. 
Furthermore, PD-L1 can be expressed on multiple tumor types and its expression is 
elevated following IFN-γ exposure9. PD-L1 molecules on tumor cells can deliver negative 
signals through PD-1 to tumor-reactive CTL, thereby inhibiting anti-tumor immunity10. In 
agreement, PD-L1 expression has been associated with poor prognosis in various cancers 
including hepatocellular carcinoma and melanoma9;11. Notably, studies in models of 
murine myeloid leukemia have also demonstrated that PD-1/PD-L1 interactions play an 
important role in immune evasion12;13. Interestingly, PD-L1 is also able to bind CD80, 
resulting in T cell inhibition14. Therefore, PD-L1 molecules on human leukemia cells may 
restrain CD8+ T cell responses involved in GVT immunity after allo-SCT. 
4
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in 96-well round bottom plates (Corning Costar, New York, NY, USA). In lymphocyte-AML 
reaction assays, allogeneic CD3+ T cells were isolated from non-adherent or complete 
PBMC fractions from healthy donors by direct magnetic labeling with the appropriate 
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer’s 
instructions. Subsequently, 104 CD3+ T cells were added to AML cells and mDCs at different 
E:T ratios. In MiHA-specific T cell expansion assays, PD-L1+ iDCs were loaded with 10 µM 
LRH-1 peptide TPNQRQNVC for 30 minutes at room temperature and co-cultured with 
LRH-1-specific CTL RP1 at a stimulation ratio of 10:1. 
 PD-1 and PD-L1 blocking antibodies were added at a final concentration of 10 μg/ml. 
Human antibodies to human PD-1 (BMS-936,558; MDX-1106; ONO-4538) and PD-L1 
(BMS-936,559; MDX-1105) and a matching IgG4 isotype control were kindly provided by dr. 
Alan Korman (Bristol-Myers Squibb, Biologics Discovery, Milpitas, CA, USA). BMS-936,558 
and BMS-936,559 are genetically engineered, fully human IgG4 antibodies currently 
evaluated in clinical trials for selected tumor treatments16. All co-cultures were performed 
in a total volume of 200 µl IMDM/10% HS. After 5 days of co-culture, supernatant was 
harvested for cytokine analysis. At day 5, 0.5 µCi [3H]-thymidine (Perkin Elmer, Groningen, 
the Netherlands) was added to each well. After overnight incubation, [3H]-thymidine 
incorporation was measured using a 1205 Wallac Betaplate counter (Perkin Elmer). 
MiHA-specific Tmem cell proliferation assays
MiHA-specific CD8+ T cells present in PBMCs from patients Pt 1, 2, 15-21 (Table 2)  were 
stimulated for one to three consecutive weeks ex vivo with either MiHA peptide alone or 
with MiHA peptide-loaded PD-L1+ iDCs or PD-L1+ PD-L2+ mDCs, as described previously15. 
PD-1 and PD-L1 blocking antibodies were added at a final concentration of 10 μg/ml. After 
5 days, 500 μl supernatant was removed and fresh IMDM/10% HS containing 50 U/ml IL-2 
(Chiron, Emeryville, CA, USA) and 5 ng/ml IL-15 (Immunotools) was added. At day 7, cells 
were harvested, counted and the percentage of MiHA-tetramer+ CD8+ T cells was 
determined. 
Flowcytometry 
Expression of co-signaling ligands on myeloid leukemia cells and DCs was analyzed by 
staining with the following fluorochrome-conjugated antibodies: CD14 (clone TÜK4, Dako, 
Glostrup, Denmark), CD33 (clone D3HL60.251), CD34 (clone 581), CD117 (clone 104D2D1), 
CD54 (clone 84H10),  CD80 (clone MAB104), CD83 (clone HB15a), CD86 (clone HA5.2B7, all 
from Beckman Coulter, Fullerton, CA, USA), anti-PD-L1 (clone MIH1), anti-PD-L2 (clone 
MIH18, both from Becton Dickinson, Franklin Lakes, NJ, USA) and isotype controls IgG1 
FITC/PE dual-color control (Dako) and IgG2b PE (Beckman Coulter). PD-1 expression on 
and percentage of MiHA-specific CD8+ T cells was determined as described previously15 
using anti-PD-1 (clone MIH4, Becton Dickinson). Cells were analyzed using the Coulter 
FC500 flowcytometer (Beckman Coulter). 
 In this study, we examined the role of PD-1/PD-L1 interactions in functional impairment 
of MiHA-specific CD8+ T cells. We observed that PD-L1 is induced following IFN-γ and 
TNF-α exposure. Furthermore, we observed that activated LRH-1-specific CD8+ T cells 
express PD-1 during the course of the immune response. Importantly, we showed that 
blockade of PD-1/PD-L1 interactions using clinical grade human antibodies increases the 
proliferation and IFN-γ production of MiHA-specific CD8+ T cells when stimulated with 
PD-L1-expressing acute myeloid leukemia (AML) cells and DCs. Together, these findings 
indicate that the PD-1 signaling pathway suppresses MiHA-specific CD8+ T cell responses 
and PD-1 blockade may be an attractive approach to boost GVT immunity in patients with 
persistent or relapsed disease. 
Materials and Methods 
Patient and donor material
Peripheral blood (PB) and bone marrow (BM) samples of leukemia patients have been 
collected after written informed consent in ongoing clinical stem cell transplantation 
protocols approved by the RUNMC Institutional Review Board. We used peripheral blood 
mononuclear cells (PBMCs) obtained from patients with hematological malignancies who 
developed MiHA-specific CD8+ T cell responses after DLI. Patient 1 (Pt 1) suffered from 
accelerated-phase (AP) chronic myeloid leukemia (CML) and was successfully treated with 
therapeutic DLI after allo-SCT3. However, the patient relapsed 4 years after DLI. Patient 2 
(Pt 2) suffered from AML and developed a strong LRH-1-specific CD8+ T cell response 
upon pre-emptive DLI, but developed extramedullary relapses without leukemic 
involvement in the bone marrow4. Characteristics of these patients and other transplanted 
patients investigated in this study are included in Table 2. 
 DCs were generated from monocytes isolated from PBMCs of healthy donors by 
plastic adherence in tissue culture flasks (Greiner Bio-One, Alphen a/d Rijn, the Netherlands). 
Immature DCs (iDCs) were generated by culturing adherent monocytes in X-VIVO 15 
medium (Lonza, Verviers, Belgium) supplemented with 2% HS, 500 U/ml IL-4 and 800 U/ml 
GM-CSF (both Immunotools, Friesoythe, Germany). After 3 days, cells were harvested, 
used for T cell stimulation experiments or further cultured as described before15. At day 8, 
mature DCs (mDCs) were harvested and used in T cell stimulation experiments. LRH- 
1-specific CD8+ cytotoxic T cell (CTL) culture RP1 was isolated from CML-AP Pt 1 and was 
cultured as described previously4. Before use in T cell stimulation experiments, leukemia 
samples and DCs were cultured overnight in the absence or presence of 100 U/ml IFN-γ 
and 1.25 ng/ml TNF-α (both Immunotools). 
Mixed lymphocyte-AML reactions and CTL stimulation assays
After culturing and preincubation, AML cells and DCs were washed, counted and seeded 
4
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stimulation with IFN-γ (Figure 1A), while expression of co-stimulatory molecules CD80 and 
CD86 on these CD34+ CML-AP cells was low. Furthermore, we observed high PD-L1 
expression on CD34+ leukemia cells in a chloroma biopsy of an AML patient (Pt 2) who 
relapsed three years after DLI (Figure 1B). Again, we found that these extramedullary AML 
cells expressed low levels of CD80 and CD86 (data not shown). Staining of specific T cell 
markers revealed that CD8+ T cells extensively infiltrated the chloroma, while FOXP3+ 
regulatory T cells were hardly detectable (Supplementary Figure 1). These data suggest 
that selective expression of PD-L1 on these relapsed leukemia cells could have been 
involved in evading LRH-1-specific CD8+ T cell immunity. 
Immunohistochemistry staining
Paraffin-embedded chloroma tissues were stained as previously described17. Briefly, 
antigen retrieval was performed using 10 minutes of boiling in 0.01 M of sodium citrate pH 
6.0 followed by incubation with primary antibodies anti-PD-L1 (clone MIH1, eBioscience, 
San Diego, CA, USA), anti-PD-L2 (clone MIH18, eBioscience), anti-CD8 (clone C8/144B, 
DAKO), anti-CD34 (clone QBEnd/10, Klinipath, Duiven, the Netherlands) and anti-FOXP3 
(clone 236A/ E7, ITK Diagnostics, Uithoorn, the Netherlands). Staining was visualized either 
by 3,3-diaminobenzidine (DAB) or aminoethyl carbazole (AEC) staining. 
IFN-γ and granzyme B ELISA
Production of IFN-γ and granzyme B by stimulated T cells was determined by enzyme- 
linked immunosorbent assay (ELISA; IFN-γ: Pierce Endogen, Rockford, IL, USA; granzyme B: 
Mabtech, Nacka Strand, Sweden) according to manufacturer’s protocol.
Real-time quantitative reverse transcription PCR and microarray analysis
Total RNA was isolated from cell samples using Trizol (Invitrogen, Carlsbad, CA, USA). cDNA 
synthesis and PCR amplification were performed as described18. The hydroxymethylbilane 
synthase (HMBS) housekeeping gene was used to normalize PD-L1  and PD-L2 expression. 
PD-L1 and PD-L2 mRNA expression is shown in ∆∆Ct values and was quantified relative to 
cell line U266, which was set at 1. ∆∆Ct was calculated as follows: 2∧(-[∆Ct
sample
]-[∆Ct
U266
]), 
in which ∆Ct was normalized for HMBS by calculating ∆Ct = Ct
gene
 - Ct
HMBS
 per sample.
 For microarray analysis, LRH-1-tetramer+ human CD8+ T cells were sorted (median 
sorted cell number: 1,300; range: 200-15,000 cells) on an Epics Elite sorter (Beckman 
Coulter), resulting in a >96% pure product, and resuspended in Trizol. RNA extraction, 
amplification, cDNA generation and microarray analysis were performed as described 
previously19. 
Statistical analysis
Paired one-tailed student-t test or one-way ANOVA followed by a Bonferroni post-hoc test 
were used when appropriate.
Results
Myeloid leukemia progenitor cells differentially express PD-L1 compared with 
CD80 and CD86
To investigate whether myeloid leukemia cells in relapsed patients after allo-SCT express 
PD-L1 under inflammatory conditions, we analyzed leukemia samples from two patients 
who relapsed despite circulating LRH-1-specific CD8+ T cells (Table 1). We found that CD34+ 
CML-AP cells from a relapsed patient (Pt 1) at four years after DLI expressed PD-L1 upon 
4
Table 1  Myeloid leukemia patient characteristics and PD-L1 expression
Patient Disease-
FAB 
classification
Sample 
type
WBC 
count at 
sample 
date
PD-L1 mRNA 
expression
PD-L1 surface 
expression (MFI)
unstim IFN-γ
TNF-α
unstim IFN-γ
TNF-α
1 CML-CP PB 11 ND ND 0.4 0.6
1-relapse CML-AP PB 105 ND ND 1.0 2.0
2-relapse AML-M0 chloroma 6 ND ND  +a ND
3 AML-M0 BM 14 0.4 140.1 1.2 7.7
4 AML-M0 BM 54 1.1 73.5 1.2 5.2
5 AML-M2 BM 47 0.2 122.8 2.0 26.5
6 AML-M4 BM 114 0.3 64.8 2.0 15.6
7 AML-M4 BM 87 0.3 483.7 1.8 14.7
8 AML-M4 BM 89 2.1 239.7 1.3 7.9
9 AML-M4 BM 20 0.9 1254.6 1.8 39.2
10 AML-M5 BM 108 0.4 2674.4 1.5 20.0
11 AML-M5 BM 259 ND ND 5.9 15.4
12 AML-M2 BM 6 4.8 254.2 1.8 6.0
13 AML-M4 BM 17 4.9 236.9 1.6 10.3
14 AML-M5 BM ND 28.3 800.2 3.5 29.5
Characteristics of myeloid leukemia patients which have been analyzed for PD-L1 expression. Patient samples 
at diagnosis, except indicated by ‘relapse’. CML-CP, chronic myeloid leukemia-chronic phase; CML-AP, chronic 
myeloid leukemia-accelerated phase; PB, peripheral blood; BM, bone marrow; unstim, unstimulated; MFI, mean 
fluorescence intensity; ND, not determined; WBC, white blood cell count in 109/L peripheral blood; aDetermined 
by immunohistochemistry. 
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 To determine whether selective induction of PD-L1 expression under inflammatory 
conditions is a general phenomenon in leukemia, we analyzed a panel of 12 primary AML 
samples for expression of co-signaling ligands following treatment with IFN-γ and TNF-α 
(Table 1). Indeed, these cytokines induced an 137-fold and 31-fold up-regulation of PD-L1 
and PD-L2 mRNA, respectively (Figure 1C). Furthermore, consistent with the findings in 
the two relapsed leukemia patients, PD-L1 cell surface expression was significantly 
up-regulated (> 20% PD-L1+ cells) on AML cells of 7 out of 10 newly diagnosed patients, 
while expression of PD-L2 was only slightly induced (Figure 1D). Notably, PD-L1-expressing 
AML cells displayed very low expression of CD80 and a variable expression of CD86, which 
was not influenced by IFN-γ/TNF-α treatment. 
 Because AML clones comprise heterogeneous populations of malignant cells, we 
studied whether different AML populations exhibited differential expression of co-signaling 
molecules. Using multi-color flowcytometry, we defined three distinct AML populations 
defined as CD33+CD117+CD14- AML progenitor cells, CD33+CD117-CD14- AML myelo/mono - 
blasts and CD33+CD117-CD14+ AML promonocytes (Supplementary Figure 2A-B). A panel 
of nine AML patients with different FAB classifications was used for analyzing expression of 
co-signaling ligands upon IFN-γ ± TNF-α stimulation. Interestingly, the most immature 
CD33+CD117+CD14- AML cells exhibited high PD-L1 expression (range: 46-94% PD-L1+ cells) 
in combination with almost absent or very low expression of PD-L2, CD80 and CD86 
under inflammatory conditions (Figure 1E). The CD33+CD117-CD14- AML myelo/monoblasts 
showed slightly more up-regulation of PD-L1 and CD80 expression as well as higher 
CD86 expression (Supplementary Figure 2C). Mature CD33+CD117-CD14+ AML promono- 
cytes displayed combined up-regulation of PD-L1, PD-L2, CD80 and CD86 expression 
(Supplementary Figure 2D).
 Collectively, these data demonstrate that immature AML cells which contain the 
putative leukemic stem cells selectively up-regulate PD-L1 expression following short-term 
exposure to IFN-γ and TNF-α, enabling these leukemia progenitor cells to inhibit T 
cell-mediated attack via the PD-1/PD-L1 pathway.
4
Leukemia cells were exposed to 100 U/ml IFN-γ and 1.25 ng/ml TNF-α 16 hours before analysis. 
(B) Expression of PD-L1 and PD-L2 by CD34+ AML cells in a chloroma biopsy of Pt 2 at time of 
relapse, 3 years after DLI, was determined by immunohistochemistry. Staining was visualized using 
DAB (CD34) or AEC (PD-L1, PD-L2 and isotype control). Magnification 1000x. (C) CD33+ AML cells 
from 9-12 different patients were incubated with 100 U/ml IFN-γ  and 1.25 ng/ml TNF-α for 16 hours, 
after which PD-L1 and PD-L2 mRNA expression with (+) and without (-) IFN-γ and TNF-α was measured. 
(D) Expression of co-stimulatory ligands on CD33+  AML cells, in the absence (-) or presence (+) of 
IFN-γ and TNF-α, was determined by flowcytometry. (E) Expression of PD-L1, PD-L2, CD80, CD86 
and CD54 on CD33+CD117+CD14- progenitor AML cells from 8 patients. Expression is depicted as 
mean + SD. Paired one-tailed student-t test was performed to identify significant differences. 
*P <0.05; **P <0.01; ***P <0.001.
Figure 1   Myeloid leukemia cells express PD-L1 under inflammatory conditions
Expression of co-signaling ligands on myeloid leukemia cells was determined by flowcytometry 
analysis, immunohistochemistry and RT-PCR. (A) Flowcytometry analysis of PD-L1, PD-L2, CD80 and 
CD86 expression on CD34+ progenitor cells of CML-AP Pt 1 at time of relapse, 4 years after DLI. 
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Effect of PD-L1-expressing AML cells on allogeneic T cells
To investigate whether PD-L1 expression on AML cells can dampen allogeneic T cell 
responses, we performed mixed lymphocyte reactions with PD-L1-expressing AML cells 
and allogeneic CD3+ T cells in the absence or presence of anti-PD-1/BMS-936,558 and 
anti-PD-L1/BMS-936,559 blocking antibodies. Blocking with either anti-PD-1 or anti-PD-L1 
antibody significantly increased proliferation of CD3+ T cells upon stimulation with 
allogeneic PD-L1+ AML cells from AML-M4 Pt 9 (Figure 2A), whereas allogeneic T cell 
proliferation stimulated with PD-L1+ and PD-L2+ mDCs could only be boosted with 
anti-PD-1 (Figure 2B). This difference can be explained by the high PD-L2 expression on 
mDCs resulting in insufficient interference of PD-1 signaling by the PD-L1 antibody. In 
agreement with the T cell proliferation data, IFN-γ production was also increased by 
blocking of PD-1 interactions between T cells and PD-L1+ AML cells (Figure 2C) or PD-L1+/
L2+ mDCs (Figure 2D). These results demonstrate that PD-L1 expression on AML cells 
decreases T cell proliferation and cytokine production.
MiHA-specific CTL expansion and function is enhanced by PD-1 blockade
To elucidate the role of PD-L1 on AML cells in inhibiting the recognition by MiHA-specific 
CD8+ T cells, we performed antigen restimulation experiments using CTL clone RP1 that 
recognizes the hematopoietic-restricted MiHA LRH-1 on AML progenitor cells4. RP1, as well 
as CTLs against other MiHAs, up-regulated expression of PD-1 upon co-culture with MiHA+ 
AML (Supplementary Figure 3 and data not shown). Antibody blockade of PD-1 signaling 
using human antibodies resulted in improved proliferation and IFN-γ production by CTL 
RP1 upon engagement of PD-L1-expressing primary AML cells from Pt 11 loaded with 
MiHA peptide (Figure 2E-G). As hypothesized, we found that PD-1 blockade strongly 
elevated the proliferation and IFN-γ production by CTL RP1 when stimulated with 
peptide-loaded PD-L1+ iDCs (Figure 2F-H). Cytotoxicity of CTLs versus AML cells was also 
enhanced after PD-1 and PD-L1 blockade (Figure 2I), whereas no cytoxicity was observed 
versus iDCs (Figure 2J). These data indicate that MiHA-specific CD8+ effector T cells can be 
inhibited via the PD-1/PD-L1 pathway either by AML or resident APC populations that 
selectively express PD-L1 in the leukemia microenvironment. 
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Figure 2   PD-1 blockade enhances T cell responses to stimulation with primary AML 
cells and DCs
Allogeneic CD3+ T cells were co-cultured with PD-L1-expressing leukemia cells of AML Pt 9 (A and C) 
or PD-L1+PD-L2+ mDCs (B and D) with addition of blocking anti-PD-1 or anti-PD-L1 antibodies. 
Proliferation was measured on day 5 (A and B) and IFN-γ production was evaluated (C and D). LRH-1-
specific CTL RP1 was co-cultured with peptide-loaded primary leukemic cells of AML Pt 11 (E, G and 
I) or peptide-loaded PD-L1+ iDCs (F, H and J), combined with blockade of PD-1 or PD-L1. Subsequently, 
proliferation was measured (E and F) in addition to IFN-γ production (G and H). Cytotoxicity was 
measured by granzyme B secretion (I and J). One representative experiment out of 3 is shown. One-
way ANOVA was performed with isotype antibody as control. *P <0.05; **P <0.01; ***P <0.001.
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patient (Figure 3A-B). After DLI, PD-1 levels at the cell surface of LRH-1-specific CD8+ T cells 
gradually declined, but >95% of the tetramer-positive T cells remained PD-1 positive 
during the contraction phase. To determine PD-1 expression on the apparently impaired 
LRH-1-specific CD8+ T
mem
 cells in the relapsed patients several years after DLI, we sorted 
LRH-1-specific CD8+ T
eff
 cells (Pt 1: 1.8% at week 28; Pt 2: 2.9% at week 15) and low 
frequencies of LRH-1-specific CD8+ T
mem
 cells (Pt 1: 0.08% at week 225; Pt 2: 0.05% at week 
151) and performed microarray analysis using amplified cDNA. PD-1 mRNA levels of 
LRH-1-specific CD8+ T
mem
 cells at the time of relapse were elevated or similar compared 
with LRH-1-specific CD8+ T
eff
 cells at the peak of the response for Pt 1 and Pt 2, respectively 
(Figure 3C). These data indicate that LRH-1-specific CD8+ T cells express elevated levels of 
PD-1 on the cell surface, which remain present during the contraction and late memory 
phase of the immune response following DLI.
PD-1 blockade augments proliferation of MiHA-specific CD8+ T cells 
To further elucidate the role of PD-1 in impairment of LRH-1-specific CD8+ T
mem
 cells, we 
performed functional assays using PBMCs from CML-AP Pt 1 containing 0.05-0.10% 
LRH-1-specific CD8+ T
mem
 cells several years after the initial response. Stimulation of PBMCs 
of Pt 1 with peptide alone in the presence of IL-2 and IL-15 did not result in an increase of 
LRH-1-specific T cells (data not shown). Notably, PD-1 or PD-L1 blockade resulted in a 2- to 
4-fold increase in the number of LRH-1-specific T cells (Figure 4A). However,  peptide 
stimulation in the presence of PD-1 blockade, but in the absence of professional APCs, 
resulted in insufficient T cell outgrowth. Therefore, we stimulated PBMCs containing 
LRH-1-specific T
mem
 cells with peptide-loaded PD-L1-expressing iDCs in the presence of 
PD-1 blockade. Blockade with anti-PD-1 antibody resulted in a 20-times higher number of 
LRH-1-specific CD8+ T cells after three stimulations with peptide-loaded PD-L1+ iDCs 
(Figure 4B). Consistently, we observed a specific increase to 4.4% LRH-1-specific CD8+ T 
cells compared to 0.6% with the isotype control after repeated DC stimulations using 
blockade with anti-PD-1 (Figure 4C). 
 Similar assays were performed with PBMCs obtained 7 and 36 months post-DLI 
containing low numbers of LRH-1-specific T
mem
 cells from AML-M0 Pt 2. In these assays, we 
used mDCs in order to prevent repetitive T cell stimulation. At 7 months post-DLI, blocking 
with anti-PD-1 and anti-PD-L1 antibody resulted in increased outgrowth of LRH-1-specific 
CD8+ T cells up to 8.1% and 6.4%, respectively, compared to 2.0% in the presence of an 
isotype control (Figure 4D). In addition, during relapse at 36 months post-DLI, upon PD-1 
and PD-L1 blockade LRH-1-specific CD8+ T cells increased to 1.16% and 0.86%, respectively, 
compared to 0.59% for isotype control (Table 2). To further confirm the effect of PD-1/
PD-L1 blockade on the proliferative capacity of other MiHA-specific T cells, we stimulated 
PBMCs from a relapsed MM patient (Pt 16) containing HA-1-specific T cells. In concordance 
with results obtained with LRH-1-specific CD8+ T cells, blockade of PD-1/PD-L1 interactions 
lead to enhanced mDC-stimulated proliferation of HA-1-specific CD8+ T cells (Figure 4E). In 
PD-1 is highly expressed by circulating MiHA-specific CD8+ T cells in vivo
Next, we investigated whether PD-1 is expressed by LRH-1-specific T cells in CML-AP Pt 1 
and AML-M0 Pt 2 who relapsed four and three years, respectively, after the initial DLI that 
induced long-lasting LRH-1-specific CD8+ T cell responses in these patients. PD-1 
expression could be detected on LRH-1-specific CD8+ T cells during the complete course 
of the immune response after DLI which peaked at week 28 for CML-AP Pt 1 and at week 
10 for AML-M0 Pt 2 (Figure 3A). We observed relatively elevated expression of PD-1 on 
LRH-1 tetramer-positive T cells compared with tetramer-negative CD8+ T cells in the same 
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Figure 3   MiHA-specific T cells express elevated levels of PD-1 in vivo
(A) PD-1 expression of LRH-1-specific T cells in CML-AP Pt 1 and AML-M0 Pt 2 was determined by 
flowcytometry. Time post-DLI is indicated in weeks, percentage of LRH-1-specific T cells of total 
CD8+ T cells in brackets and MFI of LRH-1-specific T cells is displayed. (B) PD-1 expression of LRH-1-
specific T cells compared to total CD8+ T cells in the same patient. (C) LRH-1 specific T cells were 
isolated by flowcytometry-assisted cell sorting. Subsequently, RNA was isolated and PD-1 mRNA 
levels were determined at the peak of the response, and in LRH-1-specific T
mem
 cells 4.5 or 3 years 
after the initial response. Raw intensity values measured from microarray analysis are depicted.
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Figure 4   PD-1 blockade increases ex vivo proliferation of MiHA-specific CD8+ T
mem
 cells
(A) PBMCs of CML-AP Pt 1 containing low levels of LRH-1-specific T
mem
 cells years after the initial 
response were stimulated by addition of LRH-1 peptide in the presence of blocking antibodies 
against PD-1 or PD-L1. Numbers of LRH-1-specific cells were enumerated by flowcytometry, and 
numbers at isotype control were set to 1. Results are from three independent experiments from a 
sample 225 weeks after DLI ( ,  and ) and one sample taken 275 weeks after DLI ( ). (B) iDCs were 
loaded with LRH-1 peptide and added weekly to PBMCs, containing LRH-1-specific T
mem
 cells, for 3 
weeks, combined with blocking antibodies. (C) LRH-1-specific T cell percentages of total CD8+ were 
identified by flowcytometry. iDC stimulation assays with Pt 1 are representative of 3 separate expe-
riments. (D) mDCs loaded with LRH-1 peptide were used to stimulate LRH-1-specific T
mem
 cells of 
AML-M0 Pt 2. Subsequently, the percentage of LRH-1-specific T cells after one week was determined 
by flowcytometry. (E) mDCs loaded with HA-1 peptide were used to stimulate HA-1-specific T
mem
 
cells of relapsed MM Pt 16. Subsequently, the percentage of HA-1-specific T cells after one week was 
determined by flowcytometry. 
Table 2   Characteristics of transplanted patients and effect of PD-1-blockade on MiHA-
specific T cell proliferation
Pt Disease MiHA 
T cell 
response
Sample date 
(months post-
SCT or post-DLI)
Effect PD-1
Blockadea
Clinical outcome 
1 CML-AP LRH-1 52 post-tDLI 19.8 Hematologic relapse
at 47 mo post-tDLI
2 AML LRH-1 7 post-pDLI 15.4 Chloroma relapses at 33, 
70, 78 post-pDLI
2 AML LRH-1 36 post-pDLI 2.8 Chloroma relapses at 33, 
70, 78 post-pDLI
15 CML-BC HA-1 9 post-pDLI 1.5 Remission; death due to 
GVHD at 11 mo post-pDLI
16 MM HA-1 6 post-SCT 5.5 Active disease at 6 mo 
post-SCT. Plasma cells 5%; 
M-protein 7 gr/L
17 Pre-T ALL HA-2 12 post-SCT 2.5 Remission; alive at 174 
mo post-SCT
18 CML SP110 20 post-SCT 8.7 Cytogenetic relapse at 14 
mo post-SCT
19 AML HA-8 12 post-SCT 0.7 Remission; alive at 213 
mo post-SCT
20 NHL HA-1 12 post SCT 5.9 Remission; alive at 165 
mo post-SCT
21 MM HA-1 6 post SCT 3.3 Remission; alive at 31 mo 
post-SCT
Characteristics of patients with hematological malignancies displaying MiHA-specific T cell responses. Pt, 
patient; CML-AP, chronic myeloid leukemia accelerated phase; CML-BC, chronic myeloid leukemia blast crisis; 
MM, multiple myeloma; NHL, non-Hodgkin lymphoma; T-ALL, T cell acute lymphoblastic leukemia; pDLI, pre-
emptive donor lymphocyte infusion; tDLI, therapeutic donor lymphocyte infusion; SCT, stem cell transplantation; 
MiHA-specific response: MiHA for which a response was observed; Mo, months; GVHD, graft-versus-host-disease. 
aEffect PD-1 blockade: ratio absolute number of tetramer+ cells DC + peptide + anti-PD-1/absolute number of 
tetramer+ cells DC + peptide + isotype control.
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addition, we investigated whether PD-1 blockade increased the absolute amount of 
MiHA-specific T cells. For AML Pt 2 and MM Pt 16, we observed a robust absolute increase 
of MiHA-specific T cells upon PD-1 and PD-L1 blockade (Figure 5A). 
 Next, we investigated whether the effect of PD-1/PD-L1 is exclusive for dysfunctional 
MiHA-specific T cells in relapsed patients, or that it also affects potential non-impaired T 
cells in patients with remission after allo-SCT. Therefore, we investigated the effect of 
PD-1/PD-L1 blocking in CML-BC Pt 15 and pre-T ALL Pt 17 (Table 2). PD-1 and PD-L1 
blockade enhanced the absolute number of MiHA-specific T cells, but the effect was 
moderate (Figure 5B). Finally, we compared the effect of PD-1 blockade on MiHA-specific 
T cells from relapsed patients to those from patients in remission. Importantly, we showed 
that PD-1 blockade had a significantly superior effect on dysfunctional MiHA-specific T 
cells from relapsed patients (Figure 5C). Collectively, these results demonstrate that PD-1 
signaling impairs the proliferative capacity of MiHA-specific CD8+ T cells upon antigen 
stimulation prior to or during relapse, and this functional impairment can be abrogated by 
PD-1/PD-L1 immune checkpoint blockade.
Discussion
Allo-SCT is a potentially curative treatment for advanced myeloid leukemia1. The effect 
largely depends on alloreactive CD8+ T cells targeting MiHAs on leukemic blasts and 
progenitor cells20. However, MiHA-specific CD8+ T cell responses induced after transplan-
tation are in many patients not sufficient to sustain complete remission. Distinct 
mechanisms are involved in reducing anti-tumor T cell responses, allowing malignant cells 
to escape immune destruction. Among these mechanisms, T cell inhibition or even 
exhaustion due to signaling of the PD-1/PD-L pathway may diminish immune responses 
by limiting the expansion and functionality of CD8+ T cells12;21. Recently, we showed that 
LRH-1+ leukemia can relapse without inducing secondary LRH-1-specific CD8+ T
mem
 cell 
expansion, suggesting that these T
mem
 cells are either suppressed or not activated3;4. In this 
study, we examined the role of PD-1/PD-L1 interactions in functional impairment of 
LRH-1-specific CD8+ T cells reactive to myeloid leukemia. Interestingly, we showed that 
PD-L1 and to some extent PD-L2 was expressed by CD34+ progenitor myeloid leukemia 
cells of two patients with relapses after initial efficient T cell responses. Furthermore, we 
confirmed expression of PD-L1 on a broader panel of AML samples at diagnosis. Previously, 
it has been shown that PD-L1 expression is elevated on relapse AML cells compared to 
diagnosis material22. We investigated this in one CML patient, and indeed, PD-L1 expression 
was higher on relapse tumor cells than cells at diagnosis (Table 1). Especially CD117+CD14- 
early progenitor myeloid leukemia cells, which contain the leukemic stem cells, highly 
expressed PD-L1. PD-L1 expression increased upon exposure to inflammatory cytokines, 
whereas expression of CD80 and CD86 remained low. Consequently, prolonged PD-1/
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Figure 5   The effect of PD-1 blockade on proliferation of MiHA-specific T cells in 
 relapsed patients is higher than in patients in remission
PBMCs containing MiHA-specific T cells were stimulated with DCs loaded with their cognate pep-
tide with or without anti-PD-1 or anti-PD-L1. (A) PD-1/PD-L1 blockade enhances the expansion of 
MiHA-specific T cells in relapsed patients. Pt 2 and Pt 16 experienced relapse after initial MiHA-
specific responses. PBMCs obtained prior to additional therapy to treat relapse were investigated. 
(B) PD-1/PD-L1 blockade moderately enhances expansion of MiHA-specific T cells in patients in 
long-term remission. Pt 15 and Pt 17 remained in remission after initial immune responses. (C) The 
effect of PD-1 blockade is significantly higher on MiHA-specific T cells in relapsed patients. Ratio was 
calculated by dividing the absolute number of tetramer+ T cells in the presence of anti-PD-1 anti-
body by the absolute number of tetramer+ T cells in the presence of isotype control. One-tailed 
student t-test was performed, *P <0.05. 
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minimize off-target stimulatory effects, since the hyperstimulatory DCs are loaded with 
hematopoietic-restricted MiHAs. Results of clinical trials being performed with 
BMS-936,558 and BMS-936,559 in parallel with preclinical mouse models using blocking 
antibodies in a post-SCT setting will determine the ideal therapy combination.
 In conclusion, we demonstrated PD-L expression on myeloid leukemia cells, especially 
under inflammatory conditions. Interestingly, CD117+ early progenitor myeloid leukemia 
cells express high levels of PD-L1, but low CD80 and CD86 expression. Furthermore, we 
showed that blockade by human anti-PD-1 or anti-PD-L1 results in increased proliferation 
of and IFN-γ and granzyme B production by LRH-1-specific CTLs stimulated with PD-L1+ 
leukemia cells. In addition, LRH-1-specific CD8+ T cells exhibited elevated PD-1 expression 
in vivo. Most importantly, we could specifically resuscitate initially unresponsive 
MiHA-specific T
mem
 cells by PD-1/PD-L1 blockade. Therefore, we postulate that PD-1 
blockade could be a powerful addition to post-SCT therapy. Combining MiHA-specific DC 
vaccination with PD-1 blockade may reinvigorate impaired MiHA-specific T
mem
 cells and 
restore immune control, thereby preventing or attacking leukemia relapses.
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PD-L1 interactions may lead to functional exhaustion of LRH-1-specific T
mem
 cells, and 
relapse of the leukemia may occur without induction of a secondary immune response. 
 To  investigate  whether  LRH-1-specific T cells display an impaired phenotype, we 
analyzed T cells of two patients with LRH-1-specific responses. It is known that PD-1 is 
elevated on T cells specific for viral epitopes in chronic viral infections23. Also during 
chronic CML disease it has been shown that PD-1 levels on the total population of CD8+ T 
cells are elevated12. Here, we showed for the first time that MiHA-specific T
mem
 cells can 
have an elevated level of PD-1. Both patients with non-responding T
mem
 cells had leukemia 
relapses following a robust initial LRH-1-specific T cell response. Whether or not elevated 
PD-1 expression on MiHA-specific T cells correlates with immune escape and subsequent 
relapse of myeloid leukemia needs to be determined in a larger cohort of patients. 
However, we found that the PD-1/PD-L1 pathway negatively influences the function of 
PD-1-expressing LRH-1-specific CTLs. Most importantly, we demonstrated that blocking 
PD-1/PD-L1 interactions with human blocking antibodies resulted in increased outgrowth 
of MiHA-specific T
mem
 cells from allo-SCT recipients. We also observed a stimulatory effect 
of PD-1 blockade on MiHA-specific T cells from patients in remission, which is not 
unexpected due to the role of PD-1 in regulation of T cell activation. However, the 
abrogation of PD-1 signaling had a significant stronger effect on the proliferation of 
MiHA-specific T cells in relapsed patients compared to patients in remission. 
 Besides PD-1, several other inhibitory receptors are known to play a role in functional 
T cell exhaustion, such as CTLA-4, LAG3, BTLA, TIM-3, CD160 and CD24424. In future years, 
the influence of this array of co-inhibitory receptors will be further elucidated and perhaps 
combinations of blocking antibodies against targets such as PD-1 and LAG3 will result in 
highly re-activated MiHA-specific T cell responses25. But, as PD-1 is involved in peripheral 
tolerance, autoimmune events following PD-1 blockade therapy may occur26. In a recent 
phase I study, the clinical grade anti-PD-1 antibody BMS-936,558, also used in our study, 
was administered to patients with solid tumors. Anti-PD-1 was well tolerated and only 
one serious adverse event, inflammatory colitis, was observed in a melanoma patient. 
Remarkably, one durable complete response and two partial responses were observed16. 
Our current in vitro data illustrate that PD-1 blockade is an attractive approach to 
reinvigorate impaired MiHA-specific T cells in patients with persisting or relapsed leukemia. 
However, in the setting of allogeneic SCT, PD-1 blockade could aggravate graft-versus-
host-disease. For optimal boosting selective GVT immunity in the post-SCT setting, we 
would like to combine active immunotherapy by DC vaccination using hematopoietic-
restricted MiHAs with PD-1 blockade. By inducing a time-limited alleviation of PD-1 
signaling combined with an antigen-specific stimulus, we aim to resuscitate the impaired 
MiHA-specific T cells, without causing autoimmune effects or GVHD. Another strategy is 
to specifically knock down PD-L1 and/or PD-L2 on MiHA-loaded DC vaccines by siRNA. In 
a recent article, we showed that stimulation with PD-L1/L2 knockdown DCs resulted in 
specific outgrowth of initially unresponsive MiHA-specific T cells15. This strategy would 
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4Supplementary Figure 1   
High numbers of CD8+ cells have infiltrated the extramedullary AML, whereas only 
 minimal numbers of FOXP3+ regulatory T cells are present
Staining was visualized using DAB. Magnification CD8 100x, FOXP3 400x.
Supplementary Figure 3   
LRH-1-specific CTL line expresses and up-regulates PD-1 during co-culture with primary 
AML cells
(A) During 6 days of co-culture of CTL with CD33+ AML cells of Pt 11, expression of PD-1 on LRH-1-
specific CTL was monitored by flowcytometry. (B) Expression of PD-1 on LRH-1-specific CTLs on day 6.
Supplementary Figure 2   
Subpopulation distribution and expression of co-signaling molecules within AML
(A) The total AML population was identified by CD33 expression, and AML subsets were further 
defined by CD14 and CD117 expression. Example of the gating strategy of different AML sub-
populations using a bone marrow sample of AML-M2 patient 5. (B) Distribution of leukemic sub-
populations within 9 AML samples of morphologically diagnosed FAB classification M0, M1, M2, M4 
and M5. Expression of co-stimulatory molecules after overnight incubation with IFN-γ and TNF-α on 
(C) CD117-CD14- intermediate AML cells or (D) CD117 - CD14+ AML promonocytes.
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Abstract
Allogeneic stem cell transplantation (allo-SCT) can cure hematological malignancies by 
inducing alloreactive T cell responses targeting minor histocompatibility antigens (MiHAs) 
expressed on malignant cells. Despite induction of robust MiHA-specific T cell responses 
and long-term persistence of alloreactive memory T cells specific for the tumor, often 
these T cells fail to respond efficiently to tumor relapse. Previously, we demonstrated the 
involvement of the co-inhibitory receptor Programmed death-1 (PD-1) in suppressing 
MiHA-specific CD8+ T cell immunity. Here, we investigated whether B and T lymphocyte 
attenuator (BTLA) plays a similar role in functional impairment of MiHA-specific T cells after 
allo-SCT. In addition to PD-1, we observed higher BTLA expression on MiHA-specific CD8+ 
T cells compared to the total population of CD8+ effector-memory T cells. In addition, 
BTLA’s ligand Herpes virus entry mediator (HVEM) was found constitutively expressed by 
myeloid leukemia, B-cell lymphoma and multiple myeloma cells. Interference with the 
BTLA/HVEM pathway, using a BTLA blocking antibody, augmented proliferation of 
BTLA+PD-1+ MiHA-specific CD8+ T cells by HVEM-expressing dendritic cells. Interestingly, 
we demonstrated that blocking BTLA or PD-1 enhanced ex vivo proliferation of 
MiHA-specific CD8+ T cells in respectively 7 and 9 out of 11 allo-SCT patients. Notably, in 3 
out of 11 patients the effect of BTLA blockade was more prominent than that of PD-1. 
Furthermore, these expanded MiHA-specific CD8+ T cells competently produced effector 
cytokines and degranulated upon antigen reencounter. Together, these results demonstrate 
that BTLA/HVEM interactions impair MiHA-specific T cell functionality, providing a 
rationale for interfering with BTLA signaling in post-SCT therapies. 
Introduction
Allogeneic stem cell transplantation (allo-SCT) can be a curative treatment for 
hema to logical malignancies1. The therapeutic effectiveness is attributed to the graft- 
versus-tumor (GVT) effect, which is constituted by donor T cells targeting minor histo-
compatibility antigens (MiHAs) expressed by tumor cells2. Recipient dendritic cells (DCs) 
present MiHAs to donor-derived MiHA-specific CD8+ T cells, whereupon these cells get 
activated and expand. Subsequently, they migrate to the tumor sites and lyse the cancer 
cells3. Adaptive immune responses, including alloreactive responses, terminate in a 
contraction phase, leaving a small pool of long-lived MiHA-specific memory cells4. 
Unfortunately, despite the presence of these memory cells many patients with a 
hematological malignancy relapse post-transplantation5;6, suggesting that MiHA-specific 
T cell functionality is affected. Tumor cells are known to evade immune attack via multiple 
mechanisms7, amongst which is interference with T cell activation. This is a tightly 
coordinated event, involving T cell receptor-mediated recognition of the cognate peptide, 
ligation of co-signaling receptors, and cytokine signalling8. In recent years, the distinct role 
of co-inhibitory receptors in this process has been extensively investigated9;10. Expression 
of these receptors has been linked to functional impairment of T cells in various diseases, 
such as chronic viral infections11;12 and cancer13-15. 
 We recently investigated whether MiHA-specific T cells in patients after allo-SCT are 
functionally impaired by signaling of co-inhibitory receptors, and demonstrated that 
blockade of the Programmed death-1 (PD-1; CD279) pathway augmented proliferation 
and cytokine-production of MiHA-specific T cells16. PD-1 is involved in T cell exhaustion, a 
phenomenon characterized by the gradual loss of T cell functionality, i.e. diminished 
cytokine production, proliferative capacity and cytolytic activity17. In addition, it was 
observed that concurrent expression of multiple co-inhibitory receptors determines the 
functional state of T cells18. One of these co-inhibitory receptors is B- and T-lymphocyte 
attenuator (BTLA; CD272)19. This receptor is a member of the CD28/B7 family, but in contrast 
to PD-1 and Cytotoxic T-lymphocyte antigen 4 (CTLA-4), BTLA binds to a member of the 
Tumor necrosis factor receptor superfamily, Herpes virus entry mediator (HVEM)20. Other 
binding partners of HVEM are CD160 and LIGHT (for Lymphotoxin-like, exhibits inducible 
expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T 
lymphocytes).21 HVEM ligation to the receptors BTLA and CD160 was shown to be 
inhibitory, while the interaction of HVEM with LIGHT mediates T cell stimulation22. Recently, 
a role for BTLA was implicated in the escape of melanoma cells from T cell immunity23. The 
authors demonstrated that high BTLA expression on Melan-AMART-1-specific CD8+ T cells 
correlated to inhibition of antigen-specific cytokine production in melanoma patients. 
Therefore, we investigated the role of BTLA in the functional impairment of MiHA-specific 
T cells in allo-SCT patients. Here, we demonstrated that these alloreactive cells had high 
expression of both BTLA and PD-1. Moreover, we showed that HVEM and BTLA were 
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Flow cytometry
BTLA and PD-1 expression on CD8+ T cell subsets of healthy donors and allo-SCT patients 
was analyzed by staining PBMCs with antibodies against CCR7 (clone 150503, R&D systems, 
Abingdon, United Kingdom), CD45RA (clone H100, Biolegend, Antwerp, Belgium), CD3 
(clone UCHT1, Beckman Coulter, Fullerton, CA, USA) and CD8 (clone 3B5, Invitrogen) in 
combination with BTLA (clone J168-340), PD-1 (clone MIH4, both Becton Dickinson, 
Franklin Lakes, NJ, USA) or IgG1 isotype control (Dako, Glostrup, Denmark). In case of 
PBMCs containing MiHA-,  CMV-pp65- or influenza virus (FLU)-specific CD8+ T cells, cells 
were first labeled with 1.5-2 µg APC-conjugated tetramers containing the corresponding 
peptide. Tetramers were kindly provided by prof. dr. Frederik Falkenburg (Department of 
Hematology, LUMC, Leiden, the Netherlands).
 Human AML and MM cell lines, primary patient samples and healthy donor leukocytes 
were phenotyped by staining the cells with antibodies recognizing HVEM (clone 122, 
Biolegend), BTLA, CD160 (clone BY55, Beckman Coulter), LIGHT (clone 7-3(7), eBioscience, 
Vienna, Austria) or IgG1 FITC/PE dual-color isotype control (Dako). Primary AML cells were 
gated on CD33+ cells using a CD33 antibody (clone D3HL60.251, Beckman Coulter). Primary 
MM cells were gated on CD38+CD138+ cells using antibodies against CD38 (clone HIT2, 
Becton Dickinson) and CD138 (clone B-A38, Beckman Coulter). Healthy donor leukocytes 
were labeled with antibodies recognizing CD3 (clone UCHT1), CD8 (clone SFCI21Thy2D3, 
Beckman Coulter), CD14 (clone HCD14, Biolegend) and CD19 (clone HD37, Dako).
 MiHA-specific T cell cultures were incubated with PE-labeled tetramer and, subsequently, 
labeled with FITC-conjugated CD8 (clone LT8, ProImmune, Oxford, United Kingdom) and 
PE-Cy7-conjugated CD3. After washing with PBS/0.5% bovine serum albumin (BSA; Sigma, 
St Louis, MO, USA), cells were resuspended in washing buffer containing 0.1% 7-amino-
actinomycin D (7-AAD; Sigma). Cells were analyzed using the Coulter FC500, Navios, or the 
Cyan-ADP flow cytometer (all Beckman Coulter).
BTLA and PD-1 blocking antibodies
Mouse anti-human BTLA IgG1 blocking antibody, BTLA-8.2, was kindly provided by prof. 
dr. Daniel Olive (INSERM UMR 891, Institut Paoli Calmettes, Marseille, France). Mouse IgG1 
isotype control (clone MOPC21) was obtained from BioXCell (West-Lebanon, NH, USA). 
Human PD-1 blocking antibody (BMS-936,558; MDX-1106; ONO-4538) and a matching 
IgG4 isotype control were kindly provided by dr. Alan Korman (Bristol-Myers Squibb, 
Biologics Discovery Milpitas, CA, USA). 
Ex vivo antigen-specific T cell expansion and degranulation assays 
CMV-pp65- or MiHA-specific CD8+ memory T cells present in PBMCs from respectively 
healthy donors or patients (Patients 1-11, Table 1) were stimulated for one week ex vivo 
with peptide-loaded DCs in the presence of BTLA and/or PD-1 blocking antibody. Mature 
allogeneic DCs, cultured from apheresis material of HLA-A2+ or HLA-B7+ donors, were 
constitutively expressed by hematological cancer cells, suggesting a role of the BTLA/
HVEM pathway in tumor immune evasion in allo-SCT patients. Most importantly, we 
showed augmented proliferation of MiHA-specific T cells upon ex vivo stimulation 
following BTLA blockade. Together, these results demonstrate that BTLA interactions 
contribute to the functional impairment of MiHA-specific T cells, providing a rationale for 
incorporating BTLA interference in post-SCT therapy. 
Materials and methods
Patient and donor material
Mononuclear cells were isolated from healthy donor buffy coats (Sanquin, Nijmegen, the 
Netherlands), or blood and bone marrow samples of patients with hematological 
malignancies. To examine primary tumor cells, bone marrow samples of 8 acute myeloid 
leukemia (AML) patients and 10 multiple myeloma (MM) patients obtained at diagnosis 
were used. Furthermore, we used PBMCs from transplanted patients who developed 
MiHA- or cytomegalovirus (CMV)-specific CD8+ T cell responses. These were obtained 3-13 
months after allo-SCT. Characteristics of these patients are described in Table 1. Because 
no apheresis material of the corresponding donors was available, dendritic cells were 
cultured from apheresis material of allogeneic HLA-A2+ or HLA-B7+ donors. All cells of 
healthy donors and patients were obtained after written informed consent.
Cell culture
Hematopoietic tumor cell lines were cultured in IMDM (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10-20% FCS (Integro, Zaandam, the Netherlands). UM-6 cells were cultured 
in IMDM/10% FCS with 22.5 ng/ml IL-6 (Immunotools, Friesoythe, Germany). AML-193 cells were 
cultured in IMDM/20% human serum (HS; PAA laboratories, Pasching, Austria) containing 2 ng/ml 
IL-3 (Cellgenix, Freiburg, Germany) and 2 ng/ml GM-CSF (Immunotools). 
Generation of monocyte-derived DCs
Healthy donor monocytes were isolated from peripheral blood mononuclear cells 
(PBMCs) via plastic adherence in tissue culture flasks (Greiner Bio-One, Alphen a/d Rijn, the 
Netherlands). Immature DCs were generated by culturing monocytes in X-VIVO-15 
medium (Lonza, Verviers, Belgium) supplemented with 2% HS, 500 U/ml IL-4 (Immunotools) 
and 800 U/ml GM-CSF. After 3 days, cells were harvested and cultured in 6-well plates 
(Corning Costar, Lowell, MA, USA) at 1 x 106 DCs/well in X-VIVO-15/2% HS containing 500 
U/ml IL-4 and 800 U/ml GM-CSF. Maturation of DCs was induced at day 6 by culturing in 
X-VIVO-15/2% HS containing 500 U/ml IL-4, 800 U/ml GM-CSF, 5 ng/ml IL-1ß, 15 ng/ml IL-6, 
20 ng/ml TNF-α (all Immunotools) and 1 µg/ml PGE2 (Pharmacia & Upjohn, Bridgewater, 
NJ, USA). At day 8, mature DCs were harvested and used in T cell stimulation assays.
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Results
MiHA-specific CD8+ effector memory T cells show high BTLA and PD-1 expression
Flow cytometric analysis was performed on CD8+ T cells from allo-SCT patients and healthy 
donors to determine BTLA and PD-1 expression levels on MiHA-, CMV- and FLU-specific 
CD8+ T cells in comparison to distinct CD8+ T cell differentiation stages. CD8+ T cell subset 
composition was analyzed by gating on CCR7 and CD45RA (Figure 1A-B). In healthy donors 
the total CD8+ T cell pool was comprised of naive (N), effector-memory (EM) and 
central-memory (CM) cells. Allo-SCT patients on the contrary, had very low numbers of naive 
and CM CD8+ T cells, and their CD8+ T cells predominantly consisted of EM cells (84.2% ± 
2.3%). Similar to CMV-pp65-specific CD8+ T cells in healthy donors (94.1% ± 3.0%), MiHA- and 
CMV-pp65-specific CD8+ T cells in allo-SCT patients were mainly of EM phenotype (95.7% ± 
2.1% and 95.7% ± 1.3% respectively). However, the FLU-specific CD8+ T cell population in 
healthy donors comprised both CM (35.0% ± 9.8%) and EM (62.9% ± 10.3%) cells.
 In healthy individuals, BTLA was highly expressed on naive CD8+ T cells and gradually 
decreased on more differentiated T cells, with EM CD8+ T cells showing markedly lower 
BTLA levels than the other T cell subsets (Figure 1C, Supplementary Figure 1A). When 
comparing CD8+ T cell subsets of healthy donors with those of allo-SCT patients, the 
number of naive BTLA+ T cells was significantly lower in allo-SCT patients. In contrast 
to BTLA, PD-1 expression by naive T cells was low and markedly increased upon T cell 
 differentiation into effector and memory cells (Figure 1C, Supplementary Figure 1). In 
allo-SCT patients, the percentage of PD-1+ cells within each CD8+ T cell subset was 
significantly higher than in healthy individuals.
 As most of the MiHA- and CMV-specific CD8+ T cells displayed an EM phenotype, we 
compared the expression of BTLA and PD-1 within the EM subset of tetramer+ and total 
CD8+ T cells (Figure 1D, Supplementary Figure 1B-C). Both in healthy donors and allo-SCT 
patients, the percentage of BTLA+ cells was significantly higher for CMV-specific CD8+ EM 
T cells than for total CD8+ EM T cells. The percentage of BTLA-positive FLU-specific T cells 
was similar to that in the total CD8+ EM T cell population of healthy donors, although BTLA 
levels on these T cells were slightly lower (Supplementary Figure 1C). Interestingly, 
MiHA-specific CD8+ T cells of allo-SCT patients highly expressed both BTLA and PD-1. Also 
CMV- and FLU-specific T cells in healthy donors showed increased PD-1 expression, 
however to a lesser extent than in allo-SCT patients. Collectively, these data demonstrate 
that MiHA-specific EM T cells of allo-SCT patients have elevated BTLA and PD-1 expression.
HVEM and BTLA are highly expressed by human hematopoietic tumor cells
To determine the expression of HVEM, BTLA, CD160 and LIGHT on hematopoietic 
malignancies, we analyzed various tumor cell lines, patient bone marrow samples and 
healthy donor leukocytes for cell surface expression using flow cytometry. First, we 
analyzed myeloid leukemia (both AML and chronic myeloid leukemia, CML), B-cell 
loaded with or without 10 µM MiHA or CMV-pp65 peptide (LRH-1: TPNQRQNVC; HA-1: 
VLHDDLLEA; HA-2: YIGEVLVSV; HA-8: RTLDKVLEV; HY.A2: FIDSYICQV; CMV-pp65: NLVPMVATV or 
RPHERNGFTVL) for 30 minutes at 37°C. PBMCs were pre-incubated for 30 minutes with 10 
µg/ml BTLA and/or PD-1 blocking antibody and, subsequently, stimulated with DCs at a 
ratio of 1:0.1 in 1 ml IMDM/10% HS in 24-well plates (Corning-Costar). After 5 days, 1 ml 
IMDM/10% HS supplemented with 100 U/ml IL-2 and 10 ng/ml IL-15 (Immunotools) was 
added. At day 7, cells were harvested, counted and the percentage of antigen-specific 
CD8+ T cells was determined using flow cytometry. To visualize proliferation of CMV-pp65- 
and MiHA-specific CD8+ T cells present in PBMCs, cells were labeled prior to T cell 
stimulation with CFSE (carboxyfluorescein diacetate succinimidyl ester; Molecular Probes 
Europe BV, Leiden, the Netherlands). Briefly, PBMCs were washed with PBS and resuspended 
to 10 x 106 cells/ml. Cells were labeled with 1.25 µM CFSE for 10 minutes at room 
temperature (RT). The reaction was stopped by adding an equal volume of FCS, followed 
by incubation at RT for 2 minutes, and washing. CFSE-labeled PBMCs were used in T cell 
proliferation assays as described above. At day 7, cells were overnight restimulated with 5 
µM antigen peptide in the presence of CD107a antibody (clone H4A3, Becton Dickinson). 
The following day, antigen-specific CD8+ T cell proliferation and degranulation was 
determined by analyzing CFSE dilution and CD107a staining of the tetramer+ CD8+ T cell 
population, respectively.
Intracellular cytokine stainings
CMV-pp65- or MiHA-specific CD8+ memory T cells present in PBMCs, were stimulated with 
DCs loaded with 10 µM peptide, as described before. After 7 days, cells were restimulated 
with 5 µM peptide. After 1.5 hours, Brefeldin A (Becton Dickinson) was added to inhibit 
protein transport within the cell. The next day, cells were first labeled with APC-conjugated 
tetramer, CD3 PE-Cy7 and CD8 Alexa-Fluor-700, as described previously. After washing in 
PBS/0.5% BSA, cells were fixed during 15 minutes at RT with Reagens A (Life technologies, 
Grand Island, NY, USA). Cells were washed, resuspended in Reagens B (Life technologies) 
and stained for 20 minutes at RT with IFN-γ FITC antibody (clone B27) and TNF-α PE 
antibody (clone MAb11; both Becton Dickinson) or IgG1 FITC/PE isotype control (Dako). 
Finally, cells were washed and analyzed using flow cytometry.
Statistics
To determine statistical differences, a two-sample two-tailed t-test assuming independent 
samples, One-way ANOVA with a Bonferroni post-hoc test, or a Kruskal-Wallis analysis 
followed by a Dunns post-hoc test was used, as indicated. P-values <0.05 were considered 
significant.
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non-Hodgkin lymphoma (B-NHL) and MM cell lines (Figure 2A). HVEM levels were 
constitutively high on all of these malignancies, although the membrane expression was 
slightly lower on the immature (FAB type M0-M2) leukemia cell lines compared to the 
more mature (FAB type M5) leukemia cell lines (Supplementary Table 1, Supplementary 
Figure 2A). In contrast to HVEM, BTLA was restricted to the B cell malignancies and showed 
a more heterogeneous expression pattern. No expression of CD160 was observed for any 
of the tumor cell lines examined. LIGHT expression levels, on the other hand, were highest 
on some leukemic cell lines and modest in B-NHL and MM tumor cell lines. To confirm 
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Figure 1   BTLA and PD-1 are highly expressed by MiHA-specific CD8+ T cells
CD8+ T cell subsets of healthy donors and allo-SCT patients were examined for BTLA and PD-1 
expression using flow cytometry. (A-B) T cell subset composition was analyzed by gating on CCR7 and 
CD45RA expression within the total or antigen-specific CD3+CD8+ T cell populations. Naive (N), CCR7+ 
CD45RA+; Central memory (CM), CCR7+CD45RA-; Effector memory (EM), CCR7-. (A) Representative 
examples of the CD8 subset composition in 1 HD and 1 allo-SCT patient (Pt) are given. (B) Combined 
data on CD8 subset composition for HD and allo-SCT patients is shown (HD CD8: N=8, HD CMV 
and FLU: N=5, Patient CD8: N=6, Pt CMV and MiHA: N=5). Data are expressed as mean +SEM. 
(C) The percentage BTLA and PD-1 positive cells was examined within the different CD8+ T cell 
subsets. (D) Within the EM subset of the total or antigen-specific CD3+CD8+ T cell population, the 
 percentage of BTLA and PD-1 positive cells was examined. Statistical analysis was performed 
using a two-sample two-tailed t-test assuming independent samples (C), or One-way ANOVA 
 followed by a Bonferroni post-hoc test (D).  *P <0.05, **P <0.01, ***P <0.001. CMV, cytomegalovirus; 
FLU, influenza virus; MiHA, minor histocompatibility antigen. White bars, healthy donors; grey bars, 
allo-SCT patients.
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Figure 2   Hematopoietic tumor cells highly express HVEM and BTLA
Surface expression of HVEM, BTLA, CD160 and LIGHT on hematopoietic tumor cells and healthy 
donor control cells was analyzed using flow cytometry. (A) For each protein the percentage positive 
cells was determined in various hematopoietic tumor cell lines. (B) HVEM, BTLA and LIGHT (black 
lines) protein expression by primary tumor cells as compared to isotype control (filled grey). Data of 
one representative AML and one MM patient are shown, respectively patient 19 and 24 of 
Supplementary Table 2. The numbers in the plots represent the mean fluorescence intensity (MFI). 
(C-D) The percentages of HVEM, BTLA, CD160 and LIGHT positive cells were determined in bone 
marrow samples of 8 AML patients and 10 MM patients, and PBMC samples of 5 healthy donors. (C) 
AML and MM cells were gated on the CD33+ and CD38+CD138+ populations, respectively. (D) 
Healthy donor CD4+ T cells were gated as CD3+CD8-, CD8+ T cells as CD3+CD8+, monocytes as CD14+ 
and B cells as CD19+ cells. Lines indicate the mean. Statistical analysis was performed using a two-
sample two-tailed t-test assuming independent samples (C), or One-way ANOVA followed by a 
Bonferroni post-hoc test (A and D). *P <0.05, **P <0.01, ***P <0.001. AML, acute myeloid leukemia; 
MM, multiple myeloma. 
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these expression patterns in primary human tumor cells, we analyzed bone marrow 
samples of 8 AML and 10 MM patients obtained at time of diagnosis. AML and MM cells 
were gated on the CD33+SSlow and CD38+CD138+ populations, respectively. Similar 
expression patterns were found for HVEM and LIGHT in the primary tumor samples 
compared to the tumor cell lines (Figure 2B-C, Supplementary Table 2, Supplementary 
Figure 2B). While CD160 was again not expressed by the malignant cells, BTLA expression 
was substantially higher on the primary AML and MM cells than on the corresponding 
tumor cell lines. We also examined healthy donor control cells, and observed high HVEM 
and BTLA expression on T cells, monocytes and B cells (Figure 2D). However, expression 
levels were significantly higher on the monocytes and B cells (Supplementary Figure 2C). 
Furthermore, monocytes also displayed significantly higher LIGHT expression than the 
other cell types. Together, these data show that human AML and MM cells display high 
levels of HVEM, while BTLA is highly expressed on MM cells and moderately on AML cells.
 
PD-1 blockade augments the proliferative capacity of fully functional CMV-specific 
CD8+ T cells
First, we investigated the effect of BTLA and/or PD-1 blockade on CMV-specific T cell 
responses, since in healthy donors a high level of PD-1 and BTLA on pp65-specific T cells 
was observed. Therefore, we stimulated PBMCs of 3 healthy donors with CMV-pp65 
peptide loaded DCs in the presence or absence of blocking antibody. After one week, 
CMV-specific CD8+ T cell proliferation and function was analyzed. In Figure 3A, the 
percentage of tetramer+ CD8+ T cells is shown for 1 representative healthy donor. Blockade 
of BTLA resulted in a slightly higher percentage of CMV-specific T cells after 1 week. In 
contrast, PD-1 blockade clearly boosted the percentage and absolute number of 
CMV-specific CD8+ T cells (Figure 3B). The combination of BTLA and PD-1 blockade had no 
synergistic effects in this donor. To combine data of all healthy donors, the fold expansion 
was calculated as the absolute number of MiHA-specific CD8+ T cells in the presence of 
antibody blockade relative to isotype control treatment (Figure 3C). Interestingly, only 
PD-1 blockade and the combination with anti-BTLA treatment significantly enhanced the 
expansion of CMV-specific CD8+ T cells. To visualize the proliferation of the CMV-specific T 
cells, we labeled PBMCs of donor 2 with CFSE and performed a 1 week stimulation assay. 
After overnight restimulation with 5 µM CMV peptide in the presence of anti-CD107a 
antibody, the proliferation and degranulation capacity of the CMV-specific CD8+ T cells 
was analyzed. Upon stimulation in the presence of PD-1 blocking antibody, more cells had 
a CFSE-negative phenotype as compared to isotype control treated cells (Figure 3D). 
Furthermore, more than 66% of the tetramer+ CD8+ T cells showed high CD107a staining 
upon overnight restimulation with CMV peptide (Figure 3E). Notably, in this donor BTLA 
blockade did not further increase the degranulation capacity of the CMV-specific CD8+ T 
cells, while blocking PD-1 resulted in a higher percentage of CD107a+ antigen-specific T cells. 
Moreover, combined BTLA and PD-1 blockade further boosted CMV-specific T cell 
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Figure 3   Blockade of PD-1 results in enhanced proliferation of functional CMV-specific 
CD8+ T cells in healthy donors
PBMCs of healthy donors containing CMV-pp65-specific CD8+ T cells were stimulated for 1 week 
with mature DCs loaded with the CMV peptide at a ratio of 1:0.1. To block the inhibitory interactions, 
cells were pre-incubated with 10 µg/ml anti-BTLA and/or anti-PD-1. CMV-specific T cell expansion 
and function was subsequently analyzed using flow cytometry. (A) One week after stimulation, cells 
were analyzed for tetramer-positive CD8+ T cells using flow cytometry. Data of one representative 
healthy donor out of 3 donors is shown. (B) Total number of CMV-pp65-specific CD8+ T cells of 
donor 1 after 1 week of stimulation with CMV peptide loaded DCs in the presence or absence of 
blocking antibody. (C) The effect of BTLA blockade on CMV-specific T cell expansion was calculated 
by dividing the absolute number of tetramer-positive T cells following BTLA and/or PD-1 blockade 
with the absolute number of tetramer-positive T cells treated with isotype control antibody. Data of 
3 different donors is shown. (D-F) To visualize T cell proliferation and function following 1 week 
stimulation in the presence of BTLA and/or PD-1 blockade, PBMCs labeled with or without 1.25 µM 
CFSE were restimulated overnight with 5 µM antigen peptide in the presence of CD107a antibody 
or Brefeldin A. The following day, CFSE dilution (D), CD107a staining (E), and intracellular IFN-γ and 
TNF-α levels (F) were analyzed within the CMV-specific CD8+ T cell population. Numbers in the plot 
indicate the percentage of cells in each quadrant. Data of one out of 2 donors is shown. Statistical 
analysis was performed using a Kruskal-Wallis analysis followed by a Dunns post-hoc test. *P <0.05. 
MFI, mean fluorescence intensity. 
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degranulation. Finally, we examined the production of effector cytokines IFN-γ and TNF-α of 
1 week expanded CMV-specific T cells. Following overnight restimulation, most of the 
CMV-specific CD8+ T cells produced either IFN-γ alone or in combination with TNF-α (Figure 
3F). Blockade of BTLA did not improve the percentage of antigen-specific T cells producing 
cytokines. On the contrary, blockade of PD-1 alone or in combination with BTLA, enhanced 
the percentage of IFN-γ+ and IFN-γ+TNFα+ cells within the CMV-specific CD8+ T cell population 
of this donor. These results indicate, that blockade of PD-1, but not BTLA, results in increased 
proliferation of CMV-specific CD8+ T cells of healthy donors, and that these  antigen-specific 
T cells are highly functional upon restimulation with the cognate peptide.
Both BTLA and PD-1 blockade augment expansion of MiHA-specific CD8+ T cells ex vivo 
To investigate the role of BTLA in the inhibition of MiHA-specific CD8+ T cell responses, 
we performed functional assays using PBMCs from 11 patients with a hematological 
malignancy who developed MiHA-specific T cell responses after allo-SCT. Previously, we 
demonstrated that reinvigoration of MiHA-specific CD8+ T cell responses requires mature 
DCs loaded with the cognate MiHA16;24. Therefore, we first analyzed expression levels of 
HVEM and its binding partners on mature monocyte-derived donor DCs (Figure 4A). 
Similarly to hematological tumor cells, mature DCs displayed high HVEM expression and 
moderate levels of BTLA and LIGHT. CD160, on the other hand, was not expressed. 
Subsequently, these DCs were pulsed with MiHA peptide and used for ex vivo stimulation 
of MiHA-specific memory T cells in the presence of BTLA and/or PD-1 blocking antibody. 
In Figure 4B, results of three representative patients are shown. At start, PBMCs of patients 
4, 8 and 10 contained 0.09%, 0.76% and 0.11% CD8+ T cells recognizing either the MiHA 
LRH-1 or HA-1. In these patients, we observed augmented percentages of MiHA-specific 
CD8+ T cells after blockade of BTLA and/or PD-1 compared to isotype control treated cells. 
To combine data of all patients, the fold expansion was calculated as the absolute number 
of MiHA-specific CD8+ T cells after antibody blockade relative to isotype control treatment. 
In 7 out of 11 patients, BTLA blockade augmented MiHA-specific T cell expansion more than 
2-fold (range 2.1-11.7 fold; Figure 4C, Table 1). Furthermore, PD-1 blockade enhanced 
MiHA-specific T cell numbers more than 2-fold in 9 out of 11 patients (range 2.5-12.5 fold: 
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Figure 4   BTLA blockade increases ex vivo expansion of MiHA-specific CD8+ memory  
T cells
PBMCs of patients containing MiHA-specific CD8+ T cells were stimulated for 1 week with mature 
DCs loaded with the cognate peptide at a ratio of 1:0.1. To block the inhibitory interactions, cells 
were pre-incubated with 10 µg/ml anti-BTLA and/or anti-PD-1. DC phenotype and MiHA-specific T 
cell expansion was subsequently analyzed using flow cytometry. (A) Surface expression of HVEM, 
BTLA, CD160 and LIGHT (black lines) as compared to isotype control (filled grey) was measured on 
mature monocyte-derived DCs from healthy donors. The numbers in the plots represent the MFI. 
Data of one representative donor is shown. (B) After 1 week, MiHA-specific T cell expansion was 
analyzed using tetramers. The numbers in the FACS plots represent the percentage of HA-1 or LRH-1 
specific CD8+ T cells of each patient within the total CD3+CD8+ T cell population. (C) The effect of 
BTLA blockade on MiHA-specific T cell expansion was calculated by dividing the absolute number 
of tetramer-positive T cells following BTLA blockade with the absolute number of tetramer-positive 
T cells treated with isotype control. Data of 11 different patients is shown. (D) The effect of PD-1 and 
combined BTLA/PD-1 blockade on MiHA-specific CD8+ T cell proliferation was calculated relative to 
isotype control treated cells. Data of 11 different patients is shown. Statistical analysis was  performed 
using a Kruskal-Wallis analysis followed by a Dunns post-hoc test. *P <0.05, ***P <0.001. 
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 Finally, we examined CFSE dilution, degranulation and cytokine production by the 
expanded MiHA-specific CD8+ T cells following overnight restimulation with the cognate 
peptide. After 1 week of stimulation with peptide-loaded DCs, >90% of the MiHA-specific 
CD8+ T cells were CFSE- (Figure 5A). However, no differential effect of BTLA or PD-1 blockade 
could be observed. Furthermore, these expanded MiHA-specific EM T cells efficiently 
degranulated upon antigen reencounter, as demonstrated by CD107a staining (Figure 5B). 
This in contrast to the tetramer-negative CD8+ T cell population, of which <5% of the cells 
stained positive for CD107a (data not shown). In some patients, single PD-1 blockade 
resulted in somewhat increased percentages of CD107a+ antigen-specific T cells, however 
this was not observed for the other treatments. In Figure 5C, intracellular IFN-γ and TNF-α 
expression levels by MiHA-specific T cells of one representative patient (no. 2) are shown. 
Following antigen restimulation more than 90% of the antigen-specific CD8+ T cells produced 
Figure 4D). Interestingly, in 3 out of the 7 BTLA responders the effect of BTLA blockade was 
more prominent than that of PD-1 blockade. However, no significant difference was 
observed when comparing the effects of BTLA and PD-1 blockade for all patients. Moreover, 
combined blockade of BTLA and PD-1 boosted MiHA-specific CD8+ T cell expansion, though 
when compared to single receptor blockade no additive effect was observed. 
5
Table 1   Characteristics of transplanted patients and effect of BTLA and/or PD-1 
blockade on MiHA-specific CD8+ T cell proliferation
Pt
no.
Disease MiHA T cell 
responsea
Sample date 
(months)
DLI prior to 
sample date
Disease status 
at sample date
GVHD at 
sample date
ISD at 
sample date
Clinical outcome Effect 
αBTLAb
Effect 
αPD-1
Effect 
combi
1 preT-ALL HA2 12 post-SCT No Complete 
remission
Limited 
cGVHD
CSA,
Prednisone
Remission; alive at 174 mo 
post-SCT
2.6 2.5 1.8
2 AML LRH1 12 post-SCT Yes Complete 
remission
No No Chloroma relapses at 39, 76, 
84 mo post-SCT
1.1 6.5 5.7
3 AML HA8 12 post-SCT No Complete 
remission
Limited 
cGVHD
No Remission; alive at 213 mo 
post-SCT
9.0 0.7 3.4
4 AML LRH1 6 post-SCT No Complete 
remission
Limited 
cGVHD
No Remission; alive at 136 mo 
post-SCT
2.1 12.5 18.5
5 CML HA8 11 post-SCT Yes Complete 
remission
No No Remission; alive at 171 mo 
post-SCT
0.5 5.4 2.6
6 CML-AP LRH1 13 post-SCT Yes Partial remission No No Hematologic relapse at 57 
mo post-SCT
2.5 7.0 71.7
7 CML-BC HA1 13 post-SCT Yes Complete 
remission
Extensive 
cGVHD
CSA Remission; death due to 
GVHD at 15 mo post-SCT
1.2 3.8 4.4
8 MM HA1 6 post-SCT No Complete 
remission
Limited 
cGVHD
No Remission; alive at 31 mo 
post-SCT
3.6 4.6 4.0
9 MM HA1 5 post-SCT No Partial remission No No Active disease at 6 mo 
post-SCT. Plasma cells 5%; 
M-protein 7 gr/L
1.0 8.7 9.4
10 NHL HA1 12 post-SCT No Complete 
remission
No No Remission; alive at 165 mo 
post-SCT
11.7 5.3 8.4
11 NHL HY.A2 3 post-SCT No Relapse No Prednisone Hematologic relapse at 3 
mo post-SCT
2.6 1.6 5.8
Characteristics of patients with hematological malignancies displaying MiHA-specific CD8+ T cell responses. 
aMiHA-specific response: MiHA for which a T cell response was observed. bEffect αBTLA: ratio absolute number of 
tetramer+ CD8+ cells after stimulation with DCs + peptide + αBTLA/absolute number of tetramer+ CD8+ cells after 
stimulation with DCs + peptide + isotype control.
AML, acute myeloid leukemia; CML-AP, chronic myeloid leukemia-accelerated phase; CML-BC, chronic myeloid 
leukemia-blast crisis; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; pre-T ALL, pre-T cell acute 
lymphoblastic leukemia; SCT, stem cell transplantation; DLI, donor lymphocyte infusion, given at 4-10 months after 
SCT; cGVHD, chronic graft-versus-host-disease; ISD, immunosuppressive drugs; CSA, Cyclosporine A; Mo, months.
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Discussion
Alloreactive MiHA-specific CD8+ T cells play a pivotal role in GVT responses after allo-SCT 
and DLI25;26. Unfortunately, many patients develop relapses despite the long-term presence 
of MiHA-specific memory T cells, suggesting that these cells become functionally 
impaired. Tumor cells deploy distinct mechanisms to evade immune attack7, including 
expression of ligands for co-inhibitory receptors on T cells27. Previously, we demonstrated 
that the co-inhibitory PD-1/PD-L pathway is involved in the functional impairment of 
MiHA-memory responses after allo-SCT, and that these could be reinvigorated by DC 
stimulation in combination with PD-1 blockade16. Another co-inhibitory receptor, BTLA, 
was recently shown to be involved in dysfunction of melanoma-specific T cells.23 This 
prompted us to investigate the potential inhibitory role of BTLA on MiHA-specific T cells in 
cancer patients after allo-SCT. 
 First, we investigated BTLA and PD-1 expression on the different CD8+ effector/
memory subsets in healthy donors and allo-SCT patients. In concordance with the work 
from Derre et al.23, we found that BTLA expression in healthy donors is highest on naive 
CD8+ T cells, and is gradually reduced in CM and EM cells. This phenomenon was similar 
for CD8+ T cells of patients, although overall BTLA expression was lower. In contrast, PD-1 
expression shows a reversed profile, with low expression on naive T cells and high 
presence on CM and EM, which was also reported by Duraiswamy et al.28. In allo-SCT 
patients PD-1 levels in the distinct subsets were evidently higher than those in 
corresponding healthy donor T cells. This is probably because of the presence of a 
long-lasting inflammatory milieu due to the pre-SCT conditioning regimen29, development 
of alloreactive T cell responses30, occurrence of GVHD and reactivation of viruses and 
subsequent immune responses31;32. The differential expression profiles of BTLA and PD-1 
indicate that there is a distinct role for these molecules to exert their physiological 
function. Since peripheral blood of allo-SCT patients predominantly contains EM CD8+ T 
cells with very low numbers of naive and CM T cells, analysis of BTLA and PD-1 expression 
was limited to the EM subset. Skewing of the CD8+ T cell population to the EM subset is a 
common phenomenon following allo-SCT since many T cells become activated, as 
mentioned before. When focusing on the MiHA-specific T cells these are also mainly of EM 
type, as expected due to in vivo allogeneic activation. 
 Subsequently, we investigated BTLA and PD-1 expression specifically on CMV-, FLU- and 
MiHA-specific T cells of healthy donors and allo-SCT patients, respectively. In accordance 
with findings by others23;33, healthy donor CMV-specific T cells showed relative increased 
the effector cytokines IFN-γ and/or TNF-α (Figure 5C-5E). Although, the percentage of 
cytokine producing T cells did not further increase, the expression levels of IFN-γ and 
TNF-α within the MiHA-specific CD8+ T cells seemed to be higher following prior BTLA 
and/or PD-1 blockade. Especially, TNF-α seemed differentially up-regulated in MiHA- 
specific T cells treated with BTLA blocking antibody. In conclusion, we demonstrate that 
next to PD-1, BTLA is also involved in MiHA-specific T cell inhibition, and that the relative 
contribution of these two receptors to functional impairment differs between patients.
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Figure 5   Expanded MiHA-specific CD8+ memory T cells are highly functional
PBMCs of patients containing MiHA-specific CD8+ T cells were stimulated for 1 week with mature 
DCs loaded with the cognate peptide at a ratio of 1:0.1. To visualize the effect on T cell proliferation 
and function by BTLA and/or PD-1 blockade, PBMCs labeled with or without 1.25 µM CFSE were 
after one week restimulated overnight with 5 µM antigen peptide in the presence of CD107a 
 antibody or Brefeldin A. The following day, the percentage of CFSE- (A) and CD107a+ cells (B) within 
the MiHA-specific CD8+ T cell population was analyzed. Data are depicted as mean + SEM, N=3. 
(C) Intra cellular IFN-γ and TNF-α levels within the MiHA-tetramer+ CD8+ T cell population of one 
representative patient (no. 2) out of 3 patients. Numbers in the plot indicate the percentage of cells 
in each quadrant. (D-E) Intracellular IFN-γ (D) and TNF-α levels (E) within the tetramer+ CD8+ T cell 
population. Data are depicted as mean + SEM, N=2-3. MFI, mean fluorescence intensity. 
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PD-1 blockade exerted evident boosting of antigen-specific T cell expansion in 82% of the 
patients. Interestingly, some patients responded better to BTLA blockade, while others 
showed more pronounced effects following PD-1 blockade. Whether the increase in 
number of cells is due to enhanced cell cycling was investigated in a CFSE dilution assay. 
For CMV-specific CD8+ T cells we observed a higher percentage of CFSE-diluted dividing 
cells following PD-1 blockade. However, we did not observe these effects in MiHA-specific 
CD8+ memory T cells. The increased number of antigen-specific T cells may here be 
attributed to less apoptosis following BTLA and/or PD-1 blockade. In addition, we 
examined whether the boosted antigen-specific T cells exhibited competent functionality. 
Upon antigen reencounter, both CMV- and MiHA-specific CD8+ T cells efficiently 
degranulated and produced effector cytokines. Interestingly, blocking of BTLA seemed to 
mediate increased TNF-α production in MiHA-specific T cells.
 Possibly, the differences observed between PD-1 and BTLA blocking can be attributed 
to inherent differences between the antibodies. The anti-PD-1 antibody is fully humanized 
and has proven its functionality in phase I clinical trials39, whereas the anti-BTLA antibody 
is murine and still in the pre-clinical stage. Although few immune-related adverse events 
have been reported for PD-1 blockade, dosing and timing of the BTLA blocking antibody 
has to be carefully examined in clinical trials, as both molecules are involved in the 
maintenance of self tolerance. Especially, in the allo-SCT setting interference with 
co-inhibitory molecules could deteriorate GVHD. In mouse models, however, BTLA has 
been reported to have a differential role in GVT responses, and not in GVHD40;41. Although 
we found high expression of both BTLA and PD-1 on MiHA-specific CD8+ T cells, we could 
not correlate their expression levels to the effect on T cell proliferation upon blocking 
either of these pathways (data not shown). Perhaps the impairment via these receptors 
depends more on the amount of signaling it has experienced, than the expression of the 
receptor as such, as has been suggested previously for PD-117;42. Furthermore, no evident 
correlation in BTLA effect and disease status could be observed, though patients in 
long-term remission after allo-SCT seemed to respond better. This is in contrast to PD-1, 
which was shown to be more involved in the impairment of MiHA T cell responses in 
relapsed patients.16 It could be that the inhibitory effect of BTLA and PD-1 on MiHA-specific 
T cells has been influenced by the treatment with immunosuppressive drugs, however in 
our study only few patients received ISD at time of analysis and no firm conclusions could 
be drawn. As the reversed expression profiles of BTLA and PD-1 on normal T cells already 
demonstrate, these molecules are likely to have distinct roles in hampering MiHA-specific 
T cell responses. Finally, we examined whether an additive effect could be observed by 
combined blockade of BTLA and PD-1. However, we did not observe an unambiguous 
additive effect on MiHA-specific T cell proliferation. This might suggest that the two 
receptors share common intracellular signaling pathways. It has been reported that both 
PD-1 and BTLA relay their co-inhibitory signal via SHP-1 and SHP-243;44. Nonetheless, a third 
interactor with the intracellular domain of BTLA has been described, Grb-245.
BTLA and PD-1 expression, which is probably due to frequent activation by latent CMV. On 
the contrary, lower BTLA expression was observed in case of cleared viral infections, like 
influenza. In general, BTLA levels on total CD8+ T cells in patients were slightly lower 
compared to those in healthy individuals. Interestingly, CMV- and MiHA-specific T cells of 
allo-SCT patients were highly BTLA positive despite their EM phenotype. PD-1 levels, on 
the contrary, were already high on the total CD8+ T cell pool, as well as, on CMV- and 
MiHA-specific EM T cells. These data confirm our recent observations6 and can be 
attributed to the high numbers of activated alloreactive and microbial-reactive T cells as 
mentioned before. Notably, MiHA-specific T cells of allo-SCT patients showed high 
expression levels of both PD-1 and BTLA. 
 To investigate whether BTLA ligation could be a potential evasion mechanism, we 
next examined ligand expression levels on tumor cells. Therefore, we analyzed 
hematopoietic tumor cells for the presence of BTLA, HVEM, CD160 and LIGHT. Interestingly, 
both HVEM and its binding partner BTLA were expressed on primary leukemia and 
myeloma cells, whereas LIGHT and CD160 were lowly present. Our data correspond with 
literature, describing HVEM to be constitutively expressed on primary myeloma cells34. 
Furthermore, we report here for the first time that primary AML cells highly express HVEM. 
Notably, in contrast to the ligands for PD-116, HVEM is constitutively expressed and 
further up-regulation under inflammatory conditions was not observed (data not shown). 
Since BTLA can also be expressed on the tumor cells, we also investigated whether T cells 
were positive for HVEM. Indeed, HVEM was observed on human T cells, indicating that a 
bidirectional HVEM-BTLA signaling route between tumor cell and T cells can occur. As yet, 
the effect of BTLA signal transduction into the tumor cell is unknown. Furthermore 
besides BTLA, HVEM itself has been reported to function as a receptor as well35;36. 
Altogether, this results in a complex network of interactions for BTLA, HVEM and their 
binding partners37, which needs to be elucidated in future experiments.
 The concurrent expression of BTLA on MiHA-specific T cells and HVEM by malignant 
cells suggested that this co-inhibitory pathway contributed to the functional inhibition of 
MiHA-specific T cells in vivo. Therefore, we performed ex vivo blocking experiments using 
DCs as antigen-presenting cells. Based on their strong stimulatory potential, DCs are 
attractive vaccines for ex vivo24 and in vivo38 stimulation of MiHA-specific T cell responses. 
Importantly, DCs also express HVEM, BTLA and to some extent LIGHT, providing a rationale 
for combined DC stimulation and BTLA blockade. In addition, by interfering with the 
ligation of HVEM to BTLA an additive effect could be realized by increased interaction of 
HVEM with LIGHT22, yielding a more co-stimulatory signal. After blockade of BTLA 
interactions, we observed enhanced proliferation of MiHA-specific T cells in 64% of the 
patients, indicating that BTLA ligation also contributes to impairment of alloreactive T cells 
in transplanted cancer patients. Based on our previous findings, where we identified the 
involvement of PD-1 in MiHA-specific T cell dysfunction, we next compared the relative 
contribution of both co-inhibitory receptors in this process. Compared to BTLA blockade, 
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Supplementary Table 1 
HVEM, BTLA, CD160 and LIGHT expression levels on hematopoietic tumor cell lines
Cell line Type % HVEM+ % BTLA+ % CD160+ % LIGHT+
KG1a AML-M0 85.0 8.9 3.6 6.8
KG1 AML-M1 59.1 10.0 2.1 5.3
Kasumi AML-M2 28.1 8.0 0.8 27.0
HL-60 AML-M2 93.9 10.1 1.2 9.2
AML-193 AML-M5 95.9 6.8 1.5 11.0
Mono-Mac-6 AML-M5 99.7 5.8 0.7 6.3
THP1 AML-M5 88.8 8.2 1.1 ND
LAMA-84 CML 47.6 10.3 1.1 41.9
K-562 CML 81.9 12.8 1.2 51.3
Raji B-NHL 54.9 8.2 0.7 2.3
BJAB B-NHL 90.1 7.3 0.2 1.9
RAMOS B-NHL 89.9 94.1 0.1 4.7
HS-Sultan B-NHL 88.9 60.9 3.2 5.1
RPMI-1788 B-NHL 88.7 74.6 1.1 43.0
U-698-M B-NHL 63.3 60.9 0.1 2.7
SU-DHL-6 B-NHL 80.8 53.9 1.1 11.1
L-363 MM 74.4 16.9 0.3 3.2
U266 MM 61.9 8.8 0.7 8.7
RPMI-8226 MM 89.6 24.4 4.2 2.1
UM1 MM 77.7 54.7 0.9 34.9
UM3 MM 97.8 2.3 0.1 1.1
UM6 MM 99.8 92.5 50.5 7.7
UM9 MM 99.7 39.7 1.1 6.4
Various hematopoietic tumor cell lines were analyzed for the percentage of HVEM, BTLA, CD160 and LIGHT 
positive cells. AML, acute myeloid leukemia; CML, chronic myeloid leukemia; B-NHL, B-cell non-Hodgkin 
lymphoma; MM, multiple myeloma; ND, not determined.
Supplementary Table 2
HVEM, BTLA, CD160 and LIGHT expression levels on primary AML and MM cells
Patient Type Malignant 
cells* (%)
% HVEM+ % BTLA+ % CD160+ % LIGHT+
12 AML-M0 40 84.3 21.4 8.3 10.2
13 AML-M1 91 60.9 23.8 0.2 7.5
14 AML-M1 54 61.7 29.6 0.2 4.7
15 AML-M2 64 99.0 29.3 0.7 6.8
16 AML-M2 69 52.2 32.7 0.2 23.7
17 AML-M2 30 69.9 65.7 0.3 1.4
18 AML-M4 48 89.0 33.1 0.2 2.9
19 AML-M4 22 91.0 23.5 0.3 10.4
20 MM stage 1A 16 91.0 76.2 0.2 ND
21 MM stage 1A 19 93.9 98.7 1.2 ND
22 MM stage 3A 36 71.9 56.9 0.7 0.5
23 MM stage 3A 43 85.0 63.3 0.9 ND
24 MM stage 3A 13 90.6 98.6 1.5 17
25 MM stage 3A 21 92.2 88.3 0.4 30.7
26 MM stage 3A 15 96.8 95.2 1.6 32.6
27 MM stage 3A 38 97.3 30.1 0.1 20.5
28 MM stage 3B 36 97.3 95.7 0.3 1.5
29 MM stage 3B 73 99.5 99.9 0.6 ND
Peripheral blood samples of AML and MM patients, obtained at time of diagnosis, were analyzed for percentage 
of HVEM, BTLA, CD160 and LIGHT positive cells. AML cells were gated as CD33+SSlow cells. MM cells were gated as 
CD38+CD138+ cells. *The percentage blasts was defined by morphological analysis. AML, acute myeloid leukemia; 
MM, multiple myeloma; ND, not determined.
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Supplementary Figure 1   
BTLA and PD-1 are highly expressed by MiHA-specific CD8+ T cells
CD8+ T cell subsets of healthy donors (HD) and allo-SCT patients (pt) were examined for BTLA and 
PD-1 expression using flow cytometry. T cell subsets were analyzed by gating on CCR7 and CD45RA 
expression within the total or antigen-specific CD3+CD8+ T cell populations. Naive (N), CCR7+CD45RA+; 
Central memory (CM), CCR7+CD45RA-; Effector memory (EM), CCR7-. (A) Median fluorescence inten-
sity (FI) of BTLA and PD-1 was examined within the different T cell subsets of the total CD8+ T cell 
population. (B) Surface expression of BTLA and PD-1 (filled black) as compared to isotype control 
(filled grey) on total CD8+ and antigen-specific EM T cells is depicted for the same donors and 
patients as in Figure 1A. The numbers in the plots represent the median FI. (C) BTLA and PD-1 
surface expression levels were analyzed within the EM subset of the total or antigen-specific 
CD3+CD8+ T cell populations for all donors and patients. HD CD8: N=8, HD CMV and FLU: N=5, 
Pt CD8: N=6, Pt CMV and MiHA: N=5. Statistical analysis was performed using a two-sample two-
tailed t-test assuming independent samples, or One-way ANOVA followed by a Bonferroni post-hoc 
test, when appropriate. *P <0.05, **P <0.01. CMV, cytomegalovirus; FLU, influenza virus; MiHA, minor 
histocompatibility antigen.
Supplementary Figure 2   
Hematopoietic tumor cells highly express HVEM and BTLA
Surface expression of HVEM, BTLA, CD160 and LIGHT on hematopoietic tumor cells and healthy 
donor control cells was analyzed using flow cytometry. For each protein the mean fluorescence 
intensity (MFI) was determined on (A) various hematopoietic tumor cell lines, (B) primary tumor 
cells, and (C) healthy donor control cells. (B) AML (N=8) and MM (N=10) cells were gated on the 
CD33+ and CD38+CD138+ populations, respectively. (C) Healthy donor CD4+ T cells were gated as 
CD3+CD8-, CD8+ T cells as CD3+CD8-, monocytes as CD14+ and B cells as CD19+ (N=5). Statistical 
analysis was performed using a two-sample two-tailed t-test assuming independent samples, or 
One-way ANOVA followed by a Bonferroni post-hoc test.  *P <0.05, **P <0.01, ***P <0.001.
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Abstract
Tumor relapse after HLA-matched allogeneic stem cell transplantation (SCT) remains a 
serious problem, despite long-term presence of minor histocompatibility antigen (MiHA)-
specific memory T cells. Dendritic cell (DC)-based vaccination boosting MiHA-specific T 
cell immunity is an appealing strategy to prevent or counteract tumor recurrence, but 
improvement is necessary to increase the clinical benefit. Here, we investigated whether 
knockdown of Programmed death ligand 1 (PD-L1) and PD-L2 on monocyte-derived DCs 
results in improved T cell activation. Electroporation of single siRNA sequences into 
immature DCs resulted in efficient, specific and long-lasting knockdown of PD-L1 and 
PD-L2 expression. PD-L knockdown DCs strongly augmented interferon-γ and interleukin-2 
production by stimulated T cells in an allogeneic MLR, while no effect was observed on T 
cell proliferation. Moreover, we demonstrated that PD-L gene-silencing, especially 
combined PD-L1 and PD-L2 knockdown, resulted in improved proliferation and cytokine 
production of KLH-specific CD4+ T cells. Most importantly, PD-L knockdown DCs showed 
superior potential to expand MiHA-specific CD8+ effector and memory T cells from 
leukemia patients early after donor lymphocyte infusion and later during relapse. These 
data demonstrate that PD-L siRNA electroporated DCs are highly effective in enhancing T 
cell proliferation and cytokine production, and therefore attractive for improving the 
efficacy of DC vaccines in cancer patients.
Introduction
Alloreactive CD8+ T cells play a crucial role in graft-versus-tumor (GVT) responses following 
allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusion (DLI)1;2. In 
human leukocyte antigen (HLA)-matched allo-SCT, these alloreactive CD8+ T cell responses 
are directed against minor histocompatibility antigens (MiHAs), which are HLA-bound 
peptides derived from polymorphic genes that differ between donor and recipient2;3. 
Upon infusion into the pre-conditioned patient, donor-derived MiHA-specific CD8+ T cells 
clonally expand and become effector cells, which subsequently have the capacity to target 
MiHA-expressing malignant cells4. After the primary immune response, most MiHA-reactive 
CD8+ T cells die through apoptosis and only a small pool of long-lived memory cells survives 
that is able to respond quickly upon reencounter of the antigen5. Importantly, we and 
others have shown that following DLI the emergence of MiHA-specific CD8+ effector T cells 
coincides with a decrease in number of malignant cells6-8. Moreover, years after the initial 
response MiHA-specific CD8+ memory T cells can still be detected, playing an important 
role in protective immunity in transplanted patients. However, these alloreactive CD8+ 
memory T cells do not always respond efficiently to recurring tumor cells and this failure 
may contribute to the occurrence of tumor relapses6. This lack of responsiveness may result 
from inefficient memory T cell activation due to absence of effective antigen presentation, 
impaired co-stimulation and/or enhanced signaling by co-inhibitory receptors. Interestingly, 
we recently found that the Programmed death-1 (PD-1)/PD-Ligand axis is involved in 
inhibiting the function of MiHA-specific CD8+ T cells upon their engagement with PD-L1 
expressing myeloid leukemia cells and dendritic cells (DCs)9.
 PD-1 is a co-inhibitory receptor that is inducibly expressed by T and B cells upon 
activation. Engagement of this receptor with either of its ligands, i.e. PD-L1 (B7-H1; CD274) 
and PD-L2 (B7-DC; CD273), results in phosphorylation of the cytoplasmic tail and negatively 
regulates T cell receptor (TCR)-induced cytokine production and proliferation via the 
phosphatidylinositol-3 kinase pathway10;11. While PD-L2 expression is mainly restricted to 
activated lymphocytes and antigen presenting cells (APCs) like DCs and macrophages, 
PD-L1 is also expressed by many non-lymphoid tissues and tumor cells10;12. In the past few 
years, a crucial role for the PD-1/PD-L1 pathway has been demonstrated in chronic viral 
infections like HIV and hepatitis C (HCV)13-16. It has been shown that HIV- and HCV-specific 
T cells have increased PD-1 expression resulting in functional exhaustion of these cells. 
Moreover, PD-1/PD-L interactions have been implicated in functional impairment of 
tumor antigen-reactive CD8+ T cells in solid tumors and chronic myeloid leukemia17-19. 
Therefore, tumor cells may exploit the same pathway to escape eradication by 
MiHA-specific CD8+ memory T cells after allo-SCT. 
 DC vaccination therapy would be an appealing strategy to revive functionally inactive 
MiHA-specific CD8+ memory T cells and, by this means restore an effective immune 
response against recurring or persistent MiHA-expressing tumor cells. DCs have been 
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with biweekly intervals. PBMCs obtained two weeks after the second vaccination were 
used for functional studies and DCs were cultured from autologous apheresis material 
collected before start of vaccination therapy. To examine the stimulatory capacity of PD-L 
knockdown DCs on MiHA-specific T cell responses, we used PBMCs obtained from 3 
leukemia patients who developed a MiHA-specific CD8+ T cell response after DLI. Patient 
UPN543 suffered from acute myeloid leukemia (AML) and developed a strong LRH-1- 
specific CD8+ T cell response upon preemptive DLI. Then, the patient remained in complete 
clinical and cytogenetic remission until 3 years after DLI, whereupon extramedullary 
relapses developed without leukemic involvement in the bone marrow26;27. Patient 
UPN640 had a blast crisis (BC) chronic myeloid leukemia (CML) and was treated with 
preemptive DLI after allo-SCT. This resulted in a HA-1-specific CD8+ effector T cell response. 
The third patient (UPN389) suffered from accelerated phase (AP) chronic myeloid leukemia 
(CML) and was successfully treated with therapeutic DLI after allo-SCT. Following DLI, a 
LRH-1-specific CD8+ T cell response was observed, which coincided with remission of 
CML-AP6;27. However, despite the long-term presence of LRH-1-specific CD8+ memory T 
cells the patient relapsed 4 years after DLI. Because no apheresis material of the 
corresponding donors was available, DCs were cultured from apheresis material of 
allogeneic HLA-B7+ LRH-1- or HLA-A2+ HA-1- donors. All cells of healthy donors and patients 
were obtained after written informed consent.
Cell culture
LRH-1-specific CD8+ cytotoxic T lymphocyte (CTL) culture RP1 was isolated from CML-AP 
patient UPN389 and recognizes the 9-mer epitope TPNQRQNVC in the context of 
HLA-B*0702. CTL RP1 was cultured as described previously6;26. Recipient and donor 
Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCL) of patient UPN389 
were cultured in Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen, Carlsbad, CA, 
USA) supplemented with 10% fetal calf serum (FCS; Integro, Zaandam, the Netherlands).
Generation of monocyte-derived DCs
Monocytes were isolated from PBMCs via plastic adherence in tissue culture flasks (Greiner 
Bio-One, Alphen a/d Rijn, the Netherlands). Immature DCs were generated by culturing 
monocytes in X-VIVO-15 medium (Lonza, Verviers, Belgium) supplemented with 2% 
human serum (HS; PAA laboratories, Pasching, Austria), 500 U/ml IL-4 (Immunotools, 
Friesoythe, Germany) and 800 U/ml GM-CSF (Immunotools). After 2-3 days, half of the 
medium was replaced with fresh X-VIVO-15/2% HS medium containing 1000 U/ml IL-4 and 
1600 U/ml GM-CSF. Maturation of DCs was induced at day 6-7 by culturing 0.5 x 106 
immature (electroporated) DC/ml in 6-well plates (Corning Costar) in X-VIVO-15/2% HS 
containing 500 U/ml IL-4, 800 U/ml GM-CSF, 5 ng/ml IL-1ß, 15 ng/ml IL-6, 20 ng/ml TNF-α 
(all Immunotools) and 1 µg/ml PGE2 (Pharmacia & Upjohn, Bridgewater, NJ, USA). At day 8, 
mDCs were harvested and used for T cell stimulation, unless stated otherwise.
widely exploited as adjuvants in vaccination therapy because of their capability to 
effectively initiate and reactivate T cell-based immune responses. In GVT and graft-versus-
host-disease (GVHD) responses the process of alloreactive T cell stimulation and activation 
is also orchestrated by MiHA-presenting DCs20. Nowadays, the most commonly used cell 
source for DC generation is peripheral blood monocytes, since high numbers of 
monocytes can be easily obtained and differentiated into mature DCs (mDC)21;22. Using 
IL-4 and GM-CSF, immature DCs (iDCs) are obtained after 5-7 days of culture, followed by 
2 days of maturation in the presence of a cytokine cocktail containing IL-1ß, IL-6, TNF-α and 
PGE2. Upon maturation, expression of peptide-HLA complexes is increased and many 
accessory molecules involved in cell adhesion, cell migration and co-stimulation are 
acquired. For instance, CCR7 plays an important role in DC migration to draining lymph 
nodes, while adhesion molecules CD54 and CD58 are involved in T cell activation23. 
Furthermore, mDCs have high expression of co-stimulatory molecules CD80, CD86 and 
Inducible T-cell co-stimulator ligand (ICOS-L). However, co-inhibitory molecules such as 
PD-L1, PD-L2, Herpes virus entry mediator (HVEM) and B7-H3 are also highly up-regulated. 
Expression levels and interactions of these co-stimulatory and co-inhibitory ligands with 
their counter-receptors on T cells ultimately determine the turn of the balance towards 
antigen-specific T cell activation or inhibition23-25.
 Here, we investigated whether knockdown of PD-1 ligands in monocyte-derived DCs 
results in improved T cell function. We identified small interfering RNAs (siRNAs) that 
efficiently silenced PD-L1 and PD-L2 expression following electroporation of iDCs. We 
demonstrated that PD-L gene-silencing resulted in significant improvement of IFN-γ and 
IL-2 production, and proliferation of keyhole limpet hemocyanin (KLH)-experienced T 
cells. Moreover, PD-L knockdown DCs showed superior potential to expand PD-1-express-
ing MiHA-specific CD8+ effector and memory T cells from leukemia patients shortly after 
DLI and later during relapse. Together, these findings indicate that PD-L silenced DCs are 
attractive for improving the efficacy of DC vaccines in cancer patients.
Materials and methods
Patient and donor material
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor buffy coats 
(Sanquin blood bank, Nijmegen, the Netherlands). Blood samples were collected after 
written informed consent was obtained in ongoing clinical SCT and DC vaccination 
protocols, approved by the Radboud University Nijmegen Medical Centre Institutional 
Review Board. PBMCs containing KLH-specific T cells were obtained from multiple 
myeloma (MM) patients vaccinated with autologous DCs pulsed with KLH, as an adjuvant 
and immune monitoring tool, and various tumor-associated antigens in an ongoing 
clinical trial. These patients received three DC vaccines intravenously and intradermally 
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primers and Taqman probes were used: PD-L1; PD-L1 FW 5`-CATCTTATTATGCCTTGGTG-
TAGCA-3 ,` PD-L1 RV 5`-GGATTACGTCTCCTCCAAATGTG-3` and PD-L1 MGB probe 5’-(TET)-
ACATTCATCTTCCGTTTAAG-3’, PD-L2; PD-L2 FW 5`-CAACTTGGCTGCTTCACATTTT-3 ,` PD-L2 
RV 5`-TGTGGTGACAGGTCTTTTTGTTGT-3` and PD-L2 probe 5’-(TET)-TTCATAGCCACAGT-
GATAGCCCTAAGAAAACAACTCT-(TAMRA)-3’, HMBS; HMBS-FW 5’-GGCAATGCGGCTG-
CAA-3’, HMBS-RV 5’-GGGTACCCACGCGAATCAC-3’ and HMBS-probe 5’-(VIC)-CT-
CATCTTTGGGCTGTTTTCTTCCGCC-(TAMRA)-3’. PCR amplification was performed using an 
ABI Prism 7700 (Applied Biosystems) with the following PCR conditions: enzyme activation 
for 10 min at 95°C, followed by 45 cycles of 95°C for 15 s and 60°C for 1 min. PD-L1 and 
PD-L2 ΔCt values were normalized for HMBS by calculating ΔCt = Ct
gene
 – Ct
HMBS
 per sample. 
Finally, PD-L1 and PD-L2 mRNA expression levels were quantified relative to DCs 
electroporated without siRNA as follows: 2∧(-[ΔCt
electroporated with siRNA
]-[ΔCt
electroporated without siRNA
]).
Flow cytometry
Phenotype and maturation state of DCs was analyzed by staining with the following 
antibodies: anti-CD14 (clone TÜK4, Dako, Glostrup, Denmark), anti-CD80 (clone MAB104), 
anti-CD83 (clone HB15a), anti-CD86 (clone HA5.2B7, all from Beckman Coulter, Fullerton, CA, 
USA), anti-PD-L1 (clone MIH1), anti-PD-L2 (clone MIH18, both from Becton Dickinson, Franklin 
Lakes, NJ, USA) and isotype controls IgG1 FITC/PE dual-color control (Dako) and IgG2b PE 
(Beckman coulter). LRH-1- and HA-1-specific T cells were detected by staining cell suspensions 
with PE-labeled LRH-1/HLA-B7 tetramers containing peptide TPNQRQNVC and PE-labeled 
HA-1/HLA-A2 tetramers containing peptide VLHDDLLEA, respectively. Tetramers were kindly 
provided by prof. dr. Fred Falkenburg (Department of Hematology, LUMC, Leiden, the 
Netherlands). T cell cultures were incubated with 1.5-2 μg/ml tetramer for 15 min at room 
temperature. Subsequently, cells were labeled with the appropriate concentrations of 
anti-CD8 (ProImmune, Oxford, United Kingdom) and anti-CD3 (Beckman Coulter) for 30 min 
at 4°C. After washing with PBS/0.5% bovine serum albumin (BSA; Sigma, St Louis, MO, USA), 
cells were resuspended in washing buffer containing 0.1% 7-amino-actinomycin D (7-AAD; 
Sigma). Cells were analyzed using the Coulter FC500 flow cytometer (Beckman Coulter).
Allogeneic mixed lymphocyte reactions
Allogeneic CD4+ and CD8+ T cells were isolated from non-adherent or complete PBMC 
fractions by direct magnetic labeling with the appropriate MicroBeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany) following the manufacturer’s instructions. Cells were 
resuspended in IMDM/10% HS to a concentration of 0.5 x 106 cells/ml and stimulated with 
mature PD-L knockdown DCs at T cell:DC ratios ranging from 1:0.1 to 1:0.0125. These 
co-cultures were performed in 48-wells plates (Cellstar; Greiner Bio-one) in a total volume 
of 1 ml IMDM/10% HS. After 1-5 days of co-culture, supernatant was harvested for cytokine 
analysis. At day 5, cells were resuspended and transferred to 96-wells round bottom plates 
(Corning Costar). Subsequently, 0.5 µCi [3H]-thymidine (Perkin Elmer, Groningen, the 
StealthTM siRNA duplexes
Three different PD-L1 and PD-L2 StealthTM siRNA duplexes and two recommended 
StealthTM negative control siRNA duplexes for either low or medium GC content were 
obtained from Invitrogen. The PD-L1 siRNA and PD-L2 siRNA target sequences are listed in 
Table 1. All siRNAs were dissolved or diluted to a concentration of 25 µM in DEPC-water 
(Invitrogen) and subsequently stored at -20°C.
DC electroporation
Immature DCs were harvested at day 6-7, washed once with Hank’s balanced salt solution 
(HBSS; Lonza) and twice with phenol red free Optimem buffer (Gibco Invitrogen, Carlsbad, 
CA, USA). Cells were resuspended in Optimem buffer and ≤7.5 x 106 cells were transferred 
to a 0.4 cm gene pulser cuvette (Biorad, Hercules, CA, USA). Subsequently, 0.25 nmol of a 
single siRNA or in case of double knockdown 0.125 nmol per siRNA was added. DCs were 
electroporated at 300 Volt, 150 µF using a Biorad Genepulser II. Directly after electropora-
tion, cells were resuspended in pre-warmed phenol red free X-VIVO-15/7% HS and 
incubated at 37°C. After 1 hour, phenol red free medium was replaced with conventional 
maturation medium. Cells were cultured for 1-5 days. 
RNA isolation and real-time quantitative reverse transcription PCR
Total RNA was isolated from mature PD-L knockdown DCs using the Quick-RNA-miniprep 
(Zymo Research Corporation, Orange, CA, USA). cDNA synthesis and PCR amplification 
were performed as described28;29. The Hydroxymethylbilane synthase (HMBS) housekeeping 
gene was used to normalize gene expression. One μl of cDNA was amplified in a 50 μl 
reaction mixture containing 1.25 U AmpliTaq Gold (Applied Biosystems, Forster City, CA, 
USA), 300 nM gene-specific forward and reverse primer, 100-300 nM gene-specific 
Taqman probe (100 nM for PD-L2, and 300 nM for PD-L1 and HMBS), 250 μM of each dNTP, 
5 mM MgCl
2
 and 1x Taqman PCR buffer (Applied Biosystems). The following gene-specific 
6
Table 1  Target sequences of StealthTM PD-L siRNAs
siRNA Sense sequence (5’ à 3’) Anti-sense sequence (5’ à 3’)
PD-L1 no. 1 GAGGAAGACCUGAAGGUUCAGCAUA UAUGCUGAACCUUCAGGUCUUCCUC
PD-L1 no. 2 CCUACUGGCAUUUGCUGAACGCAUU AAUGCGUUCAGCAAAUGCCAGUAGG
PD-L1 no. 3 UGAUACACAUUUGGAGGAGACGUAA UUACGUCUCCUCCAAAUGUGUAUCA
PD-L2 no. 1 GCCUGGAAUUGCAGCUUCACCAGAU AUCUGGUGAAGCUGCAAUUCCAGGC
PD-L2 no. 2 GGGACUACAAGUACCUGACUCUGAA UUCAGAGUCAGGUACUUGUAGUCCC
PD-L2 no. 3 CCCUCCUGCAUCAUUGCUUUCAUUU AAAUGAAAGCAAUGAUGCAGGAGGG
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the corresponding recipient EBV-LCLs and donor EBV-LCLs loaded with or without 5 µM 
LRH-1 peptide. Briefly, 2 x 105 cells of each T cell culture were stimulated with target cells at 
an effector:target ratio of 1:1 in a total volume of 500 µl IMDM/10% HS supplemented with 
25 U/ml IL-2 and 6.5 µl anti-CD107a (Becton Dickinson). After overnight co-culture, the 
percentage of CD107a+ cells was determined within the LRH-1-tetramer+ CD8+ T cell 
population using flow cytometry.
Cytokine analyses
IFN-γ and granzyme B levels in culture supernatants were analyzed using enzyme-linked 
immunosorbent assays (ELISA; IFN-γ: Pierce Endogen, Rockford, IL, USA; Granzyme B: 
MabTech, Nacka Strand, Sweden). Release of IL-2, IL-4, IL-5, TNF-α and IFN-γ by the T cells 
was simultaneously determined in pooled supernatant using a Th1/Th2 BDTM cytometric 
bead array (Becton Dickinson) following the manufacturer’s protocol and measured using 
flow cytometry.
Statistical analysis
Statistical significance of differences between PD-L knockdown DCs and medium GC 
siRNA control DCs was analyzed using One-way ANOVA followed by a Bonferroni post-hoc 
test. P-values <0.05 were considered significant.
Results
Efficient, specific and long-lasting siRNA-mediated knockdown of PD-L1 and 
PD-L2 on DCs
To determine the efficacy and specificity of three different siRNAs in silencing PD-L1 and 
PD-L2 expression on monocyte-derived DCs, we studied the magnitude, off-target effects 
and duration of knockdown on mRNA and protein level. Immature DCs were electroporated 
with or without 0.25 nmol siRNA and subsequently cultured in maturation medium 
containing IL-1ß, IL-6, TNF-α and PGE2. All three PD-L1 siRNAs appreciably reduced PD-L1 
mRNA levels at two days after electroporation, while the negative control siRNAs had no 
effect (Figure 1A). Similarly, all three PD-L2 siRNAs efficiently knocked down PD-L2 mRNA 
expression to the same extent. To validate knockdown on the protein level, we analyzed 
PD-L1 and PD-L2 surface expression on siRNA-electroporated DCs two days after 
maturation. PD-L1 siRNA number 2 induced the most pronounced reduction of PD-L1 cell 
surface expression, resulting in an average of 21% PD-L1+ DCs (N=6, Figure 1B-C). In case of 
PD-L2 all three siRNAs were equally effective, resulting in <10% PD-L2+ DCs. Therefore, we 
decided to continue with PD-L1 and PD-L2 siRNA number 2 and the accompanying 
medium GC negative control siRNA. To verify that our siRNAs of interest did not affect DC 
maturation or have other off-target effects, protein expression levels of various maturation 
Netherlands) was added to each well. After overnight incubation, [3H]-thymidine 
incorporation was measured using a 1205 Wallac Betaplate counter (Perkin Elmer).
KLH-specific T cell activation assays
Autologous monocyte-derived DCs were cultured from apheresis material of MM 
patients as described above. At day 3, DCs were pulsed with or without 50 µg/ml KLH 
(Vacmune®, Biosyn Corporation, Fellbach, Germany). Patient PBMCs containing KLH-specific 
T cells were thawed, resuspended in IMDM/10% HS to a concentration of 0.5 x 106 cells/ml 
and mixed with autologous 2 day mature PD-L knockdown DCs at a T cell:DC ratio of 
1:0.05. These co-cultures were performed in 6-fold in 96-wells round bottom plates 
(Corning Costar) in a total volume of 200 µl. After 1 and 5 days of co-culture, supernatant 
was harvested for cytokine analysis. At day 5, proliferation was analyzed using [3H]-
thymidine, as described before.
MiHA-specific T cell expansion assays
LRH-1-specific CTL RP1 was resuspended in IMDM/10% HS to a concentration of 0.05 x 106 
cells/ml and plated in 96-wells round bottom plates (Corning Costar). HLA-B7+ PD-L 
knockdown DCs were loaded with or without 10 µM LRH-1 peptide TPNQRQNVC for 30 
minutes at room temperature and, subsequently, co-cultured with CTLs at a stimulation 
ratio of 1:1 in a total volume of 200 µl. After 1 day, 100 µl supernatant was harvested and 
fresh IMDM/10% HS containing 100 U/ml IL-2 (Chiron, Emeryville, CA, USA) was added. At 
day 4, CTL proliferation was analyzed using [3H]-thymidine, as described before, and 
supernatant was analyzed for cytokine levels.
 MiHA-specific CD8+ memory T cells present in PBMCs from patients UPN543, UPN640 
and UPN389 were stimulated for one to three consecutive weeks ex vivo with unloaded or 
MiHA peptide-loaded PD-L knockdown DCs. Mature allogeneic PD-L knockdown or 
control DCs, cultured from apheresis material of a HLA-B7+ LRH-1- or HLA-A2+ HA-1- donor, 
were loaded with or without 5 µM MiHA peptide (LRH-1: TPNQRQNVC, HA-1: VLHDDLLEA) 
for 30 minutes at room temperature. PBMCs and DCs were subsequently co-cultured at a 
ratio of 1:0.1 in 2 ml IMDM/10% HS in 24-wells plates (Corning-Costar). After 5 days, CD4+ T 
cells were depleted from the cultures by direct magnetic labeling with CD4 IMag beads 
(Becton Dickinson). CD4-depleted fractions were resuspended in IMDM/10% HS 
supplemented with 50 U/ml IL-2 and 5 ng/ml IL-15 (Immunotools). At day 6 or 7, cells were 
harvested, counted and the percentage of LRH-1- or HA-1-specific CD8+ T cells was 
determined by flow cytometry.
CD107a degranulation assay
PBMC cultures stimulated for 2 consecutive weeks with LRH-1 peptide-loaded PD-L 
knockdown DCs were used in a CD107a secretion assay to determine functional 
recognition of the LRH-1 antigen by measuring CTL degranulation. As target cells we used 
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and co-stimulatory molecules were examined two days after electroporation. None of the 
molecules were affected by the siRNAs tested (Figure 1D). Finally, we determined the 
duration of the siRNA-mediated knockdown effects by assessing PD-L1 and PD-L2 protein 
expression over time upon DC electroporation. After two days, PD-L1 and PD-L2 were 
both maximally down-regulated by the respective siRNAs and expression remained low 
for at least three more days (Figure 1E). Collectively, these data show that siRNA electro-
poration of DCs results in efficient, specific and long-lasting silencing of PD-L1 and PD-L2.
PD-L knockdown DCs show increased capacity to stimulate cytokine production 
in allogeneic MLR assays
To investigate whether knockdown of PD-L1 and/or PD-L2 using the selected siRNAs 
(i.e. PD-L1 and PD-L2 target sequence no. 2 in Table 1) improved the stimulatory capacity 
of DCs, allogeneic T cells were co-cultured for five days with mature PD-L knockdown DCs. 
Thereafter, T cell proliferation and cytokine production was analyzed. A strong and 
dose-dependent increase in IFN-γ production was observed upon stimulation with PD-L 
knockdown DCs, but PD-L knockdown DCs were not capable of improving T cell 
proliferation of allogeneic CD4+ T cells or CD8+ T cells (Figure 2A-B). For CD4+ T cells, IFN-γ 
levels were enhanced up to 7-fold by PD-L1 knockdown DCs, whereas PD-L2 silenced DCs 
only modestly improved IFN-γ production (Figure 2B). Interestingly, stimulation with 
PD-L1/L2 double knockdown DCs resulted in a 10-fold higher IFN-γ production, indicating 
a synergistic effect when PD-L1 and PD-L2 are silenced simultaneously. Although CD8+ T 
cells produced less IFN-γ than CD4+ T cells, still considerable elevation of IFN-γ levels was 
observed upon stimulation with PD-L knockdown DCs. Especially, PD-L1 single and PD-L1/
L2 double knockdown DCs improved IFN-γ levels up to 3-fold, while the increase by PD-L2 
single knockdown DCs was again modest.
 In order to get more insight into the levels and kinetics of various cytokines produced 
by the different T cell subsets upon stimulation with PD-L knockdown DCs, co-culture 
supernatant was harvested over time and analyzed. Early after stimulation with DCs, 
allogeneic T cells started producing IL-2, while production of IFN-γ, TNF-α and IL-5 initiated 
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 electroporated without siRNA was set to 1. (B) PD-L1 and PD-L2 protein expression (black lines) as 
compared to isotype control (grey histograms) was analyzed using flow cytometry. The numbers in 
the plots represent the mean fluorescence intensity (MFI). Data of 1 representative donor out of 6 
are shown. (C) Percentage of PD-L1+ or PD-L2+ DCs was determined for 3-6 donors by flow cytome-
try. (D) Expression of maturation and co-stimulatory molecules by electroporated DCs was analyzed 
using flow cytometry. The bars represent DCs electroporated without siRNA (black), with MED GC 
control siRNA (white), PD-L1 siRNA 2 (dark grey) or PD-L2 siRNA 2 (light grey). Data are expressed as 
mean + SEM of 3-6 donors. (E) Percentage of PD-L1+ or PD-L2+ DCs over time was determined by 
flow cytometry. The percentage of PD-L+ DCs electroporated without siRNA was set to 100%. The 
lines represent DCs electroporated without siRNA (dotted line, closed circle), with MED GC control 
siRNA (dotted line, open circle), PD-L1 siRNA 2 (solid dark grey line) or PD-L2 siRNA 2 (solid light grey 
line). The data are representative for 2 independent experiments on 2 different donors.
Figure 1   Efficacy, specificity and duration of siRNA-mediated PD-L1 and PD-L2 
 silencing on DCs
Immature DCs were electroporated with 0.25 nmol PD-L1, PD-L2 or negative control (MED GC vs. 
LOW GC) siRNA duplexes and subsequently cultured in maturation medium containing IL-1ß, IL-6, 
TNF-α and PGE2 for (A-D) 2 days or (E) 1-5 days. (A) PD-L1 and PD-L2 expression was measured and 
subsequently normalized for HMBS expression using RT Q-PCR. PD-L mRNA expression in DCs 
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later (Figure 2C). No IL-4 was produced (data not shown). Overall, highest cytokine levels 
were observed in co-cultures with CD4+ T cells. Furthermore, over time PD-L knockdown 
DCs evidently elevated IL-2, IFN-γ, TNF-α and IL-5 production by CD4+ as well as CD8+ T 
cells. For all cytokines, the highest levels were obtained after stimulation with the PD-L1/
L2 double knockdown DCs.
 Altogether, these results demonstrate that stimulation with PD-L knockdown DCs 
has no effect on T cell proliferation, but profoundly enhances the cytokine production 
capacity of stimulated T cells in a primary allogeneic MLR.
KLH-specific T cell responses are strongly augmented by PD-L knockdown DCs
To examine the stimulatory capacity of PD-L-silenced DCs in secondary responses by 
 antigen-experienced T cells, we cultured PBMCs containing primed KLH-specific T cells 
together with autologous KLH-pulsed PD-L knockdown DCs. After 1-5 days, KLH-specific 
proliferation and cytokine production of DC-stimulated T cells was studied. Interestingly, 
the proliferative capacity of primed KLH-specific T cells could be significantly boosted 
with PD-L knockdown DCs (Figure 3A). Using PBMCs from MM patient 1, all three 
knockdown DC types increased KLH-specific T cell proliferation, whereas in patient 2 
significant induction of proliferation was only seen upon stimulation with PD-L1/L2 
double knockdown DCs. In accordance with the results found in the allogeneic MLR 
setting, stimulation with  PD-L knockdown DCs resulted in increased cytokine production 
by KLH-specific T cells (Figure 3B). Stimulation with PD-L1 knockdown DCs resulted in 2-5 
times higher IFN-γ levels than after co-culture with control siRNA DCs. Despite the modest 
elevation of IFN-γ production after stimulation with PD-L2-silenced DCs, an evident 
synergistic augmentation (i.e. 8-14 fold) of IFN-γ levels was observed when KLH-specific T 
cells were stimulated with PD-L1/L2 double knockdown DCs. Already one day after 
stimulation with KLH-pulsed DCs, IL-2 production was markedly elevated by all PD-L 
knockdown DC types (Figure 3C). Again, the most evident enhancement was seen for 
PD-L1 single and PD-L1/L2 dual knockdown DCs. Moreover, in PD-L1 single and PD-L1/L2 
double knockdown DC stimulated cultures, IL-2 levels remained considerably higher up to 
5 days after stimulation of the KLH-specific T cells. These data demonstrate that KLH-pulsed 
PD-L knockdown DCs augment proliferation and strongly increase cytokine production 
by primed KLH-specific T cells of DC-vaccinated cancer patients.
MiHA-specific CTL expansion and function is enhanced by PD-L silenced DCs
Recently, we have observed that activated LRH-1-specific CD8+ T cells express PD-1, and 
that in vitro antibody blockade of PD-1 signaling results in improved stimulation of 
LRH-1-specific CD8+ T cells by PD-L1-expressing DCs and myeloid leukemia cells9. To 
investigate the effect of PD-L silencing on MiHA-specific CD8+ T cell expansion and 
functionality initiated by DCs, we stimulated LRH-1-specific CTL clone RP1 with PD-L 
knockdown DCs loaded with or without LRH-1 peptide for 1-4 days. Following DC 
6
1:0.1 1:0.05 1:0.025
0
300
600
900
1200
1500
CD8
+PD-L1 siRNA  2
+PD-L2 siRNA  2
+PD-L1/L2 siRNA
+MED GC
CD8+ T cell: DC ratio
IF
N
-γ
 (p
g/
m
l)
1:0.1 1:0.05 1:0.025
0
1000
2000
3000
4000
5000
6000
CD4+ T cell: DC ratio
IF
N
-γ
 (p
g/
m
l)
1:0.1 1:0.05 1:0.025 1:0.0125
5
10
15
20
25
+P D- L1 siR NA 2
+P D- L2 siR NA 2
+P D- L1/L2 siR NA
+ME D GC
CD8+ T cell: DC ratio
C
P
M
(x
10
3 )
1:0.1 1:0.05 1:0.025 1:0.0125
0
10
20
30
40
CD4CD4+ T cell: DC ratio
C
P
M
(x
10
3 )
C
 *
**
 *
***
 *
***
A
B
    
CD
8 
    
    
    
    
   
ED GC
-L1 siRNA
-L2 siRNA
-L1/L2 siRNA
***
***
 *
*
**
**
T  cells
ED GC
PD-L1 siRNA
PD-L2 siRNA
PD-L1/L2 siRNA
250
500
750
IL
-2
 (p
g/
m
l)
2000
4000
6000
IF
N
-γ
 (p
g/
m
l)
200
400
600
TN
F-
α 
(p
g/
m
l)
50
100
200
IL
-5
 (p
g/
m
l)
150
50
100
IL
-2
 (p
g/
m
l)
300
600
1200
IF
N
-γ
 (p
g/
m
l)
900
25
50
75
TN
F-
α 
(p
g/
m
l)
100
200
400
IL
-5
 (p
g/
m
l)
300
1 2 3 4 5
Days of culture
1 2 3 4 5
Days of culture
1 2 3 4 5
Days of culture
1 2 3 4 5
Days of culture
1 2 3 4 5
Days of culture
1 2 3 4 5
Days of culture
1 2 3 4 5
Days of culture
1 2 3 4 5
Days of culture
+MED GC
+PD-L1 siRNA 2
+PD-L2 siRNA 2
+PD-L1/L2 siRNA
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
CD
4
Figure 2   PD-L knockdown DCs show enhanced stimulation of allogeneic T cells
Immature DCs were electroporated with 0.25 nmol of each single siRNA or 0.125 nmol of each siRNA 
in case of double knockdown. After 2 days of maturation, DCs were mixed with allogeneic T cells. 
(A) At day 5 of co-culture, [3H]-thymidine was added to the culture and the following day T cell 
proliferation capacity was determined by measuring [3H]-thymidine incorporation. Data are depicted 
as mean + SD and are representative for 2 different donors. CPM, counts per minute. (B) IFN-γ levels 
were measured in the supernatant at day 5 of co-culture using ELISA. Data are depicted as mean + 
SD and are representative for 3 different donors. (C) Cytokines produced by CD4+ and CD8+ T cells 
of the same donor stimulated with allogeneic DCs at a ratio of 1:0.1 were analyzed simultaneously 
at day 1-5 of the co-culture. Statistical analysis was performed using One-way ANOVA followed by 
a Bonferroni post-hoc test. *P <.05, **P <.01, *** P  <.001.
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production by LRH-1-specific CTL following stimulation with all three LRH-1 peptide-loaded 
PD-L knockdown DCs (Figure 4B). Moreover, production of granzyme B by CTL RP1 was 
augmented by PD-L1 silenced DCs upon peptide recognition (Figure 4C). These results 
indicate that PD-L silenced DCs are able to increase the proliferation rate and degranulation 
capacity of MiHA-specific CTLs.
stimulation, we measured the proliferative capacity as well as production of IFN-γ and 
granzyme B by LRH-1-specific CTL RP1. After four days of co-culture, LRH-1 dependent 
proliferation of CTL RP1 was observed (Figure 4A). Single PD-L1 and dual PD-L1/L2 
knockdown significantly enhanced DC-mediated CTL proliferation, while the effect of 
PD-L2 knockdown was only modest. Furthermore, we observed increased IFN-γ 
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Figure 3   PD-L siRNA-silenced DCs show an increased capacity to stimulate KLH-specific 
T cell proliferation and cytokine production in vaccinated cancer patients
Autologous PD-L knockdown DCs pulsed with or without KLH were co-cultured with PBMCs from 
vaccinated MM patients at a stimulation ratio of 0.1:1. (A) At day 5, [3H]-thymidine was added to the 
culture and the following day T cell proliferation capacity was determined by measuring 
[3H]-thymidine incorporation. Representative data of 2 out of 5 patients are shown and bars are 
depicted as mean + SD. CPM, counts per minute. (B) IFN-γ levels were measured in the supernatant 
at day 5 of the co-culture. Representative data of 2 out of 5 patients are shown and bars are 
 depicted as mean + SD. (C) IL-2 levels were measured in co-culture supernatant of day 1 and 5. 
Representative data of 2 out of 5 patients is shown. Statistical analysis was performed using One-
way ANOVA followed by a Bonferroni post-hoc test. *P <.05, **P <.01, ***P <.001.
Figure 4   Expansion and function of MiHA-specific CTL RP1 is augmented by PD-L 
knockdown DCs
Two days after electroporation with PD-L1 and/or PD-L2 siRNA, mature HLA-B7+ DCs were loaded 
with or without 10 µM LRH-1 peptide and co-cultured with MiHA-specific CTL RP1 at a stimulation 
ratio of 1:1. PD-L knockdown resulted in <20% PD-L1+ and/or <1% PD-L2+ DCs. (A) After 4 days, 
proliferation was determined following overnight [3H]-thymidine incorporation. Data of 1 out of 2 
independent experiments is shown and bars are depicted as mean + SD. CPM, counts per minute. 
(B) IFN-γ and (C) granzyme B levels were measured in CTL RP1 supernatant obtained at day 1 of 
co-culture. Statistical analysis was performed using One-way ANOVA followed by a Bonferroni post-
hoc test. *P <.05, ***P <.001.
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percentages of LRH-1-specific CD8+ T cells of 2.5% and 10% for PD-L single and PD-L1/L2 
double knockdown DCs compared to control DCs (0.7%). In absolute numbers the 
advantage of PD-L knockdown DCs over control DCs in augmenting LRH-1-specific CD8+ 
T cell expansion is even more evident (Figure 6D). Eventually, this resulted in 13.3-, 26.7- 
and 61-times higher numbers of tetramer+ CD8+ T cells by PD-L1, PD-L2 and PD-L1/L2 
double knockdown DCs, respectively.
PD-L knockdown DCs effectively boost ex vivo expansion and function of 
MiHA-specific CD8+ effector and memory T cells
In order to investigate the effect of stimulation with MiHA-presenting PD-L silenced DCs 
on MiHA-specific CD8+ effector and memory T proliferation, we used PBMCs from three 
different leukemia patients collected early after SCT and DLI or during relapsed disease. 
First, we cultured PBMCs of patients UPN543 and UPN640, both obtained 7 months after 
DLI during the effector response, with MiHA-presenting PD-L silenced DCs for 1 week. At 
start PBMCs contained 0.12% LRH-1-specific and 0.14% HA-1-specific CD8+ T cells, 
respectively. In both patients we observed augmented percentages of MiHA-specific 
CD8+ T cells following stimulation with MiHA-loaded PD-L silenced DCs compared to 
control DCs (Figure 5A-B). Although the best effects were observed upon stimulation with 
PD-L1/L2 double knockdown DCs, all PD-L knockdown DC types evidently increased the 
number of LRH-1-specific CD8+ T cells of patient UPN543 after 1 week of culture ranging 
from 1.5 to 2.7-fold (Figure 5C). In case of patient UPN640 the effects were even more 
pronounced. One week culture with PD-L knockdown DCs resulted in considerably 
augmented expansion of HA-1-specific CD8+ T cells of up to 12-fold for PD-L1/L2 double 
knockdown DCs (Figure 5D).
 Next, we investigated the effect of repetitive stimulations with MiHA-presenting PD-L 
silenced DCs on MiHA-specific CD8+ memory T cell proliferation and function. For this, we 
used PBMCs from CML-AP patient UPN389 and AML patient UPN543 containing, 
respectively, 0.06% and 0.09% LRH-1-specific CD8+ T cells, collected at 64 (UPN389) and 71 
(UPN543) months post-DLI during relapsed disease. These PBMCs were stimulated for two 
or three consecutive weeks with LRH-1 peptide-loaded DCs, and the number of 
LRH-1-specific CD8+ T cells was weekly determined by flow cytometry. Following 
stimulation with LRH-1 peptide-loaded control DCs, a specific increase in the percentage 
of LRH-1-tetramer+ CD8+ T cells of 8% was observed over time in patient UPN389 (Figure 
6A). Interestingly, PD-L1 single and PD-L1/L2 double knockdown DCs improved 
LRH-1-specific CD8+ memory T cell expansion up to 12% and 29%, respectively. Surprisingly, 
lower percentages of LRH-1-specific CD8+ T cells were detected upon stimulation with 
LRH-1 peptide-loaded PD-L2 knockdown DCs. Since absolute T cell numbers and the 
percentage of CD8+ T cells were higher in PD-L silenced DC-stimulated cultures compared 
to T cell cultures stimulated with control DCs, we also calculated the cumulative number 
of LRH-1-specific CD8+ T cells over time (Figure 6B). In the first week, the fold expansion 
upon stimulation with PD-L1 single and PD-L1/L2 double knockdown DCs was respectively 
1.6- and 4.7-times higher than that of LRH-1 peptide-loaded control DCs. Ultimately, 
stimulation with PD-L1 single or PD-L1/L2 double knockdown DCs resulted in a 2.8- and 
23.3-times higher number of LRH-1-specific CD8+ T cells by the end of week three. 
 Also for AML patient UPN543, we observed a specific increase in the percentage of 
LRH-1-tetramer+ CD8+ T cells to 0.7% upon repetitive stimulations with LRH-1 peptide 
loaded DCs (Figure 6C). Silencing of PD-1 ligands on these DCs resulted in improved 
6
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Figure 5   MiHA-specific CD8+ effector T cell expansion can be enhanced by PD-L 
 silenced DCs
Two days after electroporation with PD-L1 and/or PD-L2 siRNA, mature HLA-B7+ LRH-1- or HLA-A2+ 
HA-1- DCs were loaded with or without 5 µM MiHA peptide. PD-L knockdown resulted in <17% 
PD-L1+ and/or <5% PD-L2+ DCs. Patient PBMCs, containing MiHA-specific CD8+ effector T cells, 
 stimulated with PD-L knockdown DCs at a ratio of 1:0.1 were screened after 1 week for tetramer-
positive CD8+ T cells using flow cytometry. The numbers in the FACS plots represent the percentage 
of (A) LRH-1-specific (UPN543) or (B) HA-1-specific (UPN640) CD8+ T cells in the total CD3+CD8+ T cell 
population. Total numbers of (C) LRH-1-specific or (D) HA-1-specific CD8+ T cells obtained after 1 
week of stimulation with PD-L knockdown DCs loaded with or without MiHA peptide.
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 Finally, we studied the functional capacity of the expanded LRH-1-specific CD8+ T 
cells of patient UPN389 after two weeks of stimulation with LRH-1 peptide-loaded PD-L 
knockdown or control DCs. These DC-stimulated CD8+ T cell cultures were incubated 
overnight with different target cells in the presence of anti-CD107a to determine the 
percentage of degranulating CD107a+ LRH-1-specific CD8+ T cells. We observed that 
stimulation with recipient EBV-LCLs and LRH-1 peptide-loaded donor EBV-LCLs resulted in 
>75% CD107a+ LRH-1-specific CD8+ T cells (Figure 6E), whereas stimulation with donor 
EBV-LCLs or medium resulted in <25% non-specific degranulation of the LRH-1-specific 
CD8+ T cells. A slight difference in degranulation capacity was seen between the 
LRH-1-specific CD8+ T cells stimulated with PD-L knockdown DCs in comparison to control 
DCs. Together, these results demonstrate that MiHA-specific CD8+ effector and memory T 
cell expansion can be efficiently boosted using PD-L knockdown DCs and that these 
expanded MiHA-specific CD8+ T cells have the capacity to degranulate upon recognition 
of MiHA+ target cells.
Discussion
Alloreactive CD8+ T cells targeting MiHAs on malignant cells of the recipient play a key role 
in GVT immunity after allo-SCT and DLI. However, MiHA-specific CD8+ T cell responses 
induced post-transplantation are in a substantial number of patients not sufficient to 
sustain complete remission of the malignant disease. It is evident that distinct mechanisms 
are involved in dampening anti-tumor T cell responses, which may allow malignant cells 
to escape immune destruction. Among these mechanisms, T cell inhibition or even 
exhaustion due to signaling of the PD-1/PD-L pathway may contribute to abrogation of 
immune responses by limiting the expansion and functionality of CD8+ T cells13-19. Recently, 
we showed that MiHA+ leukemia can relapse without inducing MiHA-specific CD8+ 
memory T cell expansion, suggesting that these memory T cells are either inactive or are 
not activated by MiHA-presenting APCs6;26. Furthermore, we found that similar to 
virus-specific CD8+ T cells in chronic viral infections and tumor-infiltrating T cells in solid 
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Figure 6   PD-L knockdown DCs boost the proliferative capacity and function of MiHA-
specific CD8+ memory T cells
Two days after electroporation with PD-L1 and/or PD-L2 siRNA, mature HLA-B7+ LRH-1- DCs were 
loaded with or without 5 µM LRH-1 peptide. PD-L knockdown resulted in <5% PD-L1+ and/or <2% 
PD-L2+ DCs. (A) PBMCs of patient UPN389, consecutively stimulated with PD-L knockdown DCs at a 
ratio of 1:0.1, were weekly screened for tetramer-positive CD8+ T cells using flow cytometry. The 
numbers in the FACS plots represent the percentage of LRH-1-specific CD8+ T cells in the total 
CD3+CD8+ T cell population. Data are representative for 2 independent experiments. (B) Cumulative 
numbers of LRH-1-specific CD8+ T cells of patient UPN389 obtained after 3 consecutive stimulations 
with PD-L knockdown DCs loaded with or without LRH-1 peptide. (C) Percentage of LRH-1-specific 
CD8+ T cells in PBMCs of patient UPN543. PBMCs were consecutively stimulated with PD-L knock-
down DCs at a ratio of 1:0.1 and weekly screened for tetramer-positive CD8+ T cells using flow 
cytometry. (D) Cumulative numbers of LRH-1-specific CD8+ T cells of patient UPN543 obtained after 
2 consecutive stimulations with PD-L knockdown DCs loaded with or without LRH-1 peptide. 
(E) Degranulation of LRH-1-specific CD8+ T cells of patient UPN389, stimulated for 2 weeks with 
LRH-1 peptide loaded PD-L knockdown DCs, was measured by staining for CD107a during over-
night stimulation with different target cells. PBMCs were cultured 1:1 with LRH-1- donor EBV-LCLs, 
LRH-1 peptide loaded donor EBV-LCLs, LRH-1+ recipient EBV-LCLs or in medium. ND, not deter-
mined. 
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during secondary immune responses32. Therefore, we tested our PD-L knockdown DCs 
also in an antigen-experienced setting using PBMCs of MM patients containing 
KLH-specific T cells after vaccination with autologous KLH-pulsed DCs. Although effects 
vary to some extent, we observed in five different patients significant improvement of 
KLH-specific T cell proliferation after stimulation with KLH-pulsed PD-L silenced DCs. 
Furthermore, PD-L knockdown significantly enhanced IFN-γ and IL-2 production by the 
KLH-specific T cells. Interestingly, the effects of PD-L2 silenced DCs were very modest, 
while simultaneous knockdown of PD-L1 and PD-L2 on DCs resulted in a synergistic 
improvement of T cell cytokine production. A similar phenomenon was observed by Keir 
et al. following stimulation of OVA-specific CD4+ T cells with PD-L1/PD-L2-/- DCs in the 
presence of OVA-peptide33. This suggests that PD-L1 and PD-L2 can exert similar effects 
via overlapping pathways.
 In order to investigate whether our PD-L knockdown DCs were capable of improving 
MiHA-specific CD8+ T cell responses, we used LRH-1-specific CTL RP1 and PBMCs 
containing MiHA-specific CD8+ effector or memory T cells, collected from three leukemia 
patients early after DLI or years later during relapsed disease. In this MiHA-specific setting, 
LRH-1 peptide-loaded PD-L knockdown DCs improved the expansion rate of LRH-1-specific 
CTL RP1. In addition, IFN-γ and granzyme B levels produced by this CTL were significantly 
higher after stimulation with PD-L knockdown DCs. Most importantly, we demonstrated 
that LRH-1- and HA-1-specific CD8+ T cells could be more efficiently expanded by MiHA 
peptide-loaded PD-L knockdown DCs during both effector and memory T cell responses. 
After the first stimulation with DCs differences were still modest for some patient samples, 
but upon restimulation PD-L knockdown DCs profoundly improved the proliferative 
capacity of the MiHA-specific CD8+ T cells. Surprisingly, in patient UPN389 LRH-1-specific 
CD8+ memory T cell expansion was lower after stimulation with PD-L2 knockdown DCs 
than with control DCs. We are very intrigued by this observation, especially since PD-L1/L2 
double knockdown DCs are evidently the best stimulator cells. It could be that under 
certain conditions PD-L2 acts as a co-stimulatory molecule by a PD-1-independent 
mechanism, as shown by others, and that by siRNA-mediated silencing we inhibited 
LRH-1-specific T cell activation34;35. Another explanation could be that PD-L2 knockdown 
interferes with the postulated PD-L2 reverse signaling, resulting in DCs with lower 
stimulatory capacity36;37. Finally, we showed that the expanded LRH-1-specific CD8+ T cells 
have the capacity to degranulate upon recognition of MiHA-expressing target cells, 
demonstrating that these cells have competent cytotoxic functions.
 In conclusion, we demonstrated that efficient, specific and long-lasting silencing of 
PD-L1 and PD-L2 can be achieved by single siRNA electroporation of monocyte-derived 
DCs. We showed that PD-L knockdown DCs profoundly boost the proliferative capacity 
of antigen-experienced T cells specific for KLH and MiHAs. Moreover, both in primary 
allo-MLR and secondary antigen-specific T cell responses, PD-L knockdown DCs strongly 
enhanced cytokine production. Together, these findings indicate that PD-L siRNA- 
tumors the PD-1/PD-L pathway is involved in impairment of MiHA-specific CD8+ T cell 
function9.
 DC-based vaccination is an attractive strategy to prevent or treat recurrence of tumor 
cells by means of boosting MiHA-specific CD8+ T cell immunity27. Although results of DC 
vaccination therapy in cancer patients are promising the overall clinical outcome is not 
satisfactory yet21. Previously, we have shown that mature DCs have the potential to revive 
impaired MiHA-specific memory T cells from relapsed leukemia patients27. However, 
mature DCs do not only express co-stimulatory molecules, but also highly express PD-L1 
and PD-L2, which may inhibit their stimulatory capacity upon encounter of PD-1+ 
alloreactive CD8+ T cells. Here, we investigated whether PD-L1 and PD-L2 knockdown in 
DCs results in improved T cell stimulation. We silenced PD-L1 and PD-L2 expression on 
monocyte-derived DCs using StealthTM Select siRNA duplexes, which have high specificity, 
longevity and stability, and limited induction of non-specific cellular stress response 
pathways. Optimization experiments revealed that electroporation of iDCs compared to 
mDCs resulted in more efficient siRNA-mediated knockdown of PD-L2 and especially 
PD-L1 (data not shown). Therefore, we decided to continue with iDC electroporation 
followed by two days of maturation using the conventional cytokine cocktail containing 
IL-1ß, IL-6, TNF-α and PGE2. Testing of three different siRNA sequences demonstrated that 
PD-L2 expression levels could be efficiently down-regulated by all three duplexes 
following one electroporation, although duplex number 2 located on the boundary of 
exon 2 and 3 was the most efficient PD-L1 siRNA sequence. Our results contrast to findings 
reported by Breton et al, who described that a two-step electroporation method was 
necessary to obtain sufficient PD-L1 knockdown on monocyte-derived DCs30. The 
difference in efficacy could be related to the used PD-L1 siRNA sequence or different elec-
troporation conditions. Our selected PD-L1 and PD-L2 siRNAs showed specific effects for 
the targeted proteins and did not affect DC maturation or expression of co-stimulatory 
molecules. Furthermore, the siRNA-mediated PD-L knockdown lasted for at least 5 days. 
After identifying the most efficient siRNAs and electroporation protocol, we determined 
the stimulatory capacity of PD-L knockdown DCs in primary and secondary antigen- 
specific T cell responses.
 PD-L silenced DCs significantly increased cytokine production of CD4+ and CD8+ T 
cells in allogeneic MLR assays, however no improved effect of PD-L knockdown DCs on 
the induction of proliferative CD4+ and CD8+ T cell responses was observed. In the early 
phase of T cell stimulation we observed increased production of IL-2, and in the later 
phase enhanced production of IFN-γ, TNF-α and IL-5, but not IL-4. These data indicate that 
PD-L silenced DCs improve CD4+ Th1 and CD8+ T cell responses. Other studies reported 
increased T cell proliferation and cytokine production during primary allo-MLR responses 
following PD-L blockade using antibodies, especially upon initiation by weaker DCs such 
as iDCs and IL-10 pretreated mDCs31. However, more profound stimulatory effects by 
PD-L1 and PD-L2 blockade were observed on memory and recently activated T cells 
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electroporated DCs are attractive for improving the efficacy of MiHA-based DC vaccines 
to boost GVT immunity in SCT patients, as well as antigen-loaded DCs in cancer patients 
and chronic viral infections.
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Abstract
Dendritic cell (DC)-based vaccination boosting antigen-specific immunity is being 
explored for the treatment of cancer and chronic viral infections. Although DC-based 
immunotherapy can induce immunological responses, its clinical benefit has been 
limited, indicating that further improvement of DC vaccine potency is essential. In this 
study, we explored the generation of a clinical-grade applicable DC vaccine with improved 
immunogenic potential by combining PD-1 ligand siRNA and target antigen mRNA 
delivery. We demonstrated that PD-L1 and PD-L2 siRNA delivery using DLin-KC2-DMA-
containing lipid nanoparticles (LNPs) mediated efficient and specific knockdown of PD-L 
expression on human monocyte-derived DCs. The established siRNA-LNP transfection 
method did not affect DC phenotype or migratory capacity, and resulted in acceptable 
DC viability. Furthermore, we showed that siRNA-LNP transfection can be successfully 
combined with both target antigen peptide loading, as well as mRNA electroporation. 
Finally, we demonstrated that these PD-L silenced DCs loaded with antigen mRNA 
superiorly boost ex vivo antigen-specific CD8+ T cell responses from transplanted cancer 
patients. Together, these findings indicate that our PD-L siRNA-LNP modified DCs are 
attractive cells for clinical-grade production and in vivo application to induce and boost 
immune responses not only in transplanted cancer patients, but likely also in other 
settings.
Introduction
For more than 15 years, the immunotherapeutic potential of ex vivo-generated dendritic 
cells (DCs) has been explored for the treatment of cancer and chronic viral infections1-4. 
DCs are the most potent professional antigen-presenting cells (APCs) of the immune 
system, and effectively initiate and reactivate T cell-based immune responses. For that 
reason, DCs are considered to be the best means to improve antigen-specific T cell 
responses in vivo. However, so far clinical effects of DC vaccination therapy have been 
limited5-7. Despite the documented induction of antigen-specific T cell responses in 
DC-vaccinated patients, the magnitude of the immune response, the functionality of the 
boosted T cells and the induction of long-lived memory T cells need to be enhanced. 
Therefore, further improvement of DC vaccine potency is essential to improve the clinical 
potential of DC-based immunotherapy.
 Ex vivo-generated DC vaccines display high expression of peptide-HLA complexes 
and many accessory molecules involved in cell adhesion, cell migration and co-
stimulation8. However, DC maturation with pro-inflammatory cytokines and/or toll-like 
receptor ligands also strongly up-regulates co-inhibitory molecules, including PD-L1 and 
PD-L28. The balance in expression levels and interactions between these co-stimulatory 
and co-inhibitory ligands on APCs with their counter-receptors on T cells, determines the 
activation state of the T cells. By favorably modulating this balance toward increased co-
stimulation, the potency of DC vaccines could be enhanced. In this regard, we recently 
showed that by silencing the co-inhibitory molecules Programmed death ligand-1 (PD-L1) 
and PD-L2 using siRNAs, DCs with strongly improved stimulatory potential could be 
generated9. These PD-L knockdown DCs robustly boosted ex vivo expansion of both 
KLH-specific CD4+ Th1 responses, as well as minor histocompatibility antigen (MiHA)-
specific CD8+ effector-memory T cells from transplanted cancer patients. It is generally 
accepted that these MiHAs, expressed by the patient’s malignant cells, are the key antigens 
in anti-tumor immune responses after allogeneic stem cell transplantation (allo-SCT)10-12. 
In order to further increase DC immunogenicity we exploited MiHA-encoding mRNA 
electroporation of mature donor-derived DCs, that allows natural and long-lasting 
presentation of antigenic peptides by both HLA class I and II molecules13. We and others 
observed that mRNA-loaded DCs efficiently stimulate specific CD8+ T cell responses13-15. 
Furthermore, to generate a superior DC vaccine with high stimulatory potential and 
capable of eliciting a robust MiHA-specific immune response, it is desirable that PD-L 
siRNA delivery and MiHA mRNA loading are combined. However, mRNA electroporation is 
optimal at the mature DC (mDC) stage13, while PD-L siRNA electroporation must be 
performed at the immature DC (iDC) stage to efficiently prevent PD-L1 and PD-L2 
up-regulation during maturation9. Since double electroporation is undesirable due to 
substantial loss of DC yield, we explored a non-viral clinical-grade applicable siRNA 
transfection method based on lipid nanoparticles (LNPs). Using ionizable cationic lipids, 
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Carlsbad, CA, USA) according to the manufacturer’s protocols at 0.1 nM and 10 nM 
concentrations. mRNA levels for the appropriate transcript were quantified 24h after 
transfection by Q-PCR and normalized to GAPDH mRNA. Duplexes showing best 
knockdown at both concentrations were selected for 12-point dose-response ranging 
from 10 nM down to 0.01 pM to determine IC50 value for these siRNA duplexes. The best 
duplex for PD-L1 with the sequence 5’-AGAccuuGAuAcuuucAAAdTsdT-3’ (sense), 5’- 
UUUGAAAGuAUcAAGGUCUdTsdT-3’ (anti-sense) and the best duplex for PD-L2 with the 
sequence 5’-AuAAcAGccAGuuuGcAAAdTsdT-3’ (sense) and 5’-UUUGcAAACUGGCU-
GUuAUdTsdT-3’ (anti-sense) were selected for scaling up, LNP formulation and subsequent 
ex vivo work. As negative control a siRNA duplex for Luciferase was used, with the sequence 
5’-cuuAcGcuGAGuAcuucGAdTsdT-3’ (sense) and 5’-UCGAAGuACUcAGCGuAAGdTsdT-3’ 
(anti-sense). Small case represents 2’-O-methyl modified residues. 
Preparation of LNPs and siRNA encapsulation
The selected PD-L1 and PD-L2 siRNA duplexes were incorporated in the nanoparticles as 
published previously16-18. In brief, LNPs were prepared with the ionizable cationic lipid 
DLin-KC2-DMA (KC2) or DLin-MC3-DMA (MC3), DSPC, cholesterol, and PEG2000-C-DMG 
using a spontaneous vesicle formation procedure as previously described16;17. The LNPs 
had a component molar ratio of ~50/10/39.7/0.3 or ~50/10/38.5/1.5 (cationic lipid/DSPC/
cholesterol/PEG2000-C-DMG). The final lipid:siRNA weight ratio was ~10:1. The particle size 
of LNPs was determined by dynamic light scattering (Zetasizer Nano ZS; Malvern, UK) and 
the mean diameter was in the range of 60-80 nm for 1.5% PEG-LNPs and ~120 nm for 0.3% 
PEG-LNPs. siRNA content was determined by HPLC (anion-exchange  column, Dionex 
PA-200) at 260 nm, and siRNA entrapment efficiency was determined by the Quant-iT 
RiboGreen RNA assay (Invitrogen). 
siRNAs can be efficiently encapsulated in LNPs16. Due to the weak basicity of the lipid 
headgroups, these nanoparticles exhibit a nearly neutral charge at physiologic pH. 
Additionally, distearoylphosphatidylcholine (DSPC), cholesterol and polyethylene glycol 
(PEG)-lipid are incorporated for LNP stabilization and size control17. Importantly, these LNP 
formulations have been proven to be well tolerated, and efficient vehicles for low-dose in 
vivo gene silencing in animals18-20. Furthermore, LNPs efficiently delivered siRNAs into 
murine and non-human primate APCs in both healthy and diseased states21-23.
 In this study, we explored the development of a clinical-grade applicable human DC 
vaccine with improved immunogenic potential by combining PD-L siRNA and target 
antigen mRNA delivery. We identified the best siRNA sequences and LNP formulation that 
efficiently silenced PD-L1 and PD-L2 in monocyte-derived DCs with relatively low cell 
toxicity at the optimal ex vivo dose. Furthermore, we observed that this LNP-mediated 
siRNA delivery method affected neither DC phenotype, nor their migratory capacity. 
Importantly, we demonstrated that PD-L siRNA-LNP transfected DCs loaded with either 
MiHA peptide or mRNA are superior APCs, strongly augmenting the expansion of 
functional MiHA-specific CD8+ T cells from transplanted cancer patients ex vivo. These 
findings indicate that the combination of siRNA-LNP and target antigen mRNA transfection 
could be a major improvement of current DC vaccines to boost effector-memory T cell 
responses in cancer patients. Importantly, all materials used to deliver siRNAs and mRNAs 
have already been approved for use in the clinical setting; therefore the combination 
should be easily adopted for human use.
Materials and Methods
Patient and donor material
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor buffy coats 
(N=4, Sanquin blood bank, Nijmegen, the Netherlands) or apheresis material of allogeneic 
donors (N=7). Furthermore, we used PBMCs from patients who developed MiHA-specific 
CD8+ T cell responses. These samples were obtained at 12-41 months after allo-SCT (Table 1, 
N=5). All cells of healthy donors and patients were obtained after written informed consent.
Synthesis and in vitro screening of siRNAs targeting PD-L1 and PD-L2
In total, 169 and 24 siRNAs with the lowest predicted off-target potentials and 100% 
homology with the human PD-L1 or PD-L2 gene sequence NM_014143.2 or NM_025239.3, 
respectively, were selected for synthesis and screening. Single-strand RNAs were produced 
and annealed into duplexes at Alnylam Pharmaceuticals as previously described20. The 
siRNA screening for PD-L1 and PD-L2 was done in the Hep3b cell line (i.e. a human 
hepatocellular carcinoma line) and RKO cell line (i.e. a human colon cancer cell line), 
respectively. siRNAs were transfected using Lipofectamine RNAiMAX reagent (Invitrogen, 
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Table 1  Characteristics of allo-SCT patients used for MiHA T cell expansion assays
Pt Disease MiHA T cell 
response
Sample date 
(months)
DLI prior to 
sample date
% MiHA-specific
CD8+ T cells
1 MM HA-1 20 post-SCT Yes 0.03
2 NHL HA-1 14 post-SCT No 0.02
3 AML LRH-1 12 post-SCT No 0.04
4 CML-AP LRH-1 13 post-SCT Yes 0.47
5 AML LRH-1 41 post-SCT Yes 0.02
Characteristics of patients with a hematological malignancy displaying MiHA-specific CD8+ T cell responses post-
transplantation. Pt, patient; AML, acute myeloid leukemia; CML-AP, chronic myeloid leukemia-accelerated phase; 
MM, multiple myeloma; NHL, non-Hodgkin lymphoma; SCT, stem cell transplantation; DLI, donor lymphocyte 
infusion, given at 4-10 months after allo-SCT.
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lysed cell suspension, culture and wash supernatants with acetonitrile/isopropanol (v/v 
50:50) containing 50 ng/ml of IS (Internal Standard). After centrifugation at 4000 rpm for 10 
minutes, the supernatant was transferred to a clean 96-well plate for LC/MS/MS analysis 
using a Phenomenex Luna silica column (2.0 × 50 mm, 5 μm) with an isocratic mobile 
phase (90% acetonitrile/isopropanol (v/v 50:50)/10% 10 mM ammonium acetate) at 40°C 
and a flow rate of 0.7 ml/min for 6 min at 10 µl sample volume injection. All MS/MS 
experiments were performed with an API 5000 (AB Sciex, Foster City, CA, USA) with 
electrospray ionization source. KC2 was monitored using the MS/MS transition of 642.6 to 
116.1 in positive mode.  The calibration curve ranged from 0.5 to 1000 ng/mL with a lower 
limit of quantification of 0.5 ng/ml.
Flow cytometry
Phenotype and maturation state of DCs were analyzed by staining with the following 
antibodies: anti-CD14 (clone TÜK4), anti-CD83 (clone HB15a), anti-CD80 (clone MAB104), 
anti-CD86 (clone HA5.2B7, all from Beckman Coulter, Fullerton, CA, USA), anti-PD-L1 (clone 
MIH1), anti-PD-L2 (clone MIH18, both from Becton Dickinson, Franklin Lakes, NJ, USA), 
anti-CCR7 (clone 150503, R&D Systems, Abingdon, United Kingdom), anti-HLA-ABC (clone 
W6/32, Dako), anti-HLA-DR (clone Immu357, Beckman Coulter) and isotype controls IgG1 
FITC/PE dual-color control (Dako) and IgG2b PE (Beckman Coulter). The mean PD-L 
fluorescence intensity (MFI) was corrected for the MFI of the isotype control antibody 
(ΔMFI), subsequently the relative PD-L knockdown efficiency was calculated as follows: 
(ΔMFI PD-L LNP treated DCs / ΔMFI Control LNP treated DCs) x100.
 LRH-1- and HA-1-specific T cells were detected by staining cell suspensions with 
PE-labeled tetramers containing the corresponding MiHA peptide (LRH-1/HLA-B7: 
TPNQRQNVC; HA-1/HLA-A2: VLHDDLLEA). Tetramers were kindly provided by prof. dr. 
Frederik Falkenburg (Department of Hematology, Leiden University Medical Center, 
Leiden, the Netherlands). T cell cultures were incubated with 0.15-0.2 μg tetramer for 15 
min at room temperature. Subsequently, cells were labeled with the appropriate 
concentrations of anti-CD8 (clone LT8, ProImmune, Oxford, United Kingdom) and anti-CD3 
(clone UCHT1, Beckman Coulter) for 30 min at 4°C. After washing with PBS/0.5% bovine 
serum albumin (BSA; Sigma, St Louis, MO, USA), cells were resuspended in washing buffer 
containing 0.1% 7-amino-actinomycin D (7-AAD; Sigma). Cells were analyzed using the 
Coulter FC500 flow cytometer (Beckman Coulter).
 To determine the expression levels of MAGE-3 upon electroporation, DCs were 
stained with specific antibodies using an indirect labeling approach. DCs were washed 
twice with PBS, and fixed during 10 minutes at room temperature in 4% cold paraformal-
dehyde solution. After washing with PBS, cells were resuspended in 0.1% saponin buffer 
and incubated for 30 minutes at 4°C with mouse-anti-hMAGE3 (clone 57B, kindly provided 
by prof. dr. Giulio Spagnoli, University Hospital Basel, Basel, Switzerland). Then, DCs were 
washed with 0.1% saponin buffer and, subsequently, incubated with 1:100 diluted goat-
 Monocytes were isolated from PBMCs via direct magnetic labeling with CD14 MicroBeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) or via plastic adherence in tissue culture 
flasks (Greiner Bio-One, Alphen a/d Rijn, the Netherlands). iDCs were generated by 
culturing monocytes in X-VIVO-15 medium (Lonza, Verviers, Belgium) supplemented with 
2% human serum (HS; PAA laboratories, Pasching, Austria), 500 U/ml IL-4 (Immunotools, 
Friesoythe, Germany) and 800 U/ml GM-CSF (Immunotools). After 3 days, iDCs were 
transferred to 6-wells plates and pre-incubated with 125-500 nM PD-L1, PD-L2 or Luciferase 
control siRNA-LNPs (Alnylam) in the absence of HS. After 4 hours, X-VIVO-15/4% HS medium 
containing 1000 U/ml IL-4 and 1600 U/ml GM-CSF was added and cells were further 
cultured at 0.5 x 106/ml. At day 7, cells were again incubated for 4 hours with 125-500 nM 
PD-L1, PD-L2 or Luciferase control siRNA-LNPs, after which maturation was induced in 
X-VIVO-15/2% HS containing 500 U/ml IL-4, 800 U/ml GM-CSF, 5 ng/ml IL-1ß, 15 ng/ml IL-6, 
20 ng/ml TNF-α (all Immunotools) and 1 µg/ml PGE2 (Pharmacia & Upjohn, Bridgewater, 
NJ, USA). At day 9, mDCs were harvested, phenotyped and used in functional assays.
In vitro mRNA transcription and DC loading
IVT mRNA was generated using the mMessage mMachine T7 Ultra Kit according to the 
manufacturer’s instructions (Ambion-Applied Biosystems, Foster City, CA). Briefly, cDNA 
encoding the MiHAs P2X5 or truncated HMHA1, or the tumor-associated antigen (TAA) 
MAGE3, was subcloned into the pGEM4Z/A64 vector. The resulting vectors were linearized 
using restriction enzyme NotI. IVT mRNA was transcribed from the T7 promoter site in the 
linearized template DNA by incubation at 37°C for 2 hours in a reaction mixture containing 
T7 RNA polymerase. After purification, the mRNA was quantified by spectrophotometry 
and checked by agarose gel electrophoresis. mRNA was stored in aliquots at -80°C. Before 
mRNA electroporation, DCs were washed twice with phenol red free Optimem buffer 
(Gibco Invitrogen). Cells were resuspended in 200 µL Optimem buffer and transferred to a 
4 mm gene pulser cuvette (Biorad, Hercules, CA, USA) containing 20 µg mRNA. DCs were 
electroporated at 200-300 Volt, 150 µF using a Biorad Genepulser II (Biorad). Directly after 
electroporation, cells were resuspended in 4 ml pre-warmed phenol red free X-VIVO 
15/6% HS and incubated at 37°C for 1 hour before further use. For KC2 washout 
experiments, DCs were resuspended in X-VIVO/2% HS and washed twice in phenol red 
free Optimem buffer according to our standard operating procedure (SOP) used in clinical 
DC vaccination trials. Subsequently, DCs were resuspended in 200 µl Optimem buffer and 
added to 4 ml pre-warmed phenol red free X-VIVO 15/6% HS. Finally, DCs were washed 
twice in PBS/5% human serum albumin.
LC/MS/MS assay for KC2 quantification
Levels of KC2 in DCs, culture media and washouts were quantified by using LC/MS/MS 
tandem mass spectrometry. Cell pellets were resuspended in 500 µL of PBS, and lysed by 
TissueLyser LT (QIAGEN, Valencia, CA, USA). Subsequently, KC2 was extracted from 50 µL of 
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Results
LNPs containing KC2 most potently deliver siRNAs into monocyte-derived DCs, 
mediating efficient PD-L1 and PD-L2 silencing
To generate a DC vaccine lacking PD-1 ligand expression in combination with endogenous 
MiHA peptide presentation, we developed a clinical-grade and versatile application for 
siRNA transfection of ex vivo-generated DCs. In previous work, we showed efficient, 
specific and long-lasting silencing of PD-L1 and PD-L2 in human monocyte-derived DCs 
using siRNA electroporation of iDCs9. However, this strategy is incompatible with MiHA 
mRNA electroporation at the mDC stage. Therefore, we investigated PD-L siRNA delivery 
using different LNP formulations containing cationic lipids KC2 or MC3 in combination 
with high (1.5%) or low (0.3%) PEG concentrations. These formulations were tested for their 
knockdown efficiency by adding 125-500 nM of siRNA-LNPs at days 3 and 7 of DC culture. 
Following 48 hours of maturation, LNP treated versus untreated mature DCs were analyzed 
for PD-L1 and PD-L2 expression using flow cytometry. A siRNA concentration-dependent 
decrease in PD-L1 and PD-L2 expression was observed, with a more pronounced 
knockdown effect for LNPs containing cationic lipid KC2 compared to MC3-LNPs (Figure 
1A-B, Supplementary Figure 1). Furthermore, KC2-LNPs containing low concentrations of 
PEG were slightly more efficient in silencing PD-L1 and PD-L2 than 1.5% PEG-containing 
KC2-LNPs. However, in contrast to the KC2-1.5% PEG LNPs that retained a particle size of 
60-80 nm, the formulation with 0.3% PEG turned out to be unstable as the particle size 
(~120 nm) increased 1.6 ± 0.07 fold in 4 months (data not shown). The siRNA encapsulation 
of KC2-LNPs remained >90%, and no changes were observed between the 0.3% and 1.5% 
PEG particles. We chose to continue subsequent experiments with 250 nM of PD-L1 and 
125 nM of PD-L2 KC2-1.5% LNPs, referred to as siPDL-LNPs from now on, based on the 
superior combination of efficacy and stability. Collectively, these data clearly show that 
LNP-mediated siRNA delivery is an effective method for silencing of PD-L1 and PD-L2 on 
human monocyte-derived DCs.
siPDL-LNP treated DCs show a mature phenotype and good migratory capacity 
toward CCR7
To study the influence of LNP-mediated siRNA delivery on DC characteristics, we analyzed 
DC viability, phenotype and migratory capacity following transfection. At days 3 and 7, 
250 nM PD-L1 and 125 nM PD-L2 or 375 nM control siRNA-containing KC2-1.5% PEG LNPs 
was added to the DC culture. Subsequently, maturation was induced and DCs were 
examined at day 9. Combined delivery of PD-L1 and PD-L2 siRNAs resulted in efficient 
knockdown of both target molecules, i.e. 91.7% ± 1.2% for PD-L1 and 86.4% ± 2.2% for 
PD-L2 (Figure 2A). Although siRNA transfection appears non-toxic to ex vivo-generated 
DCs relative to other methods, treatment with KC2-1.5% PEG LNPs resulted in a somewhat 
reduced DC viability (79.4% ± 3.7% in case of PD-L1/L2 silencing) compared to untreated 
anti-mouse PE antibody (Biosource, Life Technologies, Bleiswijk, the Netherlands) for 30 
minutes at 4°C. After a final wash, DCs were analyzed on the FC500 flow cytometer.
Migration assay
Chemotaxis of DCs in response to CCL21 (ligand for CCR7 chemokine receptor) was 
measured, in triplo, in 24-wells plates containing transwell inserts with 5 µm pores (Corning 
Costar). IMDM/10% HS containing 0, 10 or 100 ng/mL CCL21 (Immunotools) was added to 
the lower compartment in a total volume of 600 µL, and 1 x 105 DCs in 100 µL were loaded 
into the inserts. After 2 hours of incubation at 37°C, DCs were harvested from the lower 
compartment and migration was quantified using the Coulter FC500 flow cytometer by 
acquiring events for 90 seconds. 
MiHA-specific T cell expansion and degranulation assays
MiHA-specific CD8+ memory T cells present in PBMCs from transplanted patients 1-5 
(Table 1) were stimulated for one to two consecutive weeks ex vivo with PD-L silenced DCs 
loaded with MiHA peptide or mRNA. Mature allogeneic PD-L knockdown or control DCs, 
cultured from apheresis material of a HLA-B7+ LRH-1- or HLA-A2+ HA-1- individual, were 
either loaded with 5 µM MiHA peptide for 30 minutes at 37 °C or electroporated with 20 
µg MiHA mRNA. PBMCs and DCs were subsequently co-cultured at a ratio of 1:0.1 in 2 ml 
Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen) supplemented with 10% HS in 
24-wells plates (Corning-Costar). After 5 days, IMDM/10% HS containing 50 U/ml IL-2 
(Chiron, Emeryville, CA, USA) and 5 ng/ml IL-15 (Immunotools) was added. At day 7, cells 
were harvested, counted and the percentage of MiHA-specific CD8+ T cells was determined 
using flow cytometry. 
 T cell cultures of patient 5 stimulated for two consecutive weeks with P2X5 mRNA- 
loaded PD-L knockdown DCs were used in a CD107a degranulation assay to determine 
the cytolytic capacity upon recognition of the LRH-1 peptide. Cells were overnight 
restimulated with 5 µM cognate peptide in the presence of CD107a antibody (clone H4A3, 
Becton Dickinson) and 25 U/ml IL-2. The following day, antigen-specific CD8+ T cell 
degranulation was determined by analyzing the percentage of CD107a+ cells within the 
LRH-1-tetramer+ CD8+ T cell population using flow cytometry.
Statistics
To determine statistical differences, a two-sample two-tailed t-test assuming independent 
samples was used. P-values <0.05 were considered significant.
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MiHA-specific T cell expansion is enhanced by siPDL-LNP treated DCs loaded with 
MiHA peptide
Next, we examined the stimulatory capacity of siPDL-LNP treated DCs on MiHA-specific 
CD8+ T cell expansion by loading PD-L knockdown DCs with 5 µM HA-1 peptide. 
Subsequently, DCs were cultured with PBMCs from two allo-SCT patients containing 
HA-1-specific CD8+ effector-memory T cells (Table 1). At start, PBMCs of patient 1 contained 
0.03% HA-1-specific T cells, and one week stimulation with PD-L1/L2 silenced DCs resulted 
in a substantial increase in both the percentage and absolute number of HA-1-specific 
DCs (94.1% ± 0.6%; P <0.01; Figure 2B). To exclude negative effects on DC maturation and 
phenotype, surface expression levels of various maturation and stimulatory molecules 
were determined. As shown in Figure 2C, all DCs displayed high expression of CD83, CD80, 
CD86 and HLA class I and II molecules. Neither the siRNAs themselves, nor the transfection 
procedure with the KC2-LNPs, affected expression levels of the molecules analyzed. Next, 
we also examined surface expression of lymph node homing receptor CCR7 and migration 
toward increasing concentrations of its ligand CCL21. siPDL-LNP treatment did not affect 
CCR7 expression levels (Figure 2C). Moreover, LNP treated DCs showed a substantial 
expression of CCR7 (>40%, data not shown) and, after 2 hours, 20-40% of the LNP treated 
DCs had migrated toward CCL21 (Figure 2D). In some donors, siPDL-LNP treated DCs 
showed somewhat reduced migration compared to untreated DCs, which might most 
likely be explained by the slightly lower DC viability. Taken together, these data show that 
DCs treated with siRNA-containing KC2-1.5% PEG LNPs have acceptable viability, show a 
highly mature and stimulatory phenotype, and exhibit good CCR7-mediated migratory 
capacity.
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Figure 1   LNP-mediated siRNA delivery results in efficient PD-L1 and PD-L2 silencing on 
monocyte-derived DCs
At days 3 and 7 of culture, siRNA-LNPs were added at concentrations of 125, 250 or 500 nM for PD-L1 
and PD-L2 compared to 500 nM of the control. Subsequently, DCs were matured for 2 days and 
PD-L expression levels were analyzed using flow cytometry. The relative knockdown of (A) PD-L1 
and (B) PD-L2 was determined for four different siRNA-containing LNP formulations composed of 
either cationic lipid KC2 or MC3 in combination with 1.5% or 0.3% PEG. Data of 3 donors are shown. 
The relative PD-L knockdown efficiency was calculated as follows: (ΔMFI PD-L LNP treated DCs / 
ΔMFI Control LNP treated DCs) x100.
Figure 2   PD-L silenced DCs show a mature phenotype and good migratory capacity 
toward CCL21
At days 3 and 7 of culture, 250 nM PD-L1 + 125 nM PD-L2 or 375 nM negative control siRNA-containing 
KC2-1.5% PEG-LNPs was added. Subsequently, DCs were matured for 2 days, and DC viability, phenotype 
and migratory capacity were analyzed. (A) Relative PD-L1 and PD-L2 knockdown was examined 
using flow cytometry and calculated as follows: (ΔMFI PD-L LNP treated DCs / ΔMFI Control LNP 
treated DCs) x100. (B) Viability was determined by trypan blue exclusion. Data are expressed as 
mean + SEM of 9 independent experiments. (C) Expression of maturation and co-stimulatory mole-
cules by DCs was analyzed using flow cytometry. Data are expressed as mean + SEM of 9 donors. 
The dotted line indicates the MFI of the isotype controls. (D) CCR7-mediated migratory capacity of 
DCs cultured with or without LNPs was determined toward increasing concentrations of chemokine 
CCL21. Depicted is the mean number of migrated cells + SD from triplo measurements. Data of one 
representative donor are shown. Statistical analysis was performed using a (C) One-way ANOVA or 
(D) Two-way ANOVA followed by a Bonferroni post-hoc test. *P <0.05, **P <0.01.
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CD8+ T cells as compared to stimulation with control siRNA-LNP or untreated DCs (Figure 
3A-B). PBMCs of patient 2, containing 0.02% HA-1-specific CD8+ T cells, were stimulated for 
two consecutive weeks with HA-1 peptide-loaded DCs. In the first week following 
stimulation with PD-L1/L2 double knockdown DCs, the percentage and absolute number 
of HA-1-specific CD8+ T cells increased respectively 1.9- and 1.3-fold compared to control 
siRNA-LNP DC stimulation (Figure 3C-D). Notably, the effects were more pronounced after 
the second week of stimulation, when siPDL-LNP silenced DCs further boosted 
HA-1-specific T cell proliferation 6.1-fold compared to 1.1-fold by control siRNA-LNP treated 
DCs. These data demonstrate that LNP-mediated transfection of PD-L1 and PD-L2 siRNA 
results in DCs with enhanced T cell stimulatory potential.
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Figure 4   siRNA-LNP treated DCs can be efficiently loaded with antigen-specific mRNA 
using electroporation
At days 3 and 7 of culture, 250 nM PD-L1 + 125 nM PD-L2 siRNA-containing KC2-1.5% PEG-LNPs was added. 
Mature DCs treated with or without siPDL-LNPs were electroporated with antigen-specific mRNA. (A) One 
hour after loading with 20 µg HMHA1 mRNA using different electroporation voltages, DCs were added at 
a ratio of 0.1:1 to patient PBMCs containing low numbers of HA-1 specific CD8+ T cells. After 1 week, the 
expansion of HA-1-specific CD8+ T cells was analyzed using flow cytometry. (B) One hour after electropo-
ration with 10 µg MAGE3 mRNA at 200 Volt, MAGE3 protein expression (black lines) as compared to iso-
type control (grey peaks) was analyzed using flow cytometry. Data of one representative donor out of 3 
experiments are shown.
Table 2  Removal of excess KC2-lipid from DC product
Sample Relative KC2 level
Culture supernatant 100%
Wash supernatant 1 16.36% ± 1.38%
Wash supernatant 2 3.00% ± 0.34%
Wash supernatant 3 0.95% ± 0.09%
Wash supernatant 4 0.40% ± 0.03%
Removal of excess KC2-lipid from the DC product was examined using HPLC-VLC. KC2 levels in the wash 
supernatant was calculated relative to the original KC2 level in the culture supernatant (Mean ± SEM). N=2.
Figure 3   PD-L knockdown DCs loaded with MiHA peptide enhance MiHA-specific CD8+ 
T cell proliferation
At days 3 and 7 of DC culture, 250 nM PD-L1 + 125 nM PD-L2 or 375 nM negative control KC2-1.5% PEG-
LNPs was added if indicated. Mature DCs were loaded with 5 µM HA-1 peptide and cultured at a ratio of 
0.1:1 with patient PBMCs containing low numbers of MiHA-specific CD8+ T cells for 1-2 weeks. (A) After one 
week, cells were analyzed for tetramer-positive CD8+ T cells using flow cytometry. The numbers in the 
FACS plots represent the percentage of HA-1 specific CD8+ T cells within the total CD3+CD8+ T cell 
population. Data of one representative patient (Patient 1) are shown. (B) Total number of HA-1 specific 
CD8+ T cells of Patient 1 after one week of stimulation with PD-L silenced DCs loaded with or without 
HA-1 peptide. (C-D) The percentage (C) and cumulative number (D) of HA-1-specific CD8+ T cells of 
Patient 2 obtained after stimulation with PD-L silenced DCs loaded with or without HA-1 peptide. 
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MiHA mRNA loaded PD-L knockdown DCs effectively boost the proliferative 
capacity of highly functional MiHA-specific CD8+ effector-memory T cells
To investigate the stimulatory potential of siPDL-LNP treated DCs electroporated with MiHA 
encoding mRNA, we stimulated PBMCs of 5 allo-SCT patients containing either HA-1- or 
LRH-1-specific CD8+ effector-memory T cells for one to two consecutive weeks with these 
DCs. In Figure 5A, one representative patient is shown. At start, this patient had 0.02% 
Excess siRNA-LNP is efficiently removed from the DC product upon 2 wash steps
Eventually, we aim to develop a clinical-grade applicable DC vaccine with improved 
immunogenic potential. Because some toxicities attributable to the lipid formulation 
were observed in preclinical animal models at doses well above efficacious ones 
(unpublished observations), it is important to know the amount of lipid taken up by the 
DCs, as well as extracellular residual lipid levels after washing the LNP treated DC 
end-product. Therefore, we followed the SOP applied in our DC vaccination trials to 
harvest mDCs following maturation and to quantify the amount of lipid remaining in the 
cells and washout supernatants. We observed that after the first wash already 83.6% ± 
2.0% of the KC2 lipid was removed from the DC product (Table 2). The second wash 
resulted in further reduction to 3.0% ± 0.3% of the original KC2-lipid level present during 
DC culture. Importantly, about 99% of the KC2 was removed from the cells with subsequent 
washing. Furthermore, in the DCs on average only 1.1% ± 0.4% of the added KC2-lipid was 
detected. Together, this shows that the DC end-product, including trace amounts of 
extracellular residual lipids, contains less than 2% of the ex vivo added KC2-lipid, indicating 
that excess siRNA-LNPs are efficiently removed from the DC end product following the 
established washing procedure. 
siRNA-LNP treated DCs can be efficiently loaded with target antigen mRNA using 
electroporation
Because of the observed effect on the DC viability following siRNA-LNP treatment (Figure 
2B), we had to optimize the electroporation settings for target antigen mRNA loading to 
maximally reduce harm to the DCs. Hence, siRNA-LNP treated DCs were electroporated 
with antigen mRNA at different voltages and T cell stimulatory potential of the DCs was 
examined. Electroporation of target antigen mRNA at 300 Volt and 150 μF resulted in 
reduced cell viability and loss of the advantage of PD-L knockdown DC stimulation on T 
cell expansion (Figure 4A). Lowering the voltage to 200 Volt, resulted in improved function 
of the PD-L silenced DCs as compared to untreated DCs. Importantly, lowering the voltage 
to 200 Volt did not affect mRNA loading efficacy in general, as untreated DCs demonstrated 
similar stimulatory capacity with all voltages tested (Figure 4A). Notably, further voltage 
reduction to 100 Volt was not beneficial for mRNA uptake and processing (data not 
shown). Because MiHA mRNA loading cannot be visualized by flow cytometry due to the 
lack of appropriate antibodies, we also electroporated siRNA-LNP treated DCs with the 
TAA MAGE3 and performed FACS analysis. One hour after electroporation, both siRNA-LNP 
treated and untreated DCs showed high MAGE3 protein expression (Figure 4B). Together, 
these results demonstrate that LNP-mediated siRNA delivery can be efficiently combined 
with target antigen mRNA electroporation, while preserving appropriate DC numbers 
and good functionality.
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Figure 5   The expansion of highly functional MiHA-specific CD8+ T cells is boosted by 
MiHA mRNA loaded PD-L silenced DCs
At days 3 and 7 of culture, 250 nM PD-L1 + 125 nM PD-L2 or 375 nM negative control siRNA-contai-
ning KC2-1.5% PEG-LNPs was added when indicated. Mature DCs were electroporated at 200 Volt 
with 20 µg MiHA-encoding mRNA and cultured at a ratio of 0.1:1 with patient PBMCs containing low 
numbers of MiHA-specific CD8+ T cells for 1-2 weeks. (A) One week after each stimulation, cells were 
analyzed for tetramer-positive CD8+ T cells using flow cytometry. Data of one representative patient 
(Patient 5) having a LRH-1-specific CD8+ T cell response are shown. (B) Total number of LRH-1 specific 
CD8+ T cells of Patient 5 after 1-2 consecutive weeks of stimulation with PD-L silenced DCs loaded 
with P2X5 mRNA. (C) To combine data of all patients, the increase in absolute number of MiHA-
specific CD8+ T cells after stimulation with PD-L silenced DCs was calculated relative to control 
 siRNA-LNP DC stimulation. Data of 5 and 4 patients are shown for week 1 and 2, respectively. Lines 
indicate the mean. (D) Degranulation of LRH-1-tetramer negative and positive CD8+ T cells of Patient 
5, stimulated for two weeks with P2X5 mRNA loaded PD-L knockdown DCs, was measured by stai-
ning for CD107a during overnight restimulation with 5 µM LRH-1 peptide. Statistical analysis was 
performed using a two-sample two-tailed t-test assuming independent samples. *P <0.05, **P <0.01.
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and tumor regression1;4-7. However, overall response rates and durable responses are still 
limited, implicating that further improvement of DC vaccine potency is crucial to increase 
clinical benefit.
 The efficacy of DC vaccines is dependent on a variety of variables, including DC type, 
maturation status, antigen loading strategy, dosing and frequency of the vaccine 
injections, and the route of administration4;29. The most commonly used cells for 
generating high numbers of mature DCs ex vivo, are monocytes5. We and others have 
shown that upon electroporation of monocyte-derived DCs with target antigen mRNA, 
antigen-specific CD8+ T cell responses can be efficiently boosted13-15. The advantage of 
using mRNA instead of peptide loading is that the antigen epitopes are naturally 
processed, and a variety of different epitopes are long-term presented by both HLA class 
I and class II molecules30;31. In that way, the breadth of the elicited immune response could 
be enlarged. Besides the recognition of the HLA/antigen complex by the T cell receptor, T 
cells require co-stimulatory signaling to become activated and exert their effector 
function. However, antigen-specific T cells can become functionally impaired over time 
both in chronic viral infections and in cancer32-35. It has been shown that these antigen-
specific T cells up-regulate various co-inhibitory molecules like Programmed death-1 
(PD-1) due to chronic antigen exposure. Continued downstream signaling of these 
molecules eventually results in T cell exhaustion. We previously demonstrated that the 
PD-1/PD-L pathway is involved in the functional inhibition of MiHA-specific T cell responses 
post-transplantation, and that blockade of the PD-1 receptor, using a humanized blocking 
antibody, in combination with DC stimulation boosted the ex vivo expansion of these 
MiHA-specific T cells, especially in relapsed allo-SCT patients35. Importantly, in two recently 
published reports on anti-PD-1 (BMS-936,588) and anti-PD-L1 (BMS-936,559) blocking 
antibody therapy in solid cancers, durable tumor regression was observed with objective 
clinical responses in 18-28% and 6-17% of the patients, respectively36;37. However, in vivo 
treatment of allo-SCT patients with these blocking antibodies might bring high risks of 
inducing GVHD. Therefore, we developed a more specific approach using siRNA electro-
poration to silence the co-inhibitory molecules PD-L1 and PD-L2 in DCs. In this way, we 
obtained a DC vaccine with an improved stimulatory phenotype, that strongly enhanced 
antigen-specific T cell proliferation and cytokine production (IFN-γ, IL-2, TNF-α and IL-5)  ex 
vivo9. To eventually generate a superior DC vaccine with high stimulatory potential, and 
capable of eliciting a robust MiHA-specific immune response, it is desirable to combine 
PD-L siRNA delivery and MiHA mRNA loading. 
 Lipid nanoparticles are attractive agents to deliver specific target siRNAs into ex 
vivo-generated human DC vaccines in a non-viral manner. Importantly, these LNPs can be 
generated in compliance with good manufacturing practice (GMP) guidelines, and all 
materials required have been approved for use in the clinical setting. Recently, Basha et 
al.21 demonstrated that LNPs are competent in vivo siRNA delivery reagents for silencing 
target genes in murine DCs. An advantage of using LNPs, compared to for instance 
LRH-1-specific CD8+ T cells, which increased up to 3.6% following two repetitive stimulations 
with untreated mRNA-loaded DCs. In the first week, stimulation with siPDL-LNP silenced DCs 
resulted in a moderate increase in the percentage of antigen-specific T cells, compared to 
control siRNA-LNP DC stimulated cells (2.6% vs. 2.3%). But a second stimulation with these 
PD-L knockdown DCs boosted the expansion of the LRH-1-specific CD8+ T cells up to 13.3% 
compared to 5.7% in case of control siRNA-LNP DCs. In absolute numbers the advantage of 
PD-L knockdown DCs over control DCs in augmenting LRH-1-specific CD8+ T cell expansion 
was even more pronounced, resulting in a 4.5-fold higher number of antigen-specific T cells 
after two weeks of stimulation (Figure 5B).
 To combine data of all patients, we calculated for each week the fold increase in the 
absolute number of MiHA-specific CD8+ T cells following stimulation with PD-L silenced 
DCs relative to stimulation with control siRNA-LNP DCs (Figure 5C). Importantly, PD-L1/L2 
double knockdown DCs loaded with MiHA encoding mRNA significantly boosted the 
proliferative capacity of MiHA-specific CD8+ T cells, which becomes even more pronounced 
after repetitive stimulations. Finally, we examined the functionality of the DC-stimulated 
MiHA-specific T cells of patient 5, after two weeks of expansion (Figure 5D). These 
expanded CD8+ T cell cultures were restimulated overnight with LRH-1 peptide in the 
presence of anti-CD107a to determine the percentage of degranulating CD107a+ LRH-1-
tetramer+ CD8+ T cells. Restimulation with the LRH-1 peptide resulted in a specific CD107a 
staining of >70% of the tetramer+ CD8+ T cells, whereas less than 10% of the tetramer- CD8+ 
T cells were CD107a positive. Together, these results demonstrate that antigen-specific 
CD8+ effector-memory T cell expansion can be efficiently augmented using siPDL-LNP 
silenced DCs, and that these expanded antigen-specific CD8+ T cells have the capacity to 
degranulate upon encounter with their target antigen.
Discussion
Although the immune system is capable of eliciting immune responses toward chronic 
virally infected cells and cancer, the quantity and functionality of these responses is most 
often insufficient or hampered, contributing to disease progression24;25. To eventually cure 
these patients, boosting of antigen-specific effector and memory T cell responses in vivo 
is essential. As DCs are the most potent professional APCs, they are considered to be an 
ideal cell-based therapy to enhance immune responses1;2. Especially, in the setting of 
allo-SCT, DC-based vaccination exploiting hematopoietic-restricted MiHAs as tumor target 
antigens is a promising strategy to selectively boost donor T cell-mediated graft-versus-
tumor (GVT) immunity, without evoking severe graft-versus-host-disease (GVHD)26-28. 
During the last decade, clinical DC vaccination strategies have been widely explored. In 
various hematological and metastatic solid cancers, vaccination with ex vivo-generated 
DCs loaded with tumor antigens has been reported to induce anti-tumor T cell responses 
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with hematopoietic-restricted MiHAs. Due to their restricted expression on the recipient’s 
normal and malignant hematopoietic cells, T cell responses against these MiHA vaccine 
targets will likely induce GVT immunity without causing severe GVHD10-12. Importantly, our 
data indicate that the overall dose of the KC2 lipid in the DC end-product is less than 2%, 
as only a limited part of the LNPs are taken up by the DCs during ex vivo culturing, and 
most residual lipids are efficiently removed by washing the cells. This corresponds to a 
calculated maximum dose of 0.125 µg KC2 lipid per kilogram body weight in our patients, 
which is far lower than the No Observed Adverse Effect Level (NOAEL) of 1.0 mg/kg in 
preclinical animal studies (unpublished observations).
 In conclusion, we developed a new clinical-grade applicable DC vaccine with 
improved immunogenic potential by combining PD-1 ligand siRNA and target antigen 
mRNA delivery. We demonstrated efficient and specific silencing of PD-L1 and PD-L2 on 
DCs using siRNA-LNPs, without affecting the phenotype or migratory capacity of the DCs. 
Furthermore, we showed that LNP-mediated siRNA delivery can be successfully combined 
with target antigen mRNA electroporation. Finally, we demonstrated that these PD-L 
silenced DCs loaded with MiHA mRNA have superior stimulatory potential and effectively 
boost ex vivo antigen-specific CD8+ T cell responses in transplanted cancer patients. 
Together, these findings indicate that our siPDL-LNP modified DCs are attractive cells for 
clinical-grade production and in vivo application to induce and boost immune responses 
in the allo-SCT setting, and likely also in other cancers or viral infections.
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poly(lactic-co-)glycolic acid particles, is that due to the ionizable cationic lipids and nearly 
neutral charge, these particles can be efficiently loaded with siRNA38. Furthermore, these 
cationic lipids competently mediate siRNA delivery across the cellular membrane21;39. 
Moreover, these LNPs have been proven safe and efficient vehicles for low dose in vivo 
gene silencing in animals18-20. Here, we first tested 4 formulations composed of different 
ionizable cationic lipids (KC2 vs. MC3), containing either high or low PEG concentrations, 
for their transfection efficiency of human monocyte-derived DCs. Treatment with the KC2 
siPDL-LNPs resulted in specific and efficient silencing of PD-L1 and PD-L2. Furthermore, no 
effect on DC maturation phenotype was observed, although DC viability and in some 
donors also migratory capacity were somewhat reduced upon treatment with KC2-1.5% 
PEG LNPs. As the effect on DC viability already indicates, the cell integrity may be affected 
to a minor extent by LNP-mediated siRNA delivery. Especially, for target antigen mRNA 
loading of siPDL-LNP treated DCs, milder electroporation settings had to be applied due 
to reduced DC viability and stimulatory potential at the standard voltage of 300, in contrast 
to untreated DCs. Notably, lowering the electroporation voltage did not impair mRNA 
processing and peptide presentation, while the highly stimulatory function of the PD-L 
knockdown DCs was retained.
 In accordance with our previous findings9, exogenous loading of siPDL-LNP silenced 
DCs with MiHA peptide strongly augmented the expansion of MiHA-specific CD8+ effec-
tor-memory T cell responses in allo-SCT patients. Moreover, we showed that siPDL-LNP 
treated DCs can also be effectively electroporated with MiHA-encoding mRNA. These 
improved DC products potently boosted the proliferation of antigen-specific CD8+ T cells. 
After one week of stimulation with PD-L silenced DCs increased numbers of MiHA-specific 
CD8+ T cells were observed, as has also been reported by Breton et al.40. Interestingly, these 
PD-L silenced DCs are also superior in boosting MiHA-specific T cell expansion from the 
naive repertoire of MiHA- donors (unpublished observations). In addition, we observed 
that the growth advantage was even further augmented upon repetitive stimulations 
with PD-L knockdown DCs. The amplification of the response upon restimulation with 
PD-L silenced DCs could be attributed to various mechanisms. During T cell activation 
PD-1 expression levels are up-regulated, which would normally mediate dampening of 
the T cell response. However, since our DCs no longer express the PD-1 ligands, the 
expanded MiHA-specific T cells remain in a highly activated state. Furthermore, Karwacz 
et al. reported that interference with PD-1/PD-L1 signaling inhibits TCR down-regulation 
following T cell activation, also rendering T cells in a hyperactivated state41. It is likely that 
because of these mechanisms, the expanded T cells responded better to the restimulation 
with the highly immunogenic PD-L knockdown DCs. Importantly, we demonstrated that 
these expanded MiHA-specific CD8+ T cells efficiently degranulate upon antigen 
restimulation. Soon these findings will be implemented in a clinical phase I/II proof-of-
concept trial, in which patients treated with HLA-matched partial T cell-depleted allo-SCT 
will receive DLI in combination with vaccination of PD-L1/L2 silenced donor DCs loaded 
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Supplementary Figure 1   
PD-L1 and PD-L2 are efficiently silenced upon LNP-mediated siRNA delivery
At days 3 and 7 of culture, siRNA-LNPs were added. Subsequently, DCs were cultured in maturation 
medium containing IL-1ß, IL-6, TNF-α and PGE2, and after 2 days PD-L expression levels were ana-
lyzed by flow cytometry. Surface expression of PD-L1 and PD-L2 is depicted for one representative 
donor out of 3 experiments following addition of 500 nM PD-L1 or PD-L2 siRNA-LNP (solid line), 500 
nM control (dotted line) as compared to isotype control staining (filled grey). Four different siRNA 
containing LNP formulations composed of either cationic lipid KC2 or MC3 in combination with 
1.5% or 0.3% PEG were tested. The numbers in the plots represent the mean fluorescence intensity 
of PD-L1 and PD-L2.
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Summary and general discussion
Allogeneic hematopoietic stem cell transplantation (SCT) is a powerful treatment option 
for patients suffering from a hematological malignancy, like leukemia, lymphoma and 
myeloma1;2. The therapeutic efficacy can be attributed to the graft-versus-tumor (GVT) 
effect, constituted by alloreactive cytotoxic T lymphocytes (CTL) which recognize minor 
histocompatibility antigens (MiHAs) expressed by the malignant cells3;4. These MiHAs are 
polymorphic human leukocyte antigen (HLA)-presented peptides which can elicit 
powerful alloreactive T cell responses. It has been demonstrated that emergence of 
MiHA-specific T cells precedes clinical remission in patients treated with donor lymphocyte 
infusions (DLI)5;6. While some MiHAs are exclusively expressed by malignant hematopoietic 
cells, others are also expressed by healthy tissues. These latter MiHAs can mediate graft-
versus-host-disease (GVHD), which is a common cause of post-transplant morbidity and 
mortality due to alloreactive T cell responses recognizing healthy tissues, particularly the 
skin, liver and gastrointestinal tract. Therefore, it is desirable to direct GVT immunity 
toward MiHAs selectively expressed by the residual hematopoietic cells of the patient, 
including the tumor cells, to minimize the risk of GVHD induction.
 The introduction of allogeneic SCT and DLI has greatly improved clinical response 
rates and overall survival in patients with aggressive hematological cancers. However, 
many patients relapse eventually. Despite immune surveillance by long-lived MiHA-specific 
memory T cells, these alloreactive T cells often fail to respond efficiently to the recurring 
tumor cells7;8. The failure to launch productive anti-tumor immune responses is the sum of 
various alterations in antigen presentation, antigen recognition, T cell activation and T cell 
survival, resulting in tumor cells with an immunosuppressive phenotype and surrounding9;10. 
Hence, it is crucial to gain more knowledge on these immune escape mechanisms 
exploited by the tumor cells in order to develop new and improved adjuvant immuno-
therapies that can be applied post-transplantation to boost GVT immunity and prevent or 
counteract tumor recurrences. In this thesis, the importance of genetic MiHA disparities 
and the resulting donor T cell responses on post-transplant outcome has been studied. 
Furthermore, we investigated the involvement of co-inhibitory molecules in the functional 
impairment of MiHA-specific T cell responses, which could contribute to immune evasion 
of hematological cancers. Finally, we developed new and improved immunotherapeutic 
approaches that interfere with these negative co-signaling pathways to enhance 
MiHA-specific T cell expansion and functionality in patients treated with allogeneic SCT.
 Being the dominant target antigens in HLA-matched allogeneic SCT, MiHAs play a 
pivotal role both in GVT responses and in GVHD. Precise understanding of the MiHA-specific 
T cell responses involved in these processes may not only lead to a better prediction of 
clinical outcome after allogeneic SCT, but also provides a rationale for specific selection of 
the most potent MiHAs in post-transplant immunotherapeutic strategies. In Chapter 2, 
we evaluated whether disparities in MiHAs are associated with improved clinical outcome 
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(PD-)1 pathway is involved in the functional impairment of MiHA-specific T cell immunity 
after allogeneic SCT. With flow cytometrical analysis we demonstrated that immature 
leukemic progenitor cells show high PD-L1 expression in combination with low PD-L2, 
CD80 and CD86 expression following IFN-γ and TNF-α exposure. Leukemia cells of relapsed 
patients also exhibited high PD-L1 levels under inflammatory conditions. In addition, we 
showed that MiHA-specific effector and memory T cells have elevated levels of PD-1, 
indicating that negative signaling via PD-1 can occur in these patients. Stimulation of 
MiHA-specific T cells with MiHA-peptide loaded dendritic cells (DCs) or acute myeloid 
leukemia (AML) cells in the presence of clinical grade anti-PD-1/PD-L1 blocking antibodies 
resulted in augmented proliferation and IFN-γ production by these T cells. Importantly, we 
showed that PD-1 blockade had a significantly superior effect on dysfunctional 
MiHA-specific T cells from relapsed patients. Collectively, these findings show that the 
PD-1/PD-L signaling pathway suppresses MiHA-specific CD8+ T cells responses. Therefore, 
PD-1 blockade may be an attractive approach to boost GVT immunity in patients with 
persistent or relapsed disease.
 Besides PD-1, more co-inhibitory receptors may be involved in the immune escape of 
hematological cancers. Another interesting candidate, recently described to be implicated 
in the escape of melanoma cells from T cell immunity, is B- and T-lymphocyte attenuator 
(BTLA)11. Hence, we studied in Chapter 5 whether BTLA also contributes to suppression of 
MiHA-specific T cell immunity in hematological malignancies. We showed that MiHA- 
specific CD8+ effector-memory T cells highly express BTLA. The ligand of BTLA, herpes 
virus entry mediator (HVEM), is part of an intricate signaling network as it has also other 
binding partners that distinctively mediate T cell responses, amongst which CD160 and 
LIGHT (discussed in Chapter 3). Therefore, we analyzed hematopoietic tumor cells for the 
presence of BTLA, HVEM, CD160 and LIGHT. Importantly, both primary leukemia and 
myeloma cells displayed high HVEM expression. BTLA expression, however, was higher on 
myeloma cells than on leukemia cells, while LIGHT and CD160 were present at low levels 
on both tumor types. The observation of BTLA-positive tumor cells directed us to 
investigate whether T cells could express HVEM, which was indeed the case. These 
findings indicate that a bidirectional HVEM-BTLA signaling route between tumor cell and 
T cells can occur. To investigate the effect of BTLA signaling on MiHA-specific T cell 
function, we stimulated these T cells with MiHA-peptide loaded DCs in the presence of an 
antagonistic anti-BTLA antibody. This resulted in a significant augmentation of MiHA- 
specific CD8+ T cell expansion. Furthermore, we showed that these MiHA-specific T cells 
are highly competent in proliferation, degranulation and cytokine production upon 
antigen reencounter. Interestingly, some patients responded better to BTLA blockade, 
while others showed more pronounced effects following PD-1 blockade. Unfortunately, 
we could not predict the response to either blocking antibody as we were unable to 
correlate the effects on T cell proliferation with receptor expression levels on the 
MiHA-specific T cells. Impairment via these receptors might depend more on the amount 
post-transplantation. In this retrospective analysis 327 patients have been included, who 
received partial T cell-depleted allogeneic SCT because of a hematological malignancy. In 
a comprehensive statistical analysis we observed that DNA mismatches in autosomal- 
encoded MiHAs are associated with increased relapse-free survival in patients treated 
with a sibling graft. Especially, multiple myeloma patients showed a lower incidence of 
relapse and increased relapse-free survival when transplanted with a MiHA-mismatched 
sibling stem cell graft. Moreover, mismatches for the ubiquitous Y chromosome-derived 
MiHAs resulted in a higher incidence of acute GVHD (grade 3-4), while autosomal MiHA 
mismatches, ubiquitous or restricted to hematopoietic cells, were not associated with 
severe GVHD. In addition, we assessed the in vivo presence of MiHA-specific T cell 
responses post-transplant using a dual-color tetramer analysis. We observed considerable 
differences among the studied MiHAs in their capability to induce in vivo T cell responses 
(i.e. 0-60%). Especially, T cells specific for the hematopoietic-restricted MiHAs HA-1, HA-2, 
PANE1, LRH-1 and ACC-1 and the ubiquitous HY-encoded antigens were most frequently 
observed. It could be that our data underestimate the real frequency of MiHA-specific T 
cell responses in patients as detection of tetramer-positive T cells is dependent on several 
variables, including timing of blood sampling after allogeneic SCT (effector versus 
memory phase), possible masking by other (un)known MiHAs, and localization of the T 
cells (peripheral blood versus tumor site). Nevertheless, patients in whom we could detect 
MiHA-specific T cells, including those T cells recognizing ubiquitous MiHA like HY, showed 
significantly better relapse-free survival in the first years after allogeneic SCT. Importantly, 
this was not associated with an enhanced incidence or severity of GVHD, indicating that 
not only ubiquitous antigen expression, but also inflammation in and homing to 
GVHD-prone tissues is required for the induction of GVHD. Together, these findings 
provide further evidence that MiHAs play a dominant role in the beneficial GVT immunity 
and imply that patients could benefit from transplantation with a MiHA-mismatched stem 
cell graft. Furthermore, these data provide a rationale to induce and boost GVT immunity 
towards autosomal MiHAs, with a hematopoietic-restricted expression pattern, to improve 
outcome after HLA-matched allogeneic SCT.
 Despite the powerful aspects of immune responses and presence of anti-tumor 
memory, most often tumor cells are able to evade immune recognition and destruction. 
Mechanisms exploited by tumor cells that impair T cell-mediated immunity include 
disruption of antigen presentation, down-regulation of HLA molecules, secretion of im-
munosuppressive cytokines, as well as recruitment of regulatory T cells (T
REG
) and myeloid-
derived suppressor cells. In the last decade, another powerful immunosuppressive 
mechanism gained much attention: the repressive action of co-inhibitory molecules, such 
as CTLA-4, PD-1 and BTLA. The role of these co-inhibitory molecules in the immune 
escape of hematological malignancies is reviewed in Chapter 3. The balance in positive 
and negative co-signals ultimately determines the activation state of the tumor-reactive T 
cells. In Chapter 4, we investigated whether the negative regulatory Programmed death 
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PD-1 ligand siRNA and target antigen mRNA delivery. The advantage of using mRNA 
instead of peptide loading, is that the antigen epitopes are naturally processed, and a 
variety of different epitopes are long-term presented by both HLA class I and class II 
molecules19;20. In that way, the breadth of the elicited immune response could be strongly 
enlarged. While PD-L siRNA electroporation must be performed at the immature DC 
stage, to efficiently prevent the up-regulation of PD-L1 and PD-L2 during maturation, 
mRNA electroporation is most optimal at the mature DC stage. Hence, we explored a 
non-viral siRNA transfection method based on lipid nanoparticles (LNPs), which can be 
safely applied in the clinical setting. We demonstrated that PD-L siRNA delivery using 
DLin-KC2-DMA-containing LNPs mediated most efficient and specific knockdown of PD-L 
expression on monocyte- derived DCs and this siRNA-LNP transfection could be 
successfully combined with both target antigen peptide loading, as well as mRNA electro-
poration. Finally, we demonstrated that these PD-L silenced DCs loaded with antigen 
mRNA potently boosted antigen- specific CD8+ memory T cell responses from transplanted 
cancer patients, especially after consecutive stimulations. The amplification of the 
response to restimulation with PD-L silenced DCs could be attributed to various 
mechanisms. During T cell activation PD-1 expression levels are up-regulated, which 
would normally mediate dampening of the T cell response. However, since our DCs no 
longer express the PD-1 ligands the expanded MiHA-specific T cells remain in a highly 
activated state. Furthermore, Karwacz et al. reported that interference with PD-1/PD-L1 
signaling inhibits TCR down-regulation following T cell activation, also rendering the T 
cells in a hyper-activated state21. It is likely that because of these mechanisms, the 
expanded T cells responded better to the restimulation with the highly immunogenic 
PD-L knockdown DCs. Collectively, these findings indicate that our PD-L silenced DCs 
loaded with MiHA mRNA are attractive cells for clinical-grade production and adjuvant 
immunotherapy to competently induce and boost GVT immunity after allogeneic SCT. 
Future perspective
The adaptive immune system is a powerful defense mechanism against cancer due the 
formation of tumor-reactive immune memory, thereby providing long-term surveillance 
and, ideally, protection against tumor recurrences. Nevertheless, tumor cells exploit a 
plethora of escape mechanisms to avoid recognition and attack by the immune system. 
Hence, it is important to develop more potent immunotherapeutic strategies in conjunction 
with approaches that interfere with these immunosuppressive pathways (Figure 1). 
 Interference with negative co-signaling pathways is one of the possible strategies to 
improve anti-tumor immunity. In solid cancers, monotherapy with blocking antibodies 
targeting CTLA-4, PD-1 or PD-L1 mediates tumor regression and improves overall survival14;15;18. 
However, not all patients gained clinical benefit and individual responses are hard to 
of intracellular signaling it has experienced, than the expression of the receptor as such, as 
suggested for PD-112;13. In addition, we investigated whether an additive effect could be 
observed by combined blockade of BTLA and PD-1. However, we did not observe an 
unambiguous additive effect on MiHA-specific T cell proliferation, suggesting that these 
receptors share common intracellular signaling pathways. Further research into the 
distinct roles of BTLA, PD-1 and other co-inhibitory molecules is needed to understand 
the functional state of the impaired MiHA-specific T cells. In addition, it would be 
interesting to investigate the effect of BTLA signal transduction into the tumor cells. In 
conclusion, we show that next to PD-1, BTLA is also involved in MiHA-specific T cell 
inhibition, though the relative contribution of these two receptors to functional 
impairment of GVT-specific responses differs between patients. 
 The findings described in Chapter 4 and 5 demonstrate that both PD-1 and BTLA 
interactions hamper GVT immunity, providing a rationale for incorporating co-signaling 
blockade against these receptors in post-transplant immunotherapy. Recently, two key 
reports were published on anti-PD-1 (BMS-936,588) and anti-PD-L1 (BMS-936,559) blocking 
antibody therapy in solid cancers14;15. Here, durable tumor regression was observed with 
objective clinical responses in 18-28% and 6-17% of the patients, respectively. Moreover, a 
relative limited number of the patients (9-14%) showed grade 3-4 drug-related adverse 
events. Also treatment with the anti-CTLA-4 blocking antibodies ipilimumab (MDX-010) 
and tremelimumab (CP-675,206) mediated objective clinical responses and prolonged 
survival in solid cancers, though 10-25% of the patients developed severe treatment- 
related adverse events depending on the dosing regimen used16-18. Therefore, in vivo 
treatment of allogeneic SCT patients with PD-1 blocking antibodies might deteriorate 
GVHD, because of the highly activated immunological state post-transplant due to 
 chemotherapy-induced tissue damage and inflammation, especially in GVHD-target 
tissues such as skin and gut. Releasing immune checkpoints at this time could be 
dangerous, as T cells might home to the inflamed alloantigen-expressing GVHD sites and 
destroy healthy cells. Therefore, we developed another immunotherapeutic strategy in 
Chapter 6. Here, we investigated whether we could improve MiHA-specific T cell 
activation by stimulation with PD-L1 and PD-L2 silenced monocyte-derived DCs. Electro-
poration of PD-L siRNA sequences into immature DCs, resulted in efficient, specific and 
long-lasting silencing of PD-L1 and PD-L2. These PD-L silenced DCs strongly augmented 
proliferation and cytokine production of keyhole limpet hemocyanin (KLH)-experienced 
CD4+ T cells.  Furthermore, PD-L silenced DCs showed superior potential to boost the 
expansion of MiHA-specific CD8+ effector and memory T cells from leukemia patients 
early after DLI and later during relapsed disease. Together, these data demonstrate that 
PD-L siRNA electroporated DCs are highly effective in enhancing T cell proliferation and 
cytokine production, and hence attractive cells for the induction and boosting of GVT 
immunity in cancer patients. To generate a clinical-grade applicable DC vaccine with 
further improved immunogenic potential, we studied in Chapter 7 the combination of 
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gain more knowledge on the downstream pathways of different co-inhibitory receptors 
to evaluate their importance in suppression and exhaustion of the immune system by 
hematological malignancies. Furthermore, more research on the application and timing 
of blocking antibodies in patients with hematological malignancies is warranted.
 In addition to alleviation of negative signaling pathways exploited by the tumor cell, 
it is also essential to activate MiHA-specific T cell responses in vivo. As DCs are the most 
potent professional APCs, they are considered to be the ideal means to enhance anti-tumor 
immunity. However, despite the induction of tumor-reactive T cell responses and tumor 
regression following DC vaccination, overall clinical response rates and durable responses 
are limited22-24. Therefore, further improvement of DC vaccine potency is crucial to increase 
the clinical benefit. In order to enhance the immunogenic potential of monocyte-derived 
DCs, we silenced the co-inhibitory molecules PD-L1 and PD-L2 and pulsed the DCs with 
MiHA-encoding mRNA. Based on their superior capacity to boost MiHA-specific T cell 
responses ex vivo, especially in a second or third round of stimulation, we will start soon 
with a clinical phase I proof-of-concept trial in MiHA-mismatched patients. Based on the 
immunogenic MiHA disparity rates, hematopoietic-restricted expression pattern and 
effectiveness in inducing T cell responses post-transplant, we will select 5 MiHA vaccine 
targets (i.e. HMHA1, MYO1G, P2X5, ARHGDIB and BCL2A1) allowing vaccination of 
approximately 30% of the patients treated with HLA-matched allogeneic SCT. As their 
expression is restricted to the recipient’s normal and malignant hematopoietic cells, T cells 
recognizing these MiHA vaccine targets will likely only induce GVT responses without 
causing severe GVHD. These mRNA-pulsed PD-L silenced DCs can be administered at late 
time-points after allogeneic SCT to reactivate MiHA-specific memory T cell responses, but 
can also be exploited together with pre-emptive DLI to boost naive MiHA-specific CD8+ T 
cells and thereby induce MiHA-based immunity shortly after transplantation. 
 Another application with our MiHA-loaded PD-L silenced DCs is the rapid ex vivo 
expansion of naive MiHA-specific T cells present in DLIs for adoptive transfer purposes. As 
shown in Figure 2A-B, ex vivo stimulation of MiHA- donor lymphocytes with MiHA 
peptide-loaded DCs results in efficient induction of the corresponding MiHA-specific T 
cell responses. Importantly, PD-L silenced DCs potently boost the expansion of naive 
HA-1-specific CD8+ T cells up to 41%, compared to 1.6% in case of two weeks of stimulation 
with control DCs (Figure 2C-2D). Nevertheless, it is crucial to prevent these cells from 
becoming quickly exhausted due to terminal differentiation. Recently, Gattinoni et al. 
described the identification of a stem cell memory T cell population (T
SCM
) that exhibits 
stem cell features, like a naive phenotype and high potency for self-renewal, in combination 
with memory characteristics, including a high proliferative potential and polyfunctionality. 
These cells showed superior anti-tumor immunity in humanized mice25. Importantly, 
by stimulation of T cells in the presence of small molecule inhibitors directed against 
glycogen synthase kinase-3β (TWS119) in the Wnt-pathway or Akt1/2 (Akt inhibitor VIII), 
these T cells retained a naive-like T
SCM
 phenotype (25 and personal communication). 
predict. In addition, the occurrence of adverse systemic toxicity is a major problem. This 
would be dangerous in patients treated with allogeneic SCT, as GVHD might deteriorate. 
To reduce this risk, a delayed treatment window could be applied in which patients with 
refractory disease are treated with blocking antibodies at late time-points post-transplant 
when there is no systemic ‘inflammatory’ state. Another option to prevent the risk of 
breaking tolerance systemically is by using lower levels of multiple blocking antibodies 
targeting different inhibitory molecules simultaneously, since together these may boost 
immune responses in a non-redundant manner. The forthcoming years, it is important to 
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Figure 1   Post-transplant immunotherapeutic strategies
MiHA+ patients receive CD34+ hematopoietic stem cells from a HLA-matched MiHA- donor. To 
induce GVT immunity post-transplant, patients can be treated with donor lymphocyte infusions 
either alone or in combination with PD-L silenced DC vaccines. MiHA-specific T cells could also be 
expanded with these DCs prior to T cell infusion (adoptive transfer). At later time-points after stem 
cell transplantation, PD-L silenced DC vaccines can be given as single treatment or in combination 
with antibodies that block co-inhibitory signals to boost MiHA-specific memory responses. MiHA, 
minor histocompatibility antigen.
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expressing co-inhibitory molecules. Because the administration of antagonistic antibodies 
blocking these negative signaling pathways could deteriorate GVHD, other adjuvant 
 immunotherapies have to be developed to specifically interfere with co-inhibitory 
signaling in the tumor microenvironment. Therefore, we will investigate in a follow-up 
study a new immunotherapeutic approach consisting of anti-CLEC12A antibody-coated 
nanoparticles, loaded with siRNAs specific for these co-inhibitory molecules, to selectively 
target myeloid tumor cells (Figure 3). CLEC12A is an appealing targeting molecule because 
of its discriminative expression pattern (i.e. exclusive for hematopoietic cells of the myeloid 
origin, and high expression on myeloid leukemic blasts and stem cells) and internalization 
capacity upon antibody-crosslinking26-28. Besides silencing co-inhibitory molecules 
expressed by the leukemia cells, these anti-CLEC12A coated nanocarriers can also target 
myeloid DC subsets in vivo. Upon internalization of nanoparticles loaded with siRNA, 
tumor antigen or MiHA peptide, and toll-like receptor (TLR) ligands, activated DCs with 
superior potential to stimulate antigen-specific T cell responses could be generated. Using 
this targeted approach, we aim to alleviate the inhibitory phenotype of the tumor cells 
thereby interfering with the functional suppression of MiHA-specific T cells, and at the 
same time boost the expansion of these T cells with the highly immunogenic DCs. As 
CLEC12A expression is restricted to cells of the hematopoietic system, the risk of GVHD 
induction upon nanoparticle-mediated antigen delivery is expected to be minimal. 
Furthermore in the allogeneic SCT setting, hematopoietic-restricted MiHAs can be 
selected to avoid the induction of GVHD-associated T cell responses. We believe that the 
development and implementation of this new immunotherapeutic strategy will greatly 
improve anti-tumor immunity, without inducing adverse systemic effects, and improve 
long-term protection by MiHA-specific memory T cells to prevent the patients from 
relapsing.
Conclusion
To conclude, in this thesis we provide further evidence that MiHA-specific T cell responses 
play an important role in the beneficial GVT immunity. Furthermore, we demonstrated 
that signaling via the co-inhibitory receptors PD-1 and BTLA contributes to the functional 
impairment of MiHA-specific effector and memory CD8+ T cell responses. Stimulation with 
MiHA peptide-loaded DCs in the presence of PD-1 or BTLA blocking antibodies 
reinvigorates alloreactive T cell proliferation, degranulation and cytokine production. With 
this research we gained more knowledge on how GVT immunity could be hampered 
after allogeneic SCT, which provides a rationale for the implementation of (personalized) 
therapies targeting negative co-signaling pathways after allogeneic SCT. Though, more 
research into the distinct roles of PD-1, BTLA and other co-inhibitory molecules is required 
to fully understand the functional state of the impaired MiHA-specific T cells, and to 
Addition of such small molecule inhibitors to ex vivo rapid expansion cultures, could strongly 
improve the efficacy and functionality of tumor-reactive T cells in adoptive transfer strategies.
 Nevertheless, even though activated tumor-reactive T cells are administered via 
adoptive transfer or boosted in vivo by vaccination with PD-L silenced DCs, these expanded 
T cells may still become functionally impaired when they encounter residual tumor cells 
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Figure 2   PD-L silenced DCs efficiently expand MiHA-specific T cells from the naive 
repertoire
At days 3 and 7 of DC culture, 250 nM PD-L1 + 125 nM PD-L2, 375 nM negative control KC2-1.5% 
PEG-LNPs or no LNPs were added. After 2 days of maturation, DCs were loaded with 5 µM MiHA 
peptide and cultured at a ratio of 0.1:1 with peripheral blood lymphocytes of a MiHA- donor. 
(A) After one week, cells were analyzed for tetramer-positive CD8+ T cells using flowcytometry. 
The numbers in the FACS plots represent the percentage of MiHA-specific CD8+ T cells within the 
total CD3+CD8+ T cell population. Data of 2 out of 9 independent experiments are shown. (B) Data 
of all 9 donors combined. (C-D) Naive CD45RA+CCR7+ CD8+ T cells were sorted and cultured for two 
consecutive weeks with HA-1 peptide loaded PD-L silenced or control DCs. The percentage (C) and 
cumulative numbers (D) of HA-1-specific CD8+ T cells obtained after stimulation with PD-L silenced 
or control DCs. Data of one experiment are shown. MiHA, minor histocompatibility antigen.
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predict individual responses to such treatment. Finally, we demonstrated that by silencing 
PD-1 ligands, especially in combination with MiHA mRNA pulsing, we can generate highly 
immunogenic DCs with strong stimulatory potential. Vaccination with these superior DCs 
is a highly attractive treatment option to induce and boost MiHA-specific effector and 
memory T cell responses post-transplant. By successful translation of the research described 
in this thesis into proof-of-concept clinical studies we will gain important information 
whether GVT immunity can be boosted in a specific manner using MiHA-based DC vaccination 
in combination with blockade of co-inhibitory signaling. By selecting  hematopoietic- 
restricted MiHAs as targets for therapy the risk of GVHD induction will be low, contributing 
to a better quality of life. In addition, the implementation of these novel therapeutic 
strategies holds a great promise to reduce the tumor recurrence rates, and combined with 
the low risk of GVHD this will eventually improve survival after allogeneic SCT.
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Figure 3   Targeting of co-inhibitory molecules on leukemic (stem) cells and DCs
Mature MiHA-presenting DCs highly express co-stimulatory molecules, but also co-inhibitory 
 molecules. Upon stimulation of a naive CD8+ donor T cell, this T cell acquires effector functions and 
clonally expands. Activated T cells up-regulate expression of co-inhibitory receptors, and upon 
encounter of MiHA+ leukemic cells presenting the corresponding inhibitory ligands, alloreactive T 
cell function is impaired. To improve anti-tumor immunity, patients can be treated with donor 
lymphocyte infusions in combination with anti-CLEC12A antibody-coated nanoparticles loaded 
with siRNA (with/without MiHA peptide and TLR-ligands) that can specifically target tumor cells and 
DCs in vivo. Upon siRNA delivery into the target cells, co-inhibitory molecules are silenced. This 
results in DCs with enhanced stimulatory potential, that present the MiHA peptide to the MiHA-
specific T cells, which will clonally expand and gain effector functions. At the same time, the tumor 
cell acquires a more immunostimulatory phenotype. Together, this will boost anti-tumor immunity 
and improve tumor killing. CS-L, co-stimulatory ligand; CS-R, co-stimulatory receptor; CI-L, co- 
inhibitory ligand; CI-R, co-inhibitory receptor; TCR, T cell receptor; HLA-I, human leukocyte antigen 
class I; MiHA, minor histocompatibility antigen; αCLEC12 Ab, anti-CLEC12A antibody; siRNA, small 
interfering RNA; TLR-L, Toll-like receptor ligand.
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Allogene hematopoietische stamcel transplantatie (SCT) is een krachtige behandelingsoptie 
voor patiënten met een hematologische maligniteit, zoals leukemie, lymfoom en myeloom. 
De therapeutische werkzaamheid kan worden toegekend aan het graft-versus-tumor (GVT) 
effect, een reactie waarbij de T-cellen van de donor (alloreactieve T-cellen) minor histo-
compatibiliteit antigenen (MiHAs) op de tumorcellen van de patiënt herkennen als 'vreemd' en 
deze vervolgens aanvallen. MiHAs zijn humaan leukocyten antigeen (HLA)-gebonden 
polymorfe peptiden, afkomstig van eiwitten die verschillend zijn tussen een patiënt en zijn/ 
haar donor, welke sterke alloreactieve T-cel responsen kunnen opwekken. Het is in patiënten 
aangetoond dat na behandeling met een donor lymfocyten infusie (DLI), dergelijke MiHA- 
specifieke T-cel responsen optreden en gevolgd kunnen worden door een afname van het 
aantal tumorcellen (klinische remissie). Terwijl sommige MiHAs alleen voorkomen op de 
tumorcellen van de patiënt, komen anderen ook op gezonde weefsels en organen voor. 
Dit laatste type MiHAs kan hierdoor graft-versus-host-disease (GVHD), oftewel omgekeerde 
afstotingsziekte, veroorzaken. Dit is een ernstige en soms ook fatale complicatie bij allogene 
SCT, omdat het nieuwe donor afweersysteem de gezonde weefsels afstoot, met name in de 
huid, de lever en het maag-darmkanaal. Daarom is het belangrijk om heel gericht T-cel 
responsen op te wekken tegen MiHAs die enkel tot expressie komen op de tumorcellen (GVT 
immuniteit) om zo het risico op het optreden van GVHD te beperken.
 De implementatie van allogene SCT en DLI heeft de klinische uitkomst en algehele 
overleving in patiënten met een agressieve hematologische kanker sterk verbeterd. Echter, 
bij veel patiënten komen de tumorcellen uiteindelijk terug (tumor recidief). Ondanks dat 
MiHA-specifieke geheugen T-cellen langdurig in het lichaam circuleren, zijn deze alloreactieve 
T-cellen vaak niet in staat om efficiënt te reageren op terugkerende tumorcellen. Het gebrek 
aan het opwekken van dergelijke productieve anti-tumor afweerreacties is de som van 
diverse veranderingen in antigeen presentatie, antigeenherkenning, T-cel activatie en 
T-cel overleving, waardoor de tumorcellen een afweeronderdrukkend uiterlijk en omgeving 
verkrijgen. Daarom is het cruciaal om meer kennis te vergaren over dit soort ontsnappings- 
mechanismen die door de tumorcellen gebruikt worden, zodat nieuwe en verbeterde 
adjuvante post-transplantatie immuuntherapieën ontwikkeld kunnen worden om de GVT 
immuniteit te versterken en de terugkomst van tumorcellen te voorkomen. In dit proefschrift 
is het belang van genetische ongelijkheid in MiHAs tussen patiënt en donor, en het 
optreden van de bijbehorende alloreactieve T-cel responsen op klinische uitkomsten na 
allogene SCT bestudeerd. Daarnaast hebben we de betrokkenheid van co-inhibitoire 
moleculen in de remming van MiHA-specifieke T-cel functionaliteit onderzocht, welke 
kunnen bijdragen aan de ontduiking aan het afweersysteem door hematologische tumor- 
cellen. Ten slotte hebben we nieuwe en betere immuuntherapieën ontwikkeld die 
ingrijpen op deze negatieve co-signaleringsroutes om zo MiHA-specifieke T-cel aantallen 
en functionaliteit te verbeteren in patiënten na allogene SCT.
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bepaalt uiteindelijk of tumor-reactieve T-cellen geactiveerd worden. In Hoofdstuk 4 
hebben we onderzocht of de negatief-regulerende Programmed death (PD-)1 route 
betrokken is bij de remming van MiHA-specifieke T-cel functie na allogene SCT. Met 
behulp van flowcytometrische analyses hebben we geobserveerd dat immature leukemie 
progenitor cellen hoge expressie hebben van PD-L1, in combinatie met lage PD-L2, CD80 
en CD86 expressie na blootstelling aan IFN-γ en TNF-α. Leukemiecellen van gerecidiveerde 
patiënten vertoonden ook hoge PD-L1 niveaus onder inflammatoire omstandigheden. 
Daarnaast hadden MiHA-specifieke effector en geheugen T-cellen verhoogde PD-1 
expressie, wat aangeeft dat negatieve signalering via PD-1 plaats kan vinden in deze 
patiënten. Stimulatie van MiHA-specifieke T-cellen met MiHA-peptide beladen dendritische 
cellen (DCs) of acute myeloïde leukemie (AML) cellen in de aanwezigheid van anti-PD-1/
PD-L1 blokkerende antilichamen resulteerde in toegenomen proliferatie en IFN-γ 
productie door deze T-cellen. Een belangrijke observatie was dat PD-1 blokkade een 
significant beter effect had op disfunctionele MiHA-specifieke T-cellen van gerecidiveerde 
patiënten. Samen laten deze bevindingen zien dat de PD-1/PD-L signaleringsroute MiHA-
specifieke T-cel reacties onderdrukt. Daarom zou blokkade van PD-1 een aantrekkelijke 
manier kunnen zijn om GVT immuniteit te stimuleren in patiënten met gerecidiveerde 
ziekte.
 Naast PD-1 kunnen ook andere co-inhibitoire receptoren betrokken zijn bij de 
ontsnapping van hematologische tumoren aan het immuunsysteem. Een andere 
interessante kandidaat, die beschreven is betrokken te zijn bij het ontsnappen aan T-cel 
immuniteit in melanoom, is B- and T-lymphocyte attenuator (BTLA). Daarom hebben in 
Hoofdstuk 5 onderzocht of BTLA ook betrokken is bij de remming van MiHA-specifieke 
afweerreacties in hematologische maligniteiten. We hebben laten zien dat MiHA-specifieke 
effector-geheugen T-cellen hoge BTLA expressie vertonen. De ligand van BTLA, Herpes 
virus entry mediator (HVEM), is onderdeel van een gecompliceerd signaleringsnetwerk 
aangezien het ook andere bindingspartners heeft die T-cel responsen verschillend 
beïnvloeden, waaronder CD160 en LIGHT (besproken in Hoofdstuk 3). Vandaar dat we 
hematologische tumorcellen geanalyseerd hebben op de expressie van BTLA, HVEM, 
CD160 en LIGHT. Interessant is dat zowel HVEM als zijn bindingspartner BTLA hoog tot 
expressie kwamen op primaire leukemie- en myeloomcellen, terwijl LIGHT en CD160 
niveaus laag waren. Omdat de tumorcellen positief waren voor BTLA hebben we ook 
onderzocht of T-cellen HVEM tot expressie konden brengen. Dit bleek inderdaad het geval 
te zijn. Deze bevindingen duiden er op dat een bidirectionele HVEM-BTLA signalering 
tussen tumorcel en T-cel kan plaatsvinden. Om te onderzoeken wat het effect van BTLA 
signalering op MiHA-specifieke T-cel functie is, hebben we deze T-cellen gestimuleerd 
met MiHA-peptide beladen DCs in de aanwezigheid van een blokkerend anti-BTLA 
antilichaam. Dit resulteerde in een significante vermeerdering van het aantal MiHA-specifieke 
T-cellen. Daarnaast zagen we dat deze MiHA-specifieke T-cellen uitermate bekwaam 
reageerden op restimulatie met antigeen door te prolifereren, degranuleren en cytokines 
 Aangezien MiHAs de dominante antigenen zijn in HLA-identieke allogene SCT, spelen 
ze een centrale rol in zowel GVT als GVHD immuunreacties. Beter begrip van de MiHA-
specifieke T-cel responsen die betrokken zijn bij deze processen zou niet alleen bijdragen 
aan een betere voorspelling van de klinische uitkomst na allogene SCT, maar ook een 
rationale leveren voor het specifiek selecteren van de meest potente MiHAs in post- 
transplantatie immunotherapeutische strategieën. In Hoofdstuk 2 hebben we geëvalueerd of 
ongelijkheid in MiHAs tussen patiënten en hun donoren gecorreleerd is met een betere 
klinische uitkomst na transplantatie. In deze retrospectieve analyse includeerden we 327 
patiënten met een hematologische maligniteit, die behandeld zijn met een deels T-cel 
gedepleteerd allogene SCT. Uit de analyses bleek dat ongelijkheid in autosomale MiHAs 
op DNA-niveau gecorreleerd is met een betere recidief-vrije overleving in patiënten die 
getransplanteerd zijn met stamcellen van een broer of zus. Met name in multiple myeloom 
patiënten was de recidief-incidentie lager en was ook de recidief-vrije overleving hoger in 
het geval van ongelijkheid in autosomale MiHAs. Ongelijkheid voor de breed tot expressie 
komende Y-chromosomale MiHAs resulteerde in een hogere incidentie van acute GVHD 
(graad 3-4), terwijl verschillen in autosomale MiHAs niet geassocieerd waren met ernstige 
GVHD, ongeacht of het expressiepatroon van deze laatste groep breed was of beperkt 
was tot hematopoietische cellen. Daarnaast hebben we de in vivo aanwezigheid van 
 MiHA-specifieke T-cel responsen na transplantatie bepaald met behulp van een twee-kleuren 
tetrameer analyse. Hierbij waren aanzienlijke verschillen te zien in het vermogen van de 
verschillende MiHAs om ook daadwerkelijk in vivo T-cel reacties op te wekken (i.e. 0-60%). 
In het bijzonder T-cellen specifiek voor de hematopoietische MiHAs HA-1, HA-2, PANE1, 
LRH-1 en ACC-1, en de breed tot expressie komende HY-antigenen werden het vaakst 
gedetecteerd. Belangrijk is dat patiënten met MiHA-specifieke T-cel responsen een 
significant betere recidief-vrije overleving hadden in de eerste jaren na allogene SCT en 
dat dit niet leidde tot een toename in de incidentie of ernst van GVHD. Samen leveren 
deze bevindingen nader bewijs dat MiHAs een dominante rol spelen in de gewenste GVT 
immuunreacties en dat patiënten voordeel kunnen hebben van transplantatie met 
stamcellen van een MiHA-ongelijke donor. Bovendien geven deze data een rationale om 
GVT immuunresponsen gericht tegen hematopoietische MiHAs op te wekken en te 
versterken om zo de klinische uitkomst na HLA-identieke allogene SCT te verbeteren.
 Ondanks de kracht van afweerreacties en de aanwezigheid van anti-tumor geheugen, 
zijn tumorcellen toch vaak in staat om te ontkomen aan herkenning en vernietiging door 
het immuunsysteem. Mechanismen die door tumorcellen gebruikt worden om T-cel 
gemedieerde immuniteit te verhinderen zijn verstoorde antigeen presentatie, verlaagde 
expressie van HLA moleculen, uitscheiding van afweeronderdrukkende cytokines, alsook 
het aantrekken van regulatoire T-cellen (T
REG
) en suppressieve cellen van myeloïde afkomst. 
In het afgelopen decennium heeft ook een ander krachtig afweeronderdrukkend 
mechanisme veel aandacht gekregen: de remmende werking van co-inhibitoire 
moleculen (besproken in Hoofdstuk 3). De balans in positieve en negatieve co-signalen 
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dat PD-L siRNA toediening met behulp van DLin-KC2-DMA-bevattende LNPs resulteerde 
in de meest efficiënte en specifieke verlaging van PD-L expressie niveaus op DCs en dat 
deze siRNA-LNP transfectie succesvol gecombineerd kan worden met zowel antigeen 
peptide belading alsook mRNA electroporatie. Tot slot hebben we aangetoond dat deze 
PD-L negatieve DCs, beladen met antigeen mRNA, krachtige antigeen-specifieke geheugen 
T-cel responsen stimuleren, met name na opeenvolgende stimulatierondes. Samengevat 
laten deze bevindingen zien dat PD-L negatieve DCs, beladen met MiHA mRNA, aantrekkelijke 
cellen zijn voor klinische productie als adjuvante immuuntherapie om op competente 
wijze GVT immuniteit te induceren en te versterken na allogene SCT.
Conclusie
De studies beschreven in dit proefschrift bieden aanvullend bewijs dat MiHA-specifieke 
T-cel reacties een belangrijke rol spelen in GVT immuniteit. Verder hebben we aangetoond 
dat signalering via de co-inhibitoire receptoren PD-1 en BTLA bijdraagt aan de functionele 
remming van MiHA-specifieke effector en geheugen T-cel responsen. Stimulatie met 
MiHA-peptide beladen DCs in de aanwezigheid van een PD-1 of BTLA blokkerend 
antilichaam herstelt alloreactieve T-cel proliferatie, degranulatie en cytokine-productie. 
Met dit onderzoek hebben we meer kennis vergaard over hoe GVT immuniteit belemmerd 
kan worden na allogene SCT, wat een rationale biedt voor de implementatie van 
(persoonlijke) therapieën na allogene SCT die gericht zijn tegen deze negatieve co- 
signaleringsroutes. Echter, meer onderzoek naar de verschillen in de bijdrage van PD-1, 
BTLA en andere co-inhibitoire moleculen is vereist om de functionele status van geremde 
MiHA-specifieke T-cellen beter te begrijpen en individuele responsen op dergelijke 
behandelingen te kunnen voorspellen. Tenslotte hebben we aangetoond dat we door het 
verlagen van PD-L niveaus, met name in combinatie met MiHA mRNA belading, zeer 
immunogene DCs met een krachtig stimulerend potentieel kunnen genereren. Vaccinatie 
met deze superieure DCs is een aantrekkelijke behandelingsoptie om MiHA-specifieke 
effector en geheugen T-cel responsen te induceren en te versterken post-transplantatie. 
Door het onderzoek beschreven in dit proefschrift toe te passen in klinische studies 
kunnen we onderzoeken of GVT immuniteit specifiek versterkt kan worden door middel 
van MiHA-DC vaccinatie in combinatie met blokkade van co-inhibitoire signalering. 
Implementatie van deze nieuwe therapeutische strategieën is veelbelovend voor 
patiënten na allogene SCT, om het aantal tumor recidieven te verlagen en de overleving 
te verbeteren.
te produceren. Interessant is dat sommige patiënten beter reageerden op BTLA blokkade, 
terwijl andere sterkere effecten lieten zien na PD-1 blokkade. We hebben echter geen 
additief effect geobserveerd wanneer beide receptoren tegelijk geblokkeerd werden. 
Samengevat hebben we laten zien dat naast PD-1 ook BTLA betrokken is bij de inhibitie 
van MiHA-specifieke T-cel reacties, echter de relatieve bijdrage van deze twee receptoren 
aan de functionele remming van GVT afweerresponsen verschilt tussen patiënten.
 De bevindingen beschreven in Hoofdstuk 4 en 5 laten zien dat zowel PD-1 als BTLA 
interacties GVT immuniteit hinderen, en bieden een rationale voor het toepassen van co-
signaleringsblokkade gedurende post-transplantatie immuuntherapie. Ondanks de 
goede resultaten behaald met blokkerende anti-PD-1, anti-PD-L1 en anti-CTLA-4 anti - 
lichamen in solide tumoren, zou behandeling met deze antilichamen in patiënten die een 
allogene SCT ondergaan hebben te gevaarlijk kunnen zijn. Na transplantatie bevinden de 
patiënten zich namelijk in een verhoogd geactiveerde immunologische status als gevolg 
van chemotherapie-geïnduceerde weefselschade en inflammatie, met name in GVHD- 
gevoelige organen zoals huid en darmen. Het opheffen van negatieve signalering op 
dit moment zou gevaarlijk kunnen zijn, aangezien de T-cellen dan naar de ontstoken 
allo -antigeen-positieve GVHD weefsels zouden kunnen migreren en daar gezonde cellen 
zouden kunnen vernietigen. Daarom hebben we een andere immunotherapeutische 
strategie ontwikkeld, die beschreven is in Hoofdstuk 6. Hier hebben we onderzocht of 
we MiHA-specifieke T-cel activatie konden verhogen door stimulatie met PD-L1 en PD-L2 
negatieve DCs. Electroporatie van PD-L siRNA sequenties in immature DCs leidde tot 
efficiënte, specifieke en langdurige verlaging van PD-L1 en PD-L2 niveaus. Deze PD-L1 en 
PD-L2 negatieve DCs medieerden vervolgens verhoogde proliferatie en cytokine-productie 
door keyhole limpet hemocyanin (KLH)-specifieke T-cellen. Daarnaast vertoonden PD-L 
negatieve DCs een superieur vermogen in het stimuleren van MiHA-specifieke T-cel 
expansie in leukemiepatiënten kort na DLI, en later tijdens gerecidiveerde ziekte. Samen 
laten deze data zien dat PD-L siRNA geëlectroporeerde DCs zeer effectief zijn in het 
versterken van T-cel proliferatie en cytokine productie, en aantrekkelijke cellen zijn om de 
werkzaamheid van DC vaccins in kankerpatiënten te verbeteren. Om een klinisch 
toepasbaar DC vaccin met een verder verbeterd immunogeen potentieel te genereren, 
hebben we in Hoofdstuk 7 de combinatie van PD-1 ligand siRNA en antigeen mRNA 
toediening onderzocht. Het voordeel van het gebruik van mRNA in plaats van peptide 
belading is dat de antigeen epitopen op een natuurlijke manier verwerkt worden. 
Bovendien wordt een verscheidenheid aan epitopen langdurig gepresenteerd door 
zowel HLA klasse I als II moleculen. Op deze manier kan de breedte van de afweerreactie 
sterk vergroot worden. Terwijl PD-L siRNA electroporatie uitgevoerd moet worden op 
immature DCs, voordat PD-L1 en PD-L2 expressie toeneemt als gevolg van maturatie, is 
mRNA electroporatie het meest optimaal in het mature DC stadium. Daarom hebben we 
een niet-virale siRNA transfectiemethode gebaseerd op lipide nanopartikels (LNPs) 
onderzocht, die veilig toegepast kan worden in de klinische situatie. We hebben laten zien 
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Dankwoord
Na 4 jaar van experimenten en schrijven ben ik nu bij het einde van mijn proefschrift 
aangekomen en ga ik promoveren! In de voorgaande hoofdstukken heb je kunnen lezen 
waar ik me de afgelopen jaren mee bezig heb gehouden en een indruk kunnen krijgen 
van waarom ik soms ’s avonds of in het weekend toch nog even moest werken. Hoewel 
mijn project voortvarend liep, zou ik zonder jullie hulp, advies en steun nergens zijn 
geweest. Ik ben heel trots op dit mooie eindresultaat en wil bij deze iedereen bedanken! 
Een aantal mensen wil ik in de komende alinea’s in het bijzonder noemen.
 Harry, ik ben echt ontzettend blij dat jij mijn eerste co-promotor was! Jouw enthousiasme 
voor en je geloof in de kracht van adjuvante immuuntherapie na stamceltransplantatie is 
cruciaal voor het doen van dit type translationeel onderzoek in Nijmegen. Ondanks de 
vele regelgeving en strubbelingen die je soms op de weg naar een klinische studie 
tegenkomt blijf je positief en vind je altijd een manier om bij de start uit te komen. Ook in 
de werkbesprekingen hebben jouw positieve insteek en begeleiding mij enorm geholpen 
bij de totstandkoming van nieuwe hypotheses, goede discussies en zo ook mooie 
publicaties. Daarnaast stond je deur ook altijd open voor ad-hoc vragen of overleg. 
Zonder jou zou dit proefschrift hier nu niet liggen! Ik vind het ontzettend fijn dat ik als 
post-doc in je groep blijf en zo nog veel van je kan leren. Ik kijk dan ook uit naar onze 
samenwerking de komende jaren!
 Robbert, ondanks dat ik in mijn besprekingen af en toe misschien grote (gedachten)
sprongen maakte wist jij de lijn altijd weer helder te krijgen met de juiste vragen. Daarnaast 
hebben jouw kritische blik en suggesties betreft experimenten, data en schrijfstijl ervoor 
gezorgd dat mijn artikelen nog mooier en beter werden. Bedankt voor alle begeleiding en 
samenwerking! Theo en Fred, mijn promotoren, jullie stonden beiden iets verder van mijn 
promotietraject af. Desalniettemin wil ik jullie bedanken voor jullie interesse in mijn onderzoek, 
het uitvoerig lezen van dit proefschrift en de suggesties die jullie gegeven hebben ter 
verbetering van dit werk.
 Hanny, ik vind het fijn dat je bij mijn promotie als paranimf aan mijn zijde wilt staan. 
Als analiste op mijn project was (en ben) je altijd bereid om mee na te denken over 
experimenten en kon ik de uitvoering ervan met een gerust hart aan je overlaten. Wat ik 
geweldig vind aan onze samenwerking is dat we op eenzelfde manier experimenten 
opzetten en uitvoeren en dat deze nooit te groot kunnen zijn ;). Hoewel de cellen daar niet 
altijd aan meewerken en we vaak terplekke weer veel condities moeten schrappen. Ik ben 
blij dat wij de komende jaren een duo blijven op het lab, maar ik kijk natuurlijk ook uit naar 
de vele gezellige buiten-werkse borrels, etentjes en stapavonden!
 Anniek, ondanks dat jij een jaar na mij begonnen bent met je promotieonderzoek 
kennen we elkaar intussen al weer een hele tijd. Tijdens onze stage bij Organon raakten 
we niet alleen bevriend, maar werden we ook tegelijkertijd besmet met het 'lijstjes-virus'. 
Menig collega is daar nu jaloers op ;). Ondanks dat ons muizenproject niet altijd mee zat 
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ook jullie bedankt! Daarnaast zijn ook mijn studenten Mieke, Karen, Cynthia en Anoek 
onmisbaar geweest! Ik vond het leuk om jullie wegwijs te mogen maken in de wondere 
wereld van de wetenschap, de nette labjournaals, lastige experimenten en mooie 
stageverslagen. Ook ik heb veel geleerd tijdens de begeleiding van jullie stages waaronder 
het loslaten van experimenten, het jullie zelf uit laten zoeken van achtergronden en 
methoden, het relativeren van dingen die fout gaan, maar ook hoe ik aan jullie chocolade 
kon ontfutselen :P. Ik hoop dat jullie allemaal geïnspireerd zijn door het doen van 
onderzoek en dat jullie zelf ook een mooie (AIO-)carrière tegemoet gaan.
 Maar nu is het belangrijk om even wat langer in de tijd terug te gaan en wel naar 
september 2007. Via Renoud (bedankt voor je tip!) hoorde ik over een stageplaats bij 
Organon en dus ging ik op gesprek bij John en Mieke. Bij jullie ben ik vervolgens op een 
project begonnen op het gebied van T-cel co-stimulatie/co-inhibitie en blokkade van 
deze mechanismen ter verbetering van kankertherapie. Dit was echt een geweldig project 
waarin ik veel vrijheid kreeg, veel verschillende assays mocht doen en ook al een beetje 
leerde om te netwerken met collega’s van andere afdelingen. Deze stage heeft mij echt 
laten zien waar ik goed in was, wat ik leuk vond om te doen en, heel belangrijk, hoe ik mijn 
vervolgcarrière voor me zag. Ik was dan ook ontzettend blij toen ik werd aangenomen op 
een promotieproject wat verder ging in de lijn van mijn onderzoek bij jullie. Bedankt voor 
jullie inspiratie en begeleiding tijdens mijn stage!
 Zoals elk project was ik nergens geweest zonder de samenwerking met andere 
groepen en afdelingen. Zonder alle patiënten en hematologen van ons transplantatiecen-
trum zouden wij geen materiaal hebben om onderzoek te doen. Michel en Walter, ik kon 
altijd bij jullie binnenlopen met klinische vragen of voor gegevens waardoor ik mijn data 
beter kon begrijpen. Walter, jouw hulp en begeleiding in de wereld van de statistische 
analyses was van onschatbare waarde. Daarnaast wil ik ook Ton bedanken voor alle hulp 
en inzet bij het uitvoeren van deze vele analyses, en voor de manier waarop je met steeds 
weer een nieuwe 'laatste' analyse omging (dit moet af en toe toch wel gekmakend 
geweest zijn) en de vele vragen die ik telkens weer had. Ik heb enorm veel van je geleerd! 
Voor ons MiHA onderzoek werken we nauw samen met Leiden en Utrecht. Met name 
prof. dr. Fred Falkenburg en Michel Kester van het LUMC hebben ons vele tetrameren 
toegestuurd waardoor wij in staat waren MiHA-specifieke T-cellen te detecteren en te 
volgen, bedankt daarvoor! Dr. Alan Korman and prof. dr. Daniel Olive provided us with 
anti-PD-1, anti-PD-L1 and anti-BTLA blocking antibodies, which we used to investigate the 
role of these co-inhibitory pathways in the immune inhibition of hematological 
malignancies. Thank you both for the nice collaboration! Another important collaborator 
was Alnylam Pharmaceuticals. Tatiana, Jamie and Anna, I really enjoyed working with you 
and I would like to thank you for all your help, advice and the many LNPs you send me for 
my research. Although the plans have changed a little bit, I’m happy we are still 
collaborating on the PD-L1/L2 siRNAs and I’m looking forward to test our improved DCs in 
a clinical study. Ook vele groepen binnen ons eigen laboratorium en afdeling hebben 
liep onze samenwerking gesmeerd en vond jij het niet erg om met mijn muizen-stress om 
te moeten gaan. Ook vind ik het super fijn dat ik altijd bij jou terecht kan voor advies over 
experimenten, de juiste woorden/zin als ik iets aan het schrijven ben, hoe ik een situatie 
het beste aan kan pakken, enzovoort. Ik ben daarom blij dat ook jij mijn paranimf wilt zijn.
 Niet alleen Hanny heeft als analiste op mijn project gewerkt, ook een heleboel data is 
door Niken gegenereerd tijdens de eerste twee jaar van mijn promotieonderzoek. Niken, 
although I know your Dutch is very good I’ll write to you in English this time :). We started 
almost at the same time with our first job and both really had to find our way in the 
beginning. After a while we had our 'own' projects and you spent hours not only at the 
flowcytometer, but also isolating many, many, many DNA samples and performing series 
of KASPar PCRs without any complaints. Funny to mention is that you really surprised 
everyone regularly with a 'different' look (read: diversity of different contact lenses 
amongst which cat-eyes)! Thanks for all your help and good luck with your own carrier in 
science!
 Wieger, Kelly, Sandra en Anniek, mijn mede AIO-maatjes. Samen zaten we in hetzelfde 
schuitje, hoewel sommigen van ons nattere voeten kregen dan anderen tijdens de 
promotievaart. Toch hadden we altijd wel een reden om samen op congres te gaan, gek 
te doen, lekker achterover te leunen, biertjes te drinken, te eten, etc. Ik hoop dat we dit de 
komende jaren nog vaak zullen herhalen. Wieger, jij hebt me wegwijs gemaakt in het PD-1 
project en ondanks dat we allebei heel verschillend zijn en regelmatig kunnen kibbelen, 
hebben we samen een paar mooie papers geschreven en blijven we ook in de toekomst 
samenwerken. Kelly, wij hebben samen een ander mooi, maar soms ook frustrerend, 
paper geschreven wat nu gelukkig gepubliceerd is in een mooi tijdschrift. Ik heb echt 
ontzettend veel geleerd van jouw creativiteit en voortvarende aanpak en ik ben nog 
steeds onder de indruk van de snelheid waarmee jij ideeën en artikelen op papier wist te 
krijgen. Hoewel ik het jammer vind dat je niet meer in Nijmegen woont en werkt, ben ik 
blij dat je nu de baan hebt die je ontzettend graag wilde. Sandra, we hebben dan 
misschien geen data gedeeld maar wel onze bureaus. Ook dat is wat waard, dat zonder 
gemopper de grens nog wel eens verschoof onder stapels data ;). Toen we beiden meer 
aan het schrijven waren was het ook fijn om met iemand korte deadlines af te spreken, 
zoals “over een half uur hebben we deze alinea af!”. Daarnaast denk ik met veel plezier 
terug aan onze wintersportvakanties waarbij we elkaar goed moe wisten te krijgen. Ik 
hoop dat we dat nog een keer over zullen doen!
 Natuurlijk hebben ook de andere collega’s in de CTI-groep er voor gezorgd dat mijn 
project voortvarend verliep door hun hulp, kritische blik en advies bij mijn experimenten. 
Bovenal door de gezellige sfeer op het lab was het elke dag weer leuk om naar het werk 
te komen. Frans, met jouw jarenlange ervaring op het lab en je kennis van de PD-1/PD-L 
signaleringsroute was jij een van mijn vraagbaken. Ook hebben we fijn samengewerkt op 
het BTLA paper, bedankt voor alle hulp! Annemieke, Annelies, Basav, Dirk, Henriëtte, Jan, 
Jeannette, Jeroen, Marian, Marij, Marleen, Karishma, Peter, Rob, Soley, Thomas en Viviènne 
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wanneer ik dat nodig had, en ondanks dat nu niet iedereen meer in Nijmegen woont 
weet ik zeker dat we de komende jaren nog vele leuke dingen gaan doen! Anke en Neeltje, 
met jullie heb ik echt een ontzettend gave tijd gehad in Londen toen we daar (toevallig) 
tegelijkertijd zaten voor een stage, ook daar denk ik nog vaak aan terug! Sip, wij leerden 
elkaar beter kennen tijdens onze stage bij Organon en daarna toen we tegelijkertijd aan 
ons promotieonderzoek begonnen. Bedankt voor onze vriendschap, je interesse in mijn 
werk en de leuke werk-uitstapjes naar Sardinië en Californië :). Succes met de laatste pro-
motieloodjes en ik hoop dat ook jij binnenkort een leuke nieuwe baan vindt!
 Last but not least, wil ik natuurlijk mijn familie bedanken voor alle interesse, vragen en 
tips die jullie hadden de afgelopen jaren. Hoewel mijn promotieonderzoek voor de 
meesten van jullie als abracadabra klonk, hoop ik dat jullie met het lezen van dit proefschrift 
en het zien van mijn promotie een beetje beter begrijpen wat mijn werk inhoud. Andries, 
voor ons ben je eigenlijk een extra broer. Bedankt voor je interesse in mijn werk, voor je 
advies op ICT-gebied als mijn computer weer eens niet deed wat ik wilde, en voor je 
kwaliteiten als spelling- en grammaticacontroleur ;). Lieve Derk, mijn grote broer, jij weet 
me altijd weer op de hoogte te brengen van allerlei interessante (of maffe) wetenschap-
pelijke feitjes en nieuwtjes die je tegenkomt. Jij en Petra hebben helaas van dichtbij mijn 
vakgebied meegemaakt en wisten daardoor veel van mijn onderzoek af. Bedankt voor 
jullie interesse en dat ik altijd bij jullie en mijn lieve nichtje Lena binnen kan lopen! Lieve 
Peter, mijn ‘kleine’ broertje, ik vind jouw interesse voor en kennis van techniek geweldig! 
Alhoewel ik jouw werk en ideeën vaak niet kan volgen ;). Super goed dat je nu je Master- 
studie in Eindhoven aan het doen bent en dat je daar doorzet ook al komt al die theorie 
soms je neus uit. Ik vind het ook altijd gezellig als jij en Marouschka samen met jullie 
vrienden komen logeren in Nijmegen en we weer leuke en grappige dingen meemaken! 
Ten slotte, lieve papa en mama ook jullie wil ik natuurlijk bedanken voor alle steun en 
liefde die jullie me de afgelopen jaren gegeven hebben. Ik heb ontzettend veel van jullie 
geleerd, en door de kansen die jullie me boden heb ik me kunnen ontwikkelen zoals ik 
graag wilde. Ook zonder jullie zou dit proefschrift hier niet liggen!
mijn onderzoek mogelijk gemaakt en ik wil jullie daar allen voor bedanken! De Moleculaire 
Diagnostiek en het Laboratorium Medische Immunologie hebben mij van vele DNAtjes 
van patiënt/donor-koppels voorzien waardoor ik kon onderzoeken of er op DNA-niveau 
sprake was van ongelijkheid in MiHAs. Doordat de Stamceltransplantatie-groep al jaren 
vele bloed- en beenmergmonsters isoleert en invriest, kon ik vervolgens onderzoeken of 
op cellulair niveau de MiHA-specifieke T-cel responsen ook echt optraden. Voor meer 
informatie over het type maligniteit en de kenmerken kon ik vervolgens terecht bij de 
mensen van de Morfologie en Immuunfenotypering. Weer terug op het lab was het fijn 
dat ik voor vragen over bacteriën, virussen en gels de Moleculaire Research lastig kon 
vallen. Maar wat vaker voorkwam was dat we samen gingen koffiedrinken, lunchen, 
borrelen in “de Aesculaaf” of op NHC congres gingen. Sinds jullie 2 jaar geleden onze 
buren werden is er nog meer gezelligheid op het lab bijgekomen!
 Daarnaast wil ik iedereen van de NCMLS PhD programma commissie bedanken voor 
de leuke tijd waarin we samen de verschillende componenten van het programma 
organiseerden, alsook met nieuwe ideeën kwamen ter verbetering van het traject. Met 
Renoud, Maaike, Hanneke, Ben, Tom en Elena, heb ik de jaarlijkse AIO retraite georganiseerd. 
Bedankt voor de fijne samenwerking en gezellige retraites!
 Natuurlijk was het ook belangrijk om na het werk te kunnen ontspannen. Zo kon ik 
altijd bij mijn vrienden van de tennis terecht voor het slaan van een balletje en deden we 
fanatiek mee aan de competitie en open toernooitjes. Ook daarbuiten doen we regelmatig 
leuke dingen en ik ben blij met onze gezellige groep! Zo ook met de wintersportvrienden, 
onze vakanties in Hochfügen waren altijd super leuk en vol gekkigheid. Jammer dat onze 
laatste gemeenschappelijke wintersport al weer even geleden is, maar hopelijk komt het 
er op niet al te lange termijn toch weer van en kunnen we de kleintjes in onze families ook 
die mooie witte bergen laten zien!
 Ook mijn vriend(inn)en van de middelbare school en de universiteit zijn onmisbaar in 
mijn leven! Els, Ilse, Lilian, Melanie en Truike, ik vind het geweldig dat onze vriendschap 
sinds de middelbare school niet veranderd is en dat we elkaar nog steeds vaak zien! 
Bedankt voor jullie vriendschap, interesse en wanneer nodig steun en advies de afgelopen 
jaren. Samen hebben we veel meegemaakt en zijn we volwassen geworden. Terwijl ik dit 
schrijf denk ik met een grote lach terug aan al onze leuke, gezellige en gekke momenten 
samen en ik kijk uit naar de komende jaren! In 2003 begon ik samen met Wandana, Hetty, 
Monica, Christine, Sandra, Annet, Daniëlle en Suzanne aan het Nijmegen avontuur. Vanaf 
dat we elkaar leerden kennen in de werkgroep, tijdens het introductiekamp, tijdens de 
dagelijkse treinreis van en naar Nijmegen of als huisgenootje was het meteen leuk! Of we 
nu samen opdrachten maakten, naar MFV-feesten gingen, een vrijgezellenfeestje/bruiloft 
hadden, bij iemand thuis aten, op vakantie gingen of gewoon een meidendag hadden 
het was altijd super gezellig! Daarnaast wisten jullie precies wat mij de afgelopen jaren 
bezig hield, aangezien jullie ook (bijna) allemaal een eigen promotieonderzoek doen of 
gedaan hebben. Ook jullie wil ik daarom bedanken voor jullie vriendschap en advies 
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Willemijn Hobo werd geboren op 16 augustus 1985 te Kerkwijk. In 2003 behaalde zij haar 
VWO-diploma aan de Scholengroep Cambium in Zaltbommel, en begon zij aan haar 
studie Biomedische Wetenschappen aan de Radboud Universiteit Nijmegen. In 2006 
behaalde zij haar Bachelor of Science diploma na het afronden van haar eerste onder-
zoeksstage bij afdeling Farmacologie-Toxicologie van het UMC St Radboud in Nijmegen 
onder begeleiding van prof. dr. Gerard Rongen. Zij vervolgde haar studie met de master 
Toxicologie en het bijvak Geneesmiddelenonderzoek waarvoor zij nog twee onderzoeks-
stages uitvoerde. In 2007 deed zij voor haar bijvak onderzoekservaring op bij de groep 
van dr. Stephen Stürzenbaum van de afdeling Biochemie aan het King's College in Londen. 
Ter afronding van haar opleiding verrichtte zij in 2007/2008 haar laatste onderzoeksstage 
bij de afdeling Autoimmuniteit van Organon N.V. in Oss onder begeleiding van dr. John 
Dulos. Hier raakte zij geïnteresseerd in T-cel co-stimulatie/co-inhibitie en de blokkade van 
deze mechanismen ter verbetering van de kankertherapie. Na het behalen van haar 
Master of Science diploma in 2008 begon zij in september van dat jaar aan haar promotie-
onderzoek bij het Laboratorium Hematologie, afdeling Laboratoriumgeneeskunde, aan 
het UMC St Radboud. Onder begeleiding van dr. Harry Dolstra, dr. Robbert van der Voort, 
prof. dr. Fred Sweep en prof. dr. Theo de Witte voerde zij het onderzoek uit wat geresulteerd 
heeft in dit proefschrift. Tijdens haar promotieonderzoek heeft zij verschillende bachelor- 
en masterstudenten begeleid. Aanvullend heeft zij het NCMLS PhD programma en de 
opleiding tot SMBWO Immunoloog gevolgd welke beiden afgerond worden na haar 
promotie. Daarnaast was zij van 2010 tot en met 2012 lid van de NCMLS PhD programma 
commissie en heeft zij, in samenwerking met andere commissieleden, tweemaal de 
jaarlijkse NCMLS PhD retraite georganiseerd. In juni 2010 heeft zij de AIO-award gewonnen 
tijdens het Nederlands Tumorimmunologie Congres. In juni 2012 heeft zij de Bas Mulder 
Award, onderdeel van de Stichting Alpe d'HuZes van het Koningin Wilhelmina Fonds, 
toegekend gekregen voor haar eigen onderzoeksproject. Ondertussen is zij sinds september 
2012 werkzaam als post-doc op dit nieuwe project, alsook bij de klinische studie betrokken 
die voortgekomen is uit haar promotieonderzoek.
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7AAD  7-amino-actinomycin D
Ab antibody
ADCC  antibody-dependent cell-mediated 
cytotoxicity
AEC aminoethyl carbazole
aGVHD acute GVHD
ALL acute lymphoblastic leukemia
Allo-SCT allogeneic stem cell transplantation
AML acute myeloid leukemia
APC antigen-presenting cell
ATG anti-thymocyte globulin
Bak Bcl-2 homologous antagonist/killer
Bax Bcl-2 associated X
BATF  basic leucine zipper transcription 
factor, ATF-like
Bcl-2 B cell lymphoma-2
Bcl-x
L
 B cell lymphoma extra long
Bid bi-daily
BM bone marrow
BMT bone marrow transplantation
B-NHL B-cell non-Hodgkin lymphoma
BSA bovine serum albumin
BTLA B and T lymphocyte attenuator
Bus busulfan
CFSE  carboxyfluorescein diacetate 
succinimidyl ester
CI-L co-inhibitory ligand
CI-R co-inhibitory receptor
cGVHD chronic GVHD
CLL chronic lymphoid leukemia
CM central memory
CML chronic myeloid leukemia
CML-AP CML-accelerated phase
CML-BC CML-blast crisis
CML-CP CML-chronic phase
CMV cytomegalovirus
CsA cyclosporine A
CS-L co-stimulatory ligand
CS-R co-stimulatory receptor
CTL cytotoxic T lymphocyte
CTLA-4  cytotoxic T lymphocyte associated 
antigen-4
Cy cyclophosphamide
DAB 3,3-diaminobenzidine
DC dendritic cell
DLI donor lymphocyte infusion
DNA deoxyribonucleic acid
EBV-LCL  Epstein-Barr virus lymphoblastoid  
cell lines
ELISA enzyme-linked immunosorbent assay
EM effector memory
FAB French American British
FCS fetal calf serum
FDMR female-donor-male-recipient
FLU influenza
Flu fludarabine
G-CSF  granulocyte colony-stimulating 
factor
gD herpes simplex virus glycoprotein D
GI gastro-intestinal tract
GM-CSF  granulocyte-macrophage colony-
stimulating factor
GMP good manufacturing practice
Grb-2  growth factor receptor-bound 
protein 2
GVHD graft-versus-host-disease
GVL graft-versus-leukemia
GVT graft-versus-tumor
HCV hepatitis C virus
HD healthy donor
HL Hodgkin lymphoma
HLA human leukocyte antigen
HMBS hydroxymethylbilane synthase 
HS human serum
HVEM herpes virus entry mediator
ICOS-L inducible T cell co-stimulator ligand
Ida idarubicin
iDC immature DC
IDO indoleamine 2,3-dioxygenase
IFN-γ interferon-γ
IL interleukin
KLH keyhole limpet hemocyanin
LAG3 lymphocyte-activation gene 3
LIGHT  lymphotoxin-like, exhibits inducible 
expression, and competes with HSV 
glyocoprotein D for HVEM, a receptor 
expressed by T cells
LNP lipid nanoparticle
LT-α lympotoxin-α
Mcl-1 myeloid cell leukemia-1
MDS myelodysplastic syndrome
MFI mean fluorescence intensity
MHC major histocompatibility complex
MiHA minor histocompatibility antigen
mDC mature DC
MDSC myeloid derived suppressor cell
MIC-A  MHC class I polypeptide-related 
sequence A
MM multiple myeloma
MMF mycophenolate mofetil
Mo months
MRD minimal residual disease
mRNA messenger RNA
MUD matched unrelated donor
N number
N naive
ND not determined
NHL non-Hodgkin lymphoma
NIMA non-inherited maternal antigen
NIPA non-inherited paternal antigen
NK natural killer cell
NKT natural killer T cell
NOAEL no observed adverse effect level
NRM non-relapse mortality
n.s. not significant
OS overall survival
PB peripheral blood
PBMC peripheral blood mononuclear cell
PBSC peripheral blood stem cell
PCR polymerase chain reaction
PD-1 programmed death-1
PD-1H programmed death-1 homolog
pDC plasmacytoid DC
PD-L1  programmed death-1 receptor ligand 1
PD-L2 programmed death-1 receptor ligand 2
pDLI pre-emptive DLI
PEG-lipid polyethylene glycol-lipid
PGE2 prostaglandin-2
Pt patient
RFS relapse-free survival
RNA ribonucleic acid
RT room temperature
SCT stem cell transplantation
SD standard deviation
SEM standard error of the mean
SHP-1  Src homology region 2 domain-
containing phosphatase-1
SHP-2  Src homology region 2 domain-
containing phosphatase-2
siPDL-LNP PD-L siRNA-LNP treated
siRNA small interfering RNA
Smac  small mitochondria-derived activator 
of caspases
SNP single nucleotide polymorphism
SOP standard operating procedure
TAA tumor-associated antigen
TAP-1  transporter associated with antigen 
processing 1
TBI total body irradiation
TCR T cell receptor
tDLI therapeutic DLI
T
eff
 effector T cell
TGF-β transforming growth factor-β
Th T helper cell
TIM-3  T-cell immunoglobulin and mucin 
domain 3
TLR Toll-like receptor
TLR-L Toll-like receptor ligand
TNF-α tumor necrosis factor-α
TNFR tumor necrosis factor receptor
T
mem
 memory T cell
T
REG
 regulatory T cell
TRM treatment related mortality
VISTA  V-domain Ig suppressor of T cell 
activation
WBC white blood cell
XIAP X-linked inhibitor of apoptosis
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